From 10a5047cf96aeee3c71dfba383716ef882a118f7 Mon Sep 17 00:00:00 2001 From: Fuyuan Wang <60631776+wfy1997@users.noreply.github.com> Date: Thu, 22 Aug 2024 13:40:11 -0400 Subject: [PATCH 1/5] update CDE values and permissive values --- model-desc/cds-model-props.yml | 4293 +++++++------------------------- model-desc/cds-model.yml | 2 +- 2 files changed, 870 insertions(+), 3425 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 3c64649..92d225d 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -1252,10 +1252,24 @@ PropDefinitions: - scRNA-Seq - WGA - WXS + Term: + - Origin: caDSR + Original Source: CRDC + Code: "12373576" + Value: Research Activity Experimental Method Type + Version: '1.00' # participant sex: Desc: A textual description of a person's sex at birth. - Type: string + Enum: + - Decline to answer + - Don't know + - Female + - Intersex + - Male + - None of these describe me + - Prefer not to answer + - Unknown Term: - Origin: caDSR Original Source: CRDC Standard @@ -2736,3384 +2750,851 @@ PropDefinitions: primary_diagnosis: Desc: Primary disease diagnosed for this diagnosis and subject Enum: - - 4th Ventricular Brain Tumor - - Acinar Cell Carcinoma - - Acute megakaryoblastic leukaemia - - Acute Megakaryoblastic Leukemia - - Acute Monoblastic and Monocytic Leukemia - - Acute monoblastic leukemia - - Acute myeloid leukemia with mutated CEBPA - - Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL - - Acute myeloid leukemia without maturation - - Acute myeloid leukemia, inv(16)(p13;q22) - - Acute myeloid leukemia, minimal differentiation - - Acute Myeloid Leukemia, NOS - - Acute myeloid leukemia, t(16;16)(p 13;q 11) - - Acute Myelomonocytic Leukemia - - Acute promyelocytic leukaemia, t(15;17)(q22;q11-12) - - Acute Promyelocytic Leukemia - - Adamantinomatous Craniopharyngioma - - Adamantinomatous craniopharyngioma with evidence of prior rupture - - Adamantinomatous craniopharyngioma, WHO grade 1 - - Adenocarcinoma - - Adrenal Cortical Carcinoma - - Adrenal cortical neoplasm - - Adrenal Cortical Tumor - - Alveolar Rhabdomyosarcoma - - Alveolar Soft Part Sarcoma - - Anaplastic Ependymoma - - Anaplastic Ganglioglioma - - Anaplastic Large Cell Lymphoma, ALK Positive - - Anaplastic Medulloblastoma - - Anaplastic Rhabdomyosarcoma - - Angiocentric Glioma - - Angiomatoid Fibrous Histiocytoma - - Astrocytic Glioma - - Astrocytic Neoplasm - - Astrocytic neoplasm with pilocytic/pilomyxoid features - - Astrocytoma - - Astrocytoma IDH-mutant, Atrocytoma IDH-mutant - - Astroglial neoplasm - - Atypical Cellular Proliferation with Clear Features - - Atypical Central Neurocytoma - - Atypical Choroid Plexus Papilloma - - Atypical Epithelial Neoplasm - - Atypical Spindle Cell Proliferation - - Atypical Teratoid/Rhabdoid Tumor - - Atypical Teratoid/Rhabdoid Tumor (AT/RT) - - Atypical teratoid/rhabdoid tumor, CNS WHO GRADE 4 - - Atypical teratoid/rhabdoid tumor; CNS WHO grade 4 - - Aytpical teratoid/rhabdoid tumor (AT/RT), WHO grade 4 - - B lymphoblastic leukemia/lymphoma with hyperdiploidy - - B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL) - - B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) - - B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) - - B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 - - B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged - - B Lymphoblastic Leukemia/Lymphoma, NOS - - B-lymphoblastic leukemia/lymphoma, NOS - - Biphasic Synovial Sarcoma - - Brain Mass - - Brain parenchyma with mild hypercellularity, gliosis and possible cortical dysplasia - - Brain Tumor - - Brain tumor with features most suggestive of ependymoma - - Brain, High Grade Lesion - - Carcinoma NOS - - Carcinosarcoma NOS - - Cellular Ependymoma - - Cellular Glial Neoplasm - - Cellular Neoplasm - - Cellular neoplasm; favor high grade - - Central Nervous System Tumor with High Grade Histological Features - - Central Neuroblastoma - - Central Neurocytoma - - Cerebellar Mass - - Cerebellar Tumor - - 'Cerebellar tumor: High-grade, small blue round cell tumor' - - Cerebellopontine Angle Tumor - - Cervical; INI1-Deficient Hematological Malignancy - - Chondroblastic Osteosarcoma - - Chondrosarcoma, NOS - - Chordoma - - Choroid Plexus Carcinoma - - Choroid plexus carcinoma, CNS WHO grade 3 - - Choroid Plexus Neoplasm - - Choroid Plexus Papillary Tumor - - Choroid Plexus Papilloma - - Choroid plexus papilloma, WHO grade 1 - - Chronic Myelogenous Leukemia, BCR-ABL Positive - - Chronic Myeloid Leukemia, BCR-ABL1-Positive - - Classic Ependymoma, Posterior fossa group A by Immunohistochemistry - - Classic Medulloblastoma - - Clear Cell Meningioma - - Clear Cell Sarcoma - - CNS Embryonal Tumor - - CNS primative neuroectodermal tumor (PNET) - - CNS Primitive Neuroectodermal Tumor (PNET) - - Compound melanocytic neoplasm - - Consistent With Oligodendroglioma, IDH Mutant - - Control - - Craniopharyngioma - - Desmoid fibromatosis with CTNNB1 gene mutation - - Desmoid-type Fibromatosis - - Desmoid/fibromatosis - - Desmoplastic Nodular Medulloblastoma - - Desmoplastic/Nodular Medulloblastoma - - Desmoplastic/nodular medulloblastoma, CNS WHO grade 4 - - Diffuse astrocytic glioma with mitotic activity and necrosis - - Diffuse Astrocytoma - - Diffuse Glioma - - Diffuse midline glioma, H3 K27-altered - - Diffuse midline glioma, H3 K27-mutant - - Diffuse midline glioma, H3K27-altered (WHO grade 4) - - Diffuse midline glioma, H3K27M altered, CNS WHO grade 4 - - Diffusely infiltrating high grade glioma - - Ductal Carcinoma NOS - - Dysembryoplastic Neuroepithelial Tumor - - Embryonal Neoplasm - - Embryonal neoplasm most consistent with Medulloblastoma + - Reactive Connective Tissue + - Acute Lymphoblastic Leukemia + - Medulloblastoma, Classic Histologic Type (CNS WHO Grade 4) + - Undifferentiated Small Round Cell Sarcoma - Embryonal Rhabdomyosarcoma - - Embryonal rhabdomyosarcoma, botryoid type - - Embryonal rhabdomyosarcoma, minimal focal anaplasia - - Embryonal Tumor - - Endometrioid Adenocarcinoma, NOS - - Endometrioid carcinoma - - Epdendymoma, Ependymoma - - Ependymoma NOS - - Ependymoma, WHO GRADE III - - Ependymoma-like lesion - - Epitheliod sarcoma - - Epitheloid neoplasm - - Epitheloid Sarcoma - - Ewing Sarcoma - - Extrarenal Malignant Rhabdoid Tumor - - Familial Adenomatous Polyposis - - Fatty neoplasm with myxoid features, no definitive high grade features, favor lipoblastoma - - Favor Infiltrating High-Grade Glioma - - Fibromatosis - - Fibromatosis Colli - - Follicular Hyperplasia/Metastatic Papillary Thyroid Cancer - - Fragments of Schwannoma, CNS WHO GRADE 1, with some mild degenerative changes - - Frontal tumor, favor infant-type hemispheric glioma - - Fundic gastrointestinal stromal tumor - - Fusion negative embryonal rhabdomyosarcoma - - Ganglioglioma + - Undifferentiated Sarcoma + - Dermoid Cyst + - Glioma, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma + - Nephroblastoma (Wilms Tumor) + - Metaplastic Carcinoma, NOS + - Hemangioblastoma, CNS WHO Grade 1 + - Rhabdoid Tumor, NOS + - Low Grade Neoplasm. Features Suggestive Of Pilocytic Astrocytoma. + - Lobular Adenocarcinoma + - Low Cumulative Sun Damage Melanoma + - Malignant Neoplasm Of Prostate + - Osteoblastoma + - Choroid Plexus Carcinoma WHO Grade 3 + - Diffuse Midline Glioma, H3K27M-Mutant, CNS WHO Grade 4 + - Lipoblastomatosis + - Melanotic Neuroectodermal Tumor + - Ependymoma, NOS, Atypical Meningioma + - Mycosis Fungoides, Langerhans Cell Histiocytosis, NOS + - Embryonal Tumor With Multi-Layered Rosettes + - Synovial Sarcoma, Spindle Cell + - Liposarcoma, NOS + - Chordoma, NOS, Chordoma (Including Poorly Differentiated Chordoma), Other + - Neoplasm, Uncertain Whether Benign Or Malignant, Meningioma, Other + - Neoplasm, Uncertain Whether Benign Or Malignant, Ependymoma, Posterior Fossa Ependymoma, Group PFA + - Schwannian Stroma Poor Peripheral Neuroblastic Tumor, Consistent With Neuroblastoma + - Adult Granulosa Cell Tumor Of Testis + - B-Lymphoblastic Leukemia/Lymphoma, NOS + - Astrocytoma, IDH-Mutant, CNS WHO Grade 4 + - Synovial Sarcoma, NOS + - Acute Myeloid Leukemia, Inv(16)(P13;Q22) + - Perineuroma + - Yolk Sac Tumor + - Paraganglioma, NOS + - Langerhans Cell Histiocytosis + - Neoplasm, Uncertain Whether Benign Or Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma + - Intraductal Papillary Carcinoma + - Acute Erythroid Leukemia - Ganglioneuroblastoma - - Ganglioneuroma - - Gastrointestinal stromal tumor (GIST) - - Gastrointestinal stromal tumor (GIST) epithelioid type, high grade - - Germinoma - - Giant Cell Glioblastoma + - Meningioma, Atypical, CNS WHO Grade 2 + - Ganglioneuroma, Maturing Type, Favorable Histology + - Adenocarcinoma, NOS + - Glioma, Malignant, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors + - Medulloblastoma, SHH-Activated And TP53-Mutant + - Neoplasm, Uncertain Whether Benign Or Malignant + - Oligodendroglioma, Anaplastic, NOS + - Astrocytoma, IDH-Mutant, WHO Grade 2 + - Plexiform Fibrohistiocytic Tumor + - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Fibroma + - Hemangioblastoma, Other + - Diffuse Midline Glioma, H3 K27-Altered + - Multiple Myeloma + - HHV8 Positive Diffuse Large B-Cell Lymphoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Adamantinomatous Craniopharyngioma, Craniopharyngioma + - Solitary Fibrous Tumor, NOS, Other + - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Precursor Cell Lymphoblastic Leukemia, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor + - Chronic Myelogenous Leukemia, BCR-ABL Positive + - Ganglioglioma, NOS, Glioneuronal And Neuronal Tumors + - Anaplastic Large Cell Lymphoma, T-Cell And Null-Cell Type + - Mixed Phenotype Acute Leukemia, B/Myeloid, NOS + - Ependymoma (CNS WHO Grade 3) + - Pheochromocytoma, NOS + - Astroblastoma + - Ossifying Fibroma + - Papillary Intralymphatic Angioendothelioma + - Telangiectatic Osteosarcoma + - Choroid Plexus Papilloma, NOS + - Spinal Ependymoma, Histologically Low Grade (CNS WHO Grade 2) + - Embryonal Rhabdomyosarcoma With Anaplastic Features + - Lentiginous Melanocytic Nevus + - Precursor T-Cell Lymphoblastic Leukemia, Acute Myeloid Leukemia, NOS + - Residual Astrocytoma + - Ependymoma, NOS, Posterior Fossa Ependymoma, NOS Or NEC + - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young + - Medulloblastoma, NOS, Medulloblastoma, Group 3 + - Pilocytic Astrocytoma + - Neoplasm, Metastatic + - Adenocarcinoma, Pancreatobiliary Type, Pancreatobiliary-Type Carcinoma + - Angiomyofibroblastoma + - Supratentorial Ependymoma, NOS + - Pleomorphic Xanthoastrocytoma, NOS, High-Grade Glioma + - Primary Cutaneous Follicle Center Lymphoma + - Chondroblastic Osteosarcoma + - Myxopapillary Ependymoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Oxyphilic Adenocarcinoma + - Pleuropulmonary Blastoma + - Myoepithelial Carcinoma + - Acute Myeloid Leukemia With T(9;11)(P22;Q23); MLLT3-MLL + - Melanotic Schwannoma, Other + - Dysplasia + - Central Neurocytoma, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Invasive Carcinoma + - Ependymoma, Anaplastic, Supratentorial Ependymoma, NOS Or NEC + - Pilocytic Astrocytoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Astroblastoma, Other, Other CNS Tumor, NOS Or NEC + - Neurocytoma + - Ependymoma WHO Grade 2 + - Desmoplastic Melanoma, NOS + - "Neoplasm, Malignant, CNS Neuroblastoma,\_FOXR2-Activated, Other CNS Embryonal Tumors" + - Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation + - Carcinoid Tumor Of Uncertain Malignant Potential + - Choroid Plexus Carcinoma, Choroid Plexus Tumors + - Mixed Phenotype Acute Leukemia, T/Myeloid, NOS + - Paraganglioma, Malignant - Glial Neoplasm - - Glial neoplasm favor optic glioma + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Soft Tissue Sarcoma + - Transitional Cell Carcinoma, NOS + - Ganglioglioma + - Glioma, Malignant, Malignant Peripheral Nerve Sheath Tumor, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, Choroid Plexus Tumors, Choroid Plexus Papilloma + - Acute Myeloid Leukemia With Abnormal Marrow Eosinophils - Glial Tumor - - Glial-neuronal neoplasm - - Glioblastoma - - Glioma - - Glioma, histologically consistent with pilocytic astrocytoma, CNS WHO grade 1 - - Glioma, most consistent with astrocytoma with worrisome features in clinical context - - Glioneuronal Lesion - - Glioneuronal Neoplasm - - Glioneuronal Tumor - - Granulosa cell tumor - - Hemangioblastoma - - Hemangioblastoma, WHO Grade 1 - - Hepatoblastoma - - Hepatocellular Carcinoma, Fibrolamellar - - High grade cellular, malignant neoplasm with necrosis and cellular pleomorphism R/O Medulloblastoma - - High Grade Diffuse Glioma - - High Grade Ependymal Tumor - - High Grade Glioma with H3 K27M and BRAF V600E mutations - - High grade glioma, NOS, WHO CNS histologic grade 4 - - High Grade Neoplasm - - High Grade Neuroepithelial Tumor - - High grade neuroepithelial tumor with glial and neuronal differentiation and focal embryonal morphology. - - High grade neuroepithelial tumor, favor medulloblastoma - - High Grade Sarcoma - - High grade spindle cell sarcoma - - High Grade Tumor - - High grade tumor consistent with embryonal tumor - - High-grade Angiosarcoma - - High-grade astrocytic neoplasm - - High-grade Astrocytoma - - High-grade blue cell tumor - - High-grade Central Nervous System Neoplasm Favor Embryonal - - High-grade CNS embryonal tissue - - High-grade CNS Neoplasm - - High-grade Ependymal Neoplasm - - High-grade Ependymal Tumor - - High-grade glioma with DICER1 and other mutations - - High-grade glioma, favor ependymoma, WHO GRADE III - - High-grade infiltrating glioma - - High-grade Malignant Neoplasm - - High-grade malignant neoplasm with mesenchymal phenotype - - High-grade malignant neoplasm, small round blue cell category. - - High-grade neoplasm, favor embryonal tumor - - High-grade neoplasm, favor high-grade glioma - - High-grade neuroepithelial neoplasm - - High-grade neuroepithelial tumor - - High-grade neuroepithelial tumor, consistent with supratentorial ependymoma - - High-grade pleomorphic sarcoma - - High-grade primary CNS neoplasia - - High-grade primitive appearing neoplasm - - High-grade rhabdomyosarcoma with pleomorphic features - - High-grade sarcoma with myogenic differentiation - - High-grade serous carcinoma - - High-grade spindle cell sarcoma compatible with high grade malignant peripheral nerve sheath tumor - - High-grade Synovial Sarcoma - - High-grade tumor - - High-grade undifferentiated sarcoma - - High-grade, primitive neuroepithelial neoplasm - - Histiocytic Malignancy - - Histologically low-grade glioneuronal tumor - - Histologically low-grade neuroepithelial tumor + - Glioma, Malignant, Ganglioglioma, Glioneuronal And Neuronal Tumors + - Pilocytic Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Dermatofibrosarcoma Protuberans, NOS + - Pancreas-Adenocarcinoma Ductal Type + - Sarcoma + - Gliosarcoma + - Giant Cell Tumor Of Bone, NOS + - Pilocytic Astrocytoma, Low-Grade Glioma + - Embryonal Carcinoma, NOS, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors + - "Astroblastoma, Astroblastoma,\_MN1-Altered, High-Grade Glioma" + - Adenoma, NOS + - Combined Small Cell-Adenocarcinoma + - Combined Small Cell-Large Carcinoma + - Soft Tissue Tumor, Benign + - Colorectal Carcinoma + - Mixed Adenocarcinoma And Squamous Cell Carcinoma, Pancreatobiliary-Type Carcinoma + - Desmoplastic Nodular Medulloblastoma + - Small Cell Sarcoma + - Hemangioendothelioma, Malignant + - Diffuse Glioma, Favor High Grade + - Squamous Cell Carcinoma, Metastatic, NOS + - Invasive Lobular Carcinoma + - Pinealoblastoma + - Endometrioid Carcinoma, NOS + - Medulloblastoma, NOS, Medulloblastoma, Non-WNT/Non-SHH + - Malignant Melanocytic Neoplasm + - Hypercellular Neuroepithelial Tumor With Some Features Of Glioma, Possibly High Grade + - Glioblastoma, IDH Wildtype + - Craniopharyngioma, Adamantinomatous + - Epithelial Tumor, Benign - Hodgkin Lymphoma, NOS - - Infant Hemispheric Glioma - - Infant-type hemispheric glioma - - Infantile Fibrosarcoma - - Infiltrating duct and lobular carcinoma - - Infiltrating duct and mucinous carcinoma - - Infiltrating duct carcinoma NOS - - Infiltrating Duct Carcinoma, NOS - - Infiltrating Glioma - - Infiltrating high grade neoplasm, favor infiltrating high grade glioma - - Infiltrating Lobular Carcinoma, NOS - - Infiltrating Neoplasm - - Infiltrating neuroepithelial neoplasm - - Inflammatory Myofibroblastic Tumor - - INI-Deficient High-grade Malignant Neoplasm - - Intracerebral schwannoma - - Intraductal Carcinoma NOS - - Intraductal papillary carcinoma - - Intradural tumor with marked atypia c/w malignant lesion, Marked atypia c/w malignant lesion, Marked atypia consistent with malignant lesion - - Intraventricular Tumor - - Invasive lobular carcinoma - - Juvenile Granulosa Cell Tumor - - Juvenile Myelomonocytic Leukemia - - Large Cell Medulloblastoma - - Large cell/anaplastic Medulloblastoma - - Laryngeal Papilloma - - Left Biopsy Chest Lesion - - Left Cp Angle Mass; Schwannoma - - Left Temporal Tumor - - Left Thoracic Tumor - - Lobular Adenocarcinoma - - Lobular And Ductal Carcinoma - - Lobular Carcinoma NOS - - Low Cellularity Glioma - - Low Grade Astrocytoma - - Low Grade Fibromyxoid Sarcoma - - Low Grade Glial Neoplasm - - Low Grade Glial Tumor - - Low Grade Glial-Glioneuronal Tumor - - Low Grade Glioma - - Low grade glioma which morphologically aligns best with pilocytic astrocytoma, CNS WHO Grade 1 - - Low grade glioma, cannot rule out additional neuronal component - - Low grade glioma, morphologically aligning best with pilocytic astrocytoma - - Low Grade Glioneuronal Neoplasm - - Low Grade Glioneuronal Tumor - - Low grade mixed glial-neuronal tumor, morphology is consistent with/ aligns with/ favors ganglioglioma - - Low Grade Neuroepithelial Tumor - - Low grade neuroepithelial tumor (preliminary path report) - - Low grade neuroepithelial tumor consistent with polymorphous low grade neuro-epithelial tumor of the young - - Low Grade Neuroglial Tumor - - Low Grade Primary CNS Neoplasm - - Low Grade Spindle Cell Neoplasm - - Low Grade Tumor - - Low-cellularity glioma - - Low-grade astrocytoma - - Low-grade circumscribed glial/glioneuronal tumor - - Low-grade fibromyxoid sarcoma - - Low-grade Glial Neoplasm - - Low-grade glial neoplasm, favor pilomyxoid/pilocytic actrocytoma - - Low-grade glial neoplasm, with features most consistent with a pilocytic astrocytoma. - - Low-grade glial-glioneuronal tumor - - Low-grade glial/glioneuronal neoplasm - - Low-grade Glial/Glioneuronal tumor - - Low-grade glial/glioneuronal tumor with adjacent cortical dysplastic changes. - - Low-grade Glioma - - Low-grade glioma, favored to represent a pilocytic astrocytoma - - Low-grade Glioneuronal Neoplasm - - Low-grade glioneuronal tumor - - Low-grade glioneuronal tumor, favor Dysembryoplastic neuroepithelial tumor - - Low-grade spindle cell neoplasm - - Low-grade tumor - - Lymphoma, NOS - - Malignant embryonal tumor, favor medulloblastoma - - Malignant epithelioid neoplasm, Malignant epithelioid neoplasm with EWSR1::KLF5 fusion - - Malignant glioma - - Malignant Melanoma NOS - - Malignant melanoma, spitzoid type - - Malignant myoepithelial of pediatric type - - Malignant Neoplasm - - Malignant neoplasm most consistent with embryonal tumor - - Malignant neoplasm of prostate - - Malignant neuroepithelial tumor - - Malignant Pecoma - - Malignant peripheral nerve sheath tumor - - Malignant primary brain tumor - - Malignant Rhabdoid Tumor - - Malignant small blue cell neoplasm, consistent with rhabdomyosarcoma - - Malignant small round blue cell neoplasm, favor rhabdomyosarcoma - - Malignant small round blue cell tumor, most consistent with desmoplastic small round cell tumor - - Malignant Tumor - - Mast Cell Leukemia - - Medullary Carcinoma - - Medulloblastoma - - Medulloblastoma (CNS WHO grade 4) - - Medulloblastoma, anaplastic histology, WHO grade 4 - - Medulloblastoma, anaplastic/large cell histology, Non-WNT NON-SHH (By IHC), WHO grade 4 - - Medulloblastoma, classic - - Medulloblastoma, classic histologic type, non-WNT/non-SHH molecular group, CNS WHO grade 4 - - Medulloblastoma, classical histology - - Medulloblastoma, CNS WHO Grade 4 - - Medulloblastoma, desmoplastic/nodular histology, SHH-activated (WHO grade 4) - - Medulloblastoma, favored - - Medulloblastoma, non-WNT, non-SHH - - Medulloblastoma, SHH-activated and TP53-wild type - - Medulloblastoma, SHH-activated and TP53-wildtype, Medulloblastoma with extensive nodularity (MBEN) - - Medulloblastoma, WHO Grade 4 - - Medulloblastoma, WHO Grade IV - - Melanoma + - Medulloblastoma, Classic Variant, WHO Grade 4 + - Myofibroblastic Tumor, NOS + - Glioma, Malignant, Angiocentric Glioma, Low-Grade Glioma + - Hodgkin Lymphoma, Nodular Sclerosis, NOS - Meningioma - - Merkel Cell Tumor - - Mesenchymal Chondrosarcoma - - Mesenchymal Neoplasm - - Metastatic Alveolar Rhabdomyosarcoma - - Metastatic Carcinoma - - Metastatic Embryonal Rhabdomyosarcoma - - Metastatic embryonal rhabdomyosarcoma in three nodules - - Metastatic nasopharyngeal carcinoma, nonkeratinizing squamous cell carcinoma subtype - - Metastatic Papillary Thyroid Carcinoma - - Metastatic Polyphenotypic Malignant Neoplasm - - Metastatic Rhabdomyosarcoma - - Mixed Germ Cell Tumor - - Mixed germ cell w/ matrue teratoma - - Mixed malignant germ cell tumor with components of embryonal carcinoma, choriocarcinoma, and mature teratoma - - Mixed malignant germ cell tumor with yolk sac tumor - - Mixed-Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified + - Glioma, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Choroid Plexus Papilloma, NOS, Choroid Plexus Tumors + - High-Grade Serous Carcinoma + - Adenocarcinoma, Metastatic NOS + - Melanoma, NOS + - Myofibroblastic Tumor + - Unknown, To Be Completed Later, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma + - Papillary Thyroid Carcinoma + - Choriocarcinoma Combined With Other Germ Cell Elements + - Acute Myeloid Leukemia With Myelodysplasia-Related Changes + - Pheochromocytoma + - Germ Cell Tumor, Nonseminomatous, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Astrocytoma, NOS, Low-Grade Glioma, Pilocytic Astrocytoma + - Glomus Tumor, Malignant + - Juvenile Myelomonocytic Leukemia, NOS + - Mitotically Active Glial/ Glioneuronal Neoplasm + - Pancreatic Neuroendocrine Tumor, Nonfunctioning + - High Grade Glioma With Necrosis, WHO Grade 4 + - Oligodendroglioma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Atypical Choroid Plexus Papilloma, Choroid Plexus Tumors + - Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, Group 4 + - Supratentorial Ependymoma - Mixed-Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified - - Monophasic Synovial Sarcoma, Intermediate-Grade (FNCLCC Grade 2 Of 3) - - Most consistent with atypical teratoid/rhabdoid tumor, most consistent with atypical teratoid/rhabdoid tumor - - Mucinous Carcinoma - - Mucoepidermoid carcinoma - - Myelodysplastic Syndrome With Multilineage Dysplasia - - Myelodysplastic Syndrome With Single Lineage Dysplasia - - Myeloid leukemia associated with Down Syndrome - - Myofibroblastic proliferation suggestive of inflammatory myofibroblastic tumor + - Therapy Related Myeloid Neoplasm + - Low Grade Fibromyxoid Sarcoma + - Favor Anaplastic Ependymoma + - Central Neuroblastoma + - Astrocytoma, NOS, High-Grade Glioma, Infant-Type Hemispheric Glioma + - Hepatoblastoma + - Not Applicable + - Solitary Fibrous Tumor, NOS + - Atypical Choroid Plexus Papilloma + - High Grade Neuroepithelial Tumor + - Acute Monocytic Leukemia + - Mesenchymal Chondrosarcoma + - Embryonal Sarcoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - Inflammatory Myofibroblastic Tumor With An Associated Odontogenic Keratocyst + - Renal Cell Adenocarcinoma + - Oligodendroglioma, NOS, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted - Myofibroma - - Myxoid Glioneuronal Tumor - - Myxoid Liposarcoma - - Myxoid Neoplasm - - Myxopapillary Ependymoma - - Myxopapillary ependymoma, CNS WHO grade 2 - - Nasopharyngeal Carcinoma Metastatic - - Nasopharyngeal carcinoma, non-keratinizing squamous cell carcinoma type - - Neoplasm - - Nephroblastoma (Wilms Tumor) + - Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorder + - Meningioma, NOS + - Embryonal Rhabdomyosarcoma, NOS, CNS Embryonal Tumor, NOS + - Lactotroph Adenoma + - Malignant Melanoma, NOS, Meningeal Melanocytic Neoplasms (Includes Melanoma), Other + - Pancreatoblastoma + - Synovial Sarcoma + - Glioma, Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Residual Low Grade Neuroendocrine Tumor (Typical Carcinoid) + - Lobular Carcinoma, NOS + - Unknown, To Be Completed Later, Glioneuronal And Neuronal Tumors, Papillary Glioneuronal Tumor + - Germinoma + - Langerhans Cell Histiocytosis, Disseminated + - Epithelial-Myoepithelial Carcinoma + - Ependymoma (WHO Grade 2) + - "Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And\_TP53-Mutant" + - Neurofibroma, NOS, Other, Solitary Fibrous Tumor + - Adenoma + - Clear Cell Sarcoma, NOS + - Medulloblastoma, NOS, Medulloblastoma, NOS Or NEC + - Epithelioid Hemangioendothelioma, NOS + - Follicular Adenocarcinoma, Well Differentiated, Neuroblastoma, NOS + - Ependymoma, NOS, Choroid Plexus Tumors, Choroid Plexus Papilloma + - Hemangioblastoma + - Rhabdomyosarcoma, Most Likely An Embryonal Carcinoma + - Clear Cell Sarcoma Of Kidney + - Glioneuronal Tumor With Focal Increased Atypia + - Metastatic Neuroblastoma + - Classic Medulloblastoma, CNS WHO Grade 4 + - Adrenal Cortical Tumor, NOS + - Alveolar Rhabdomyosarcoma + - Schwannoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Bronchiolo-Alveolar Carcinoma, Non-Mucinous + - Glioma, Malignant, Astrocytoma, IDH-Mutant, High-Grade Glioma + - Glioma, Malignant, High-Grade Glioma, Pleomorphic Xanthoastrocytoma + - Infiltrating Lobular Carcinoma, NOS + - Leiomyoma, NOS + - Malignant Peripheral Nerve Sheath Tumor + - Adenocarcinoma Combined With Other Types Of Carcinoma + - Papillary Glioneuronal Tumor + - Spindle Cell Melanoma, NOS + - Oligodendroglioma + - Papillary Glioneuronal Tumor, WHO Grade 1 + - Spindle Cell Rhabdomyosaroma + - Neuroendocrine Tumor, NOS + - Papillary Lesion With Atypical/High Grade Features + - Glioma, Malignant, Low-Grade Glioma, Polymorphous Low-Grade Neuroepithelial Tumor Of The Young + - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFB + - Glioma, Histologically Low Grade + - Atypical Lymphoid Infiltrate + - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Neuroendocrine Carcinoma, NOS + - Synovial Sarcoma, Biphasic - Neuroblastoma - - Neurocytoma - - Neuroectodermal Tumor - - Neuroectodermal tumor, NTRK1 altered, with low-grade morphologic features - - Neuroendocrine Tumor - - Neuroepithelial Neoplasm - - Neuroepithelial neoplasm, Glioma - - Neuroepithelial Tumor - - Neurofibromatosis; Moderately cellular neoplasm - - Non-WNT/non-SHH medulloblastoma - - Not Reported - - Optic Pathway Glioma - - Osteosarcoma, NOS - - Ovarian Sclerosing Stromal Tumor - - Pancreatobiliary-Type Carcinoma + - Small Blue Cell Tumor. Favor Medulloblastoma + - Not Specified In Data + - Large Cell Medulloblastoma, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors + - Choroid Plexus Carcinoma + - Adrenal Cortical Carcinoma + - T-Cell/Histiocyte Rich Large B-Cell Lymphoma + - Acute Myeloid Leukemia, Minimal Differentiation + - Gliomatosis Cerebri + - Medulloblastoma, Classic Morphology, CNS WHO Grade 4, NON-WNT/NON-SHH, Group 4 Subtype By Methylation + - Ewing Sarcoma + - Adenocarcinoma, Pancreatobiliary Type + - Diffuse Large B-Cell Lymphoma, NOS + - Chronic Myelogenous Leukemia, BCR/ABL Positive + - Adenocarcinoma In Situ, NOS + - Epithelioid Sarcoma, NOS + - Papillary Microcarcinoma + - Medulloblastoma + - Hepatocellular Carcinoma, NOS + - Renal Cell Carcinoma + - Germinoma, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Acute Myeloid Leukemia With Mutated CEBPA + - Invasive Ductal Carcinoma + - Myxoid Liposarcoma - Papillary Carcinoma - - Papillary carcinoma of thyroid - - Papillary Neoplasm, Favor Choroid Plexus Tumor - - Papillary Thyroid Carcinoma - - Papillary thyroid carcinoma, classic - - Papillary Tumor of The Pineal Region - - Paraganglioma - - Paratesticular Rhabdomyosarcoma - - Paratesticular rhabdomyosarcoma, favor embryonal - - Paratesticular Spindle Cell/Sclerosing Rhabdomyosarcoma - - Pediatric neuroepithelial tumor with ROS1 fusion - - Pediatric type diffuse low grad astrocytoma, consistent with methylation array finding suggestive of MYB/MYBL1-altered (CNS WHO grade 1) - - PFA Ependymoma - - Pheochromocytoma - - Pilocytic Astrocytoma - - Pilocytic astrocytoma (WHO Grade 1) - - Pilocytic astrocytoma, CNS WHO grade 1 - - Pilocytic astrocytoma, CNS WHO GRADE 1, Pilocytic astrocytoma, CNS WHO grade 1 - - Pilocytic Astrocytoma, CNS WHO Grade I - - Pilocytic astrocytoma, KIAA1549::BRAF fusion-positive (WHO grade 1) - - Pilocytic astrocytoma, WHO Grade 1 - - Pilocytic astrocytoma, WHO grade I - - Piloid Glial Proliferation - - Pilomyxoid Astrocytoma - - Pineal Parenchymal Tumor - - Pineoblastoma - - Pineoblastoma, WHO grade 4 - - Pituitary Adenoma - - Pituitary Tumor + - Glioblastoma, NOS, Medulloblastoma, NOS + - Rhabdomyosarcoma, Favor Alveolar Type + - Neoplasm, Uncertain Whether Benign Or Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor - Pleomorphic Sarcoma - - Pleomorphic Xanthoastrocytoma - - Pleuropulmonary Blastoma - - Plexifrom Fibrohistiocytic Tumor - - Polymorphous Low Grade Neuroepithelial Tumor - - Poorly Differentiated Malignant Neoplasm with Sarcomatoid Features - - Poorly Differentiated Pulmonary Adenocarcinoma - - Poorly Differentiated Ring Cell Adenocarcinoma - - Poorly Differentiated Sarcoma - - Poorly Differentiated Sertoli-Leydig Cell Tumor - - Positive for lesional tissue, favor low-grade glioma, additional studies pending. - - Possible Synovial Sarcoma - - Posterior Fossa Ependymoma - - Posterior fossa ependymoma, group A - - Posterior fossa ependymoma, group A (CNS group grade III) - - Posterior fossa ependymoma, group B - - Posterior fossa ependymoma, WHO grade 2, with retained H3 K27 tri-methylation - - Posterior fossa group A (PFA) Ependymoma (WHO GRADE 3) - - Posterior fossa group A ependymoma - - Posterior Fossa Tumor - - Posterior Fossa, Forth Ventricular Tumor, Posterior Fossa, Fourth Ventricular Tumor - - Precursor B-Cell Acute Lymphoblastic Leukemia with Hyperdiploidy - - Primary central nervous system neoplasm consistent with high grade glioma - - Primary mediastinal (thymic) large B-cell lymphoma - - Primitive malignant neoplasm with mesenchymal features - - Primitive Neuroectoderma Tumor - - Primitive Sarcoma - - Primitive/embryonal tumor with high-grade features; compatible with medulloblastoma - - Psammomatous Meningioma - - Pure Germinoma - - PXA Vs Ganglioglioma - - Renal Cell Adenocarcinoma - - Renal cell carcinoma, NOS - - Renal medullary carcinoma - - Residual CIC-Rearranged Sarcoma - - Residual Dermatofibrosarcoma Protuberans - - Residual High Grade Astrocytoma With Piloid Features - - Residual High-Grade Sarcoma - - Residual Malignant Melanoma - - Residual Papillary Tumor of Pineal Region - - Residual Pineoblastoma - - Residual/Recurrent Extraventricular Neurocytoma - - Retinoblastoma - - Retinoblastoma, moderately differentiated - - Rhabdoid Tumor, Malignant - - Rhabdomyoma NOS - - Rhabdomyosarcoma - - Rhabdomyosarcoma strongly suspected - - Rhabdomyosarcoma, favor embryonal subtype pending molecular studies - - Right Thigh Mass - - Round Blue Cell Tumor - - Round Cell Sarcoma - - Round To Spindle Cell Sarcoma - - Sarcoma - - Schwannoma - - Sclerosing Stromal Tumor - - Seroli-leydig cell tumor - - Serous Adenocarcinoma, NOS + - Poorly-Differentiated Neuroblastoma + - Ganglioneuroma, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Medullary Carcinoma, NOS + - Atypical Teratoid-Rhabdoid Tumor, WHO Grade 4 + - Low Grade Glial/ Glioneuronal Tumor + - Medulloblastoma, Nodular/Desmoplastic With Anaplastic/Large Cell Features, Non-WNT/Non-SHH; WHO Grade 4 + - High Grade Follicular Derived Thyroid Carcinoma + - Ossifying Fibromyxoid Tumor, NOS + - Astrocytoma, NOS + - CNS Primative Neuroectodermal Tumor (PNET) + - B Lymphoblastic Leukemia/Lymphoma With Hyperdiploidy + - Medulloblastoma By Morphology, NON-WNT By Immunohistochemistry + - Acute Monoblastic And Monocytic Leukemia + - Hemangioma, NOS + - Meningioma, NOS, Other + - Neoplasm, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Mucoepidermoid Carcinoma + - Atypical Meningioma + - Yolk Sac Tumor, NOS + - Aggressive Fibromatosis + - Malignant Tumor, Spindle Cell Type, CNS Sarcoma, CNS Sarcoma, NOS Or NEC + - Langerhans Cell Histiocytosis, NOS + - Acute Myelomonocytic Leukemia + - Pleomorphic Xanthoastrocytoma, NOS + - Pleomorphic Xanthoastrocytoma, NOS, Low-Grade Glioma + - Plasmacytoma, Extramedullary + - Primary Mediastinal (Thymic) Large B-Cell Lymphoma + - Neoplasm, Malignant, ATRT-SHH, Atypical Teratoid/Rhabdoid Tumor + - Teratoma, NOS + - Astrocytoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Astrocytoma, NOS, Angiocentric Glioma, Low-Grade Glioma + - Sertoli-Leydig Cell Tumor, Poorly Differentiated, With Heterologous Elements + - Diffuse Midline Glioma, H3 K27M-Mutant + - Dedifferentiated Liposarcoma + - Benign Cystic Nephroma + - Medulloblastoma; Hypercellular Lesion With Marked Atypia + - Pilocytic Astrocytoma, WHO Grade 1 + - Teratoma, Malignant, NOS + - Carcinoid Tumor + - Craniopharyngioma + - Mesothelioma, Biphasic, Malignant, B Lymphoblastic Leukemia/Lymphoma, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted + - 'B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy ' + - Glioblastoma + - Leydig Cell Tumor, NOS + - Mixed Type Rhabdomyosarcoma + - Glioma, Malignant, Other, Other CNS Tumor, NOS Or NEC + - Spinal Ependymoma, WHO Grade 2 + - Spindle Cell Carcinoma, NOS + - Neoplasm, Malignant, Low-Grade Glioma, Pilocytic Astrocytoma + - Mast Cell Leukaemia + - Neurofibroma + - Mucinous Adenocarcinoma, Endocervical Type + - Subependymoma, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - High Grade Malignant Epithelioid Neoplasm + - Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Neoplasm, Malignant, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Differentiating Neuroblastoma - Serous Cystadenocarcinoma NOS - - Serous Surface Papillary Carcinoma - - Sertoli Leydig Cell Tumor - - Sertoli-Leydig cell tumor, moderately differentiated - - Sertoli-Leydig cell tumor, poorly differentiated - - Sertolig Leydig Cell Tumor - - Signet Ring Cell Carcinoma - - Small Blue Cell Tumor - - Small Cell Neuroendocrine Carcinoma - - Small Round Blue Cell Sarcoma - - Small Round Blue Cell Tumor - - Small round blue cell tumor consistent with rhabdomyosarcoma - - 'Small round blue cell tumor: rhabdomyosarcoma' - - SMARCB1-deficient undifferentiated round cell sarcoma - - Spinal Ependymoma Myxopapillary - - Spinal Tumor - - Spindle Cell Lesion - - Spindle Cell Neoplasm - - Spindle Cell Rhabdomyosarcoma - - Spindle Cell Sarcoma - - Squamous Cell Carcinoma NOS - - Subependymal Giant Cell Astrocytoma - - Supertentorial Ependymoma - - Suprasellar Mass - - Supratentorial Choroid Plexus Papilloma - - Supratentorial Ependymoma - - Supratentorial ependymoma, WHO Grade 2 - - Synovial Sarcoma + - Medullary Carcinoma + - Blue Nevus, Malignant + - Giant Cell Glioblastoma + - Oligodendroglioma, NOS + - Retinoblastoma, NOS + - Intraductal Papillary Mucinous Neoplasm With An Associated Invasive Carcinoma + - Vascular Lesion, Consistent With Hemangioma + - Malignant Tumor, Small Cell Type + - Meningioma, Malignant + - Carcinoma, Diffuse Type + - Myxopapillary Ependymoma, Anaplastic + - Desmoplastic Infantile Astrocytoma + - Giant Cell Glioblastoma, Glioblastoma, IDH-Wildtype, High-Grade Glioma + - Myeloid Leukemia With Myelodysplasia-Related Changes + - Ganglioglioma, NOS + - B Lymphoblastic Leukemia/Lymphoma, NOS + - Atypical Teratoid Rhabdoid Tumor, CNS WHO Grade 4 - T Lymphoblastic Leukemia/Lymphoma - - T-lymphoblastic Leukemia - - T-lymphoblastic Lymphoma - - Testicular mass - - Thalamic Brain Tumor - - Therapy Related Myeloid Neoplasm - - Therapy-related myeloid neoplasms - - Unclassified pleomorphic sarcoma - - Undifferential Small Round Blue Cell Tumor - - Undifferentiated leukaemia - - Undifferentiated Leukemia - - Undifferentiated Malignant Neoplasm with Rhabdoid Morphology And INI1 Loss - - Undifferentiated Round Cell Sarcoma - - Undifferentiated sarcoma - - Undifferentiated small round cell sarcoma - - Undifferentiated, high-grade neoplasm/sarcoma - - Unknown - - Well Differentiated Embryonal Rhabdomyosarcoma - - Well Differentiated Neuroendocrine Tumor - - Well To Moderately Differentiated Colonic Adenocarcinoma - - Yolk Sac Tumor - - Rasmussen Encephalitis - - Neoplasm, Nos - - Atypical Tetroid/Rhabdoid Tumor WHO Grade 4 - - High-grade Small Round Blue Cell Tumor - - Histologically Low-Grade Glioma With Pilocytic Features, Most Suggestive Of Pilocytic Astrocytoma - - High-grade Glioneuronal Tumor - - Aggressive Spindle Cell Neoplasm - - 'Intraoperative Consultation: Calcified Glial Lesion Dx: Markedly Calcified Lesion' - - Rhabdoid Tumor, NOS - - Nodular Spindle Neoplasm - - '8806/3 : Desmoplastic Small Round Cell Tumor' - - Favor Pilocytic Astrocytoma - - Pediatric Type Diffuse Glioma With Angiocentric Pattern - - Teratoma, malignant, NOS - - Reactive Connective Tissue - - Low Grade Glioma Most Consistent With Pilocytic/Pilomyxoid Astrocytoma. WHO Grade 1 - - Adrenalcortical Carcinoma - - Osteoblastoma - - High-Grade Infiltrating Astrocytoma - - '9400/3 : Astrocytoma, NOS' - - Small Round Cell Sarcoma - - Desmoplastic Small Round Cell Tumor - - Compact Neoplasm with MesenchymalFfeatures - - Meningioangiomatosis - - Carcinoma, Metastatic, NOS - - Diffuse Midline Glioma H3 K27 Altered CNS WHO Grade 4 - - Glioneuronal Tumor With BRAF V600E Mutation - - Clear Cell Sarcoma, NOS - - Thyroid Carcinoma - - Lobular and Ossifying Round Cell Neoplasm - - Malignant Peripheral Nerve Sheath Tumor (Mpnst) - - Low Grade Glioma, Consistent With Pilocytic Astrocytoma, WHO Grade 1 - - Pilocytic Astrocytoma WHO Grade 1 - - Fibroma - - Glioma With Low Grade Histologic Features - - Subependymal Giant Cell Astrocytoma (WHO Grade 1) - - Rhabdomyosarcoma, Favor Embryonal Subtype - - Low Grade Glial Neoplasm, Consistent With Pilocytic Astrocytoma - - Glioneuronal - - Embryonal Tumor With Multilayered Rosettes, C19MC-Altered - - Diffuse Midline Glioma, H3K27M Mutated By IHC, WHO Grade IV - - Pancreatobiliary-Type Carcinoma;Adenocarcinoma, Pancreatobiliary Type - - High Grade Glioneuronal Tumor - - Oncocytic Adrenal Cortical Carcinoma - - Multiple Myeloma - - High Grade Neoplasm, Consistent With Metastatic Pleuropulmonary Blastoma - - '9040/3 : Synovial Sarcoma, NOS' - - Mucoepidermoid Carcinoma Low Grade - - Endometrioid Carcinoma, NOS - - Diffuse Astrocytic Neoplasm - - Oxyphilic Adenocarcinoma - - Gastrointestinal Stromal Tumor - - CNS Neuroblastoma - - Infiltrating Glial Neoplasm - - Low-Grade Glial/ Glial Neuronal Tumor, Histologic CNS WHO Grade 1 - - Central Primary Primitive Neuroectodermal Tumor - - Malignant Neoplasm With Primitive Morphology, Favor Medulloblastoma + - Chronic Eosinophilic Leukemia + - Glial Neoplasm, Favor Pilocytic Astrocytoma + - Mixed Germ Cell Tumor, Acute Megakaryoblastic Leukemia + - Atypical Teratoid/Rhabdoid Tumor + - Favor Ganglioglioma + - Tubular Adenocarcinoma + - Precursor T-Cell Lymphoblastic Leukemia + - Astrocytoma, Anaplastic + - Osteosarcoma, NOS + - Pilocytic Astrocytoma, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors + - Diffuse Glioma + - B Lymphoblastic Leukemia/Lymphoma With T(V;11q23); MLL Rearranged + - "Ependymoma, NOS, Supratentorial Ependymoma,\_ZFTA\_Fusion-Positive" + - Acinar Cell Carcinoma + - Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Juvenile Myelomonocytic Leukemia, NOS + - "Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, SHH-Activated And\_TP53-Wildtype" + - Anaplastic Ganglioglioma + - Squamous Cell Carcinoma, Small Cell, Nonkeratinizing + - "Ganglioglioma, NOS, Diffuse Astrocytoma,\_MYB- Or\_MYBL1-Altered, Low-Grade Glioma" + - Unclassified Sarcoma With Round Cell Morphology + - Pilomyxoid Astrocytoma - Lung Squamous Cell Carcinoma, NOS - - Low-grade Glial or Glioneuronal neoplasm - - Epithelioid Sarcoma - - '8550/3 : Acinar Cell Carcinoma' - - Acute Lymphoblastic Leukemia - - Anaplastic Medulloblastoma WHO Grade 4 - - '9421/1 : Pilocytic Astrocytoma' - - IDH Mutant Gliomaa - - Ganglioma, CNS WHO Grade 1 - - Synovial Sarcoma, NOS - - Cellular Schwannoma - - Glial/Glioneuronal Neoplasm - - Atypical Teratoid/ Rhabdoid Tumor, CNS WHO Grade IV - - Pediatric-Type Glioma, CNS WHO Grade 4 - - Malignant Spindle Cell Neoplasm - - CNS Neoplasm - - Diffuse Leptomeningeal Melanocytic Neoplasm - - Mucous Adenocarcinoma - - Glioma Subependymal Giant Cell Astrocytoma CNS WHO Grade 1 - - Leiomyosarcoma, NOS - - Synovial sarcoma, NOS - - Pancreatobiliary-Type Carcinoma;Mixed Adenocarcinoma And Squamous Cell Carcinoma - - Aggressive Fibromatosis - - Bronchio-alveolar Carcinoma - - Acute Myeloid Leukemia - - Probable Pilocytic Astrocytoma - - '9413/0 : Dysembryoplastic Neuroepithelial Tumor' - - Fibroblastic Spindle Cell Lesion - - Diffuse Glioma High-grade - - Ductal Carcinoma, NOS - - '9400/0 : Astrocytoma, Benign' - - Choroid Plexus Carcinoma, TP53 Mutant - - Medulloblastoma, Classic Histologic Type, Non-WNT/Non-SHH Molecular Subtype, WHO Grade 4 - - Atypical Lymphoid Infiltrate - - Liposarcoma - - Malignant Melanocytic Neoplasm - - Low-grade Glial/Glioneuronal Tumor - - Myofibroblastic Tumor + - Medulloblastoma, NOS, Diffuse Hemispheric Glioma, H3 G34-Mutant, High-Grade Glioma + - Hepatocellular Carcinoma, NOS, Nephroblastoma, NOS + - Glioma, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma + - Papillary Carcinoma, Follicular Variant + - Malignant Histiocytosis + - Acute Myeloid Leukemia, NOS + - Pineoblastoma, Other, Other CNS Tumor, NOS Or NEC + - Choroid Plexus Papillary Tumor + - Atypical Teratoid/Rhabdoid Tumor, ATRT, NOS Or NEC + - Pancreatobiliary-Type Carcinoma + - Cribriform Carcinoma, NOS + - Neoplasm, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, WNT-Activated + - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Pilocytic Astrocytoma + - Cystosarcoma Phyllodes, NOS + - Rhabdomyosarcoma, NOS + - Carcinoma NOS + - Atypical Teratoid/Rhabdoid Tumor, ATRT-TYR + - Genital Rhabdomyoma + - Oligodendroglioma, NOS, High-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted + - Neuroepithelioma, NOS + - Mixed Epithelioid And Spindle Cell Melanoma + - Teratoma + - Neoplasm, Malignant, Diffuse Midline Glioma, H3 K27-Altered, High-Grade Glioma - Mucinous Adenocarcinoma - - Omentum; Pancreatic Acinar Cell Carcinoma - - '9380/3 : Glioma, Malignant' - - Embryonal Tumor With Multilayered Rosettes, CNS WHO Grade 4 - - Diffuse Hemispheric Glioma - - Dermatofibrosarcoma Protuberans - - Parosteal Osteosarcoma - - Ependymoma, NOS - - Follicular Carcinoma - - NTRK-1 Altered Mesenchymal Tumor - - Myxopapillary Ependymoma WHO Grade 2 - - Small Cell Squamous Cell Carcinoma - - '9192/3 : Parosteal Osteosarcoma' - - Basaloid Squamous Cell Carcinoma - - Cervical Thoracic Spinal Cord Tumor.Ependymoma With High-Grade Features - - Malignant Somatic Neoplasm With Multiphase Sarcomatous Components Consistent With Embryonal-Type Sarcoma - - Pseudomyogenic Hemangioendothelioma - - Hemangioma - - Low-grade Astrocytic tumor - - '8171/3 : Hepatocellular Carcinoma, Fibrolamellar' - - Medulloblastoma Classic Type CNS Who Grade 4 - - Precursor T-Cell Lymphoblastic Leukemia - - Metastatic Secondary Tumors - - Adenocarcinoma In Situ, Non-Mucinous - - Diffuse Hemispheric Glioma CNS WHO Grade 4 - - '9478/3 : Embryonal Tumor With Multilayered Rosettes With C19MC Alteration' - - Ossifying Fibroma - - '8910/3 : Embryonal Rhabdomyosarcoma, NOS' - - Small Cell Carcinoma of Ovary - - Langerhans Cell Histiocytosis - - Low Grade Glioma With Apparent BRAF V600E Expression - - Diffuse Midline Glioma - - Pilocytic Astrocytoma, CNS WHO Grade 1 - - Meningioma, WHO Grade 2 - - Schwannoma, Benign Conventional Type WHO Grade 1 - - Teratoma, Malignant, NOS - - Metastatic Adrenal Cortical Carcinoma - - Oligodendroglioma - - Fibroblastic/Myofibroblastic Lesion - - Metaplastic Carcinoma - - Dysplasia + - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Sarcoma, Ewing Sarcoma + - Hamartoma + - Astrocytoma + - Adamantinomatous Craniopharyngioma (CNS WHO Grade 1) + - Malignant Epithelioid And Myxoid Neoplasm + - Adamantinomatous Craniopharyngioma + - Sex Cord-Gonadal Stromal Tumor, Mixed Forms + - Hepatocellular Carcinoma, Fibrolamellar + - Pilocytic Astrocytoma, WHO Grade 1, KIAA1549-BRAF Fusion + - Ganglioglioma, Anaplastic + - Head & Neck Squamous Cell Carcinoma + - Mixed Glioma + - Renal Cell Carcinoma, NOS + - Tumor Cells, Malignant + - Low Grade Glioneuronal Tumor + - Myxofibrosarcoma + - Chordoma + - Infiltrating Duct Carcinoma NOS + - Squamous Cell Carcinoma NOS + - Posterior Fossa Ependymoma, CNS WHO Grade 2 + - "Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, SHH-Activated And\_TP53-Wildtype" + - Choroid Plexus Neoplasm + - Chordoma, NOS, Ganglioneuroblastoma + - Colon Adenocarcinoma + - Hypocellular Low Grade Lesion + - Mucous Adenocarcinoma + - Glioma, Malignant, High-Grade Glioma, Infant-Type Hemispheric Glioma + - Myeloid Sarcoma + - Smooth Muscle Tumor Of Uncertain Malignant Potential + - Serous Surface Papillary Carcinoma + - Desmoplastic Fibroma + - Astrocytoma, NOS, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma + - Ependymoma NOS + - Morphologically Consistent With Pilocytic Astrocytoma, WHO Grade 1 + - Sclerosing Stromal Tumor + - Astrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Embryonal Rhabdomyosarcoma, High-Grade + - Lymphoid Leukemia, NOS + - Nephroblastoma, NOS + - Tumor Cells, Uncertain Whether Benign Or Malignant + - Astrocytic Glioma, Histologically Low-Grade, Most Compatible With Pilocytic Astrocytoma + - Adenocarcinoma With Mixed Subtypes + - Neoplasm, Malignant, Uncertain Whether Primary Or Metastatic + - Stroma Poor, Poorly Differentiated Neuroblastoma With Low MKI, Favorable Histology + - Meningiomatosis, NOS + - Meningothelial Meningioma, Grade 1 + - Ganglioglioma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - Spindle Cell Melanoma, Type B + - Dysembryoplastic Neuroepithelial Tumor With Adjacent Cortical Dysplasia, WHO Grade 1 + - Atypical Teratoid/Rhabdoid Tumor, ATRT-MYC + - Clear Cell Meningioma, Meningioma, Other + - Atypical Teratoid/Rhabdoid Tumor, INI1/SMARCB1-Altered, WHO Grade 4 + - Favor Pilocytic Astrocytoma With Increased Proliferation Indices + - Medulloblastoma, NOS + - Neuroblastoma, Schwannian Stroma Poor, Poorly Differentiated, Low MKI, Favorable Histology + - Cholangiocarcinoma + - Rhabdomyosarcoma, Embryonal Subtype + - Dermatofibrosarcoma Protuberans, Fibrosarcomatous + - Olfactory Neuroblastoma + - Familial Adenomatous Polyposis + - Glioma, Malignant, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Ameloblastic Carcinosarcoma + - Amelanotic Melanoma + - Myelodysplastic Syndrome With Single Lineage Dysplasia + - Neoplasm, Malignant + - Malignant Lymphoma, NOS + - Astrocytoma, IDH-Mutant, CNS WHO Grade 3 + - Favor Teratoma + - Pineoblastoma + - Thymoma, NOS + - Hemangiosarcoma + - Myeloid Leukemia, NOS + - Meningeal Melanomatosis + - Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH Wildtype + - CNS Embryonal Tumor With Rhabdoid Features + - Abdominal Fibromatosis + - Embryonal Neoplasm With INI-1 Loss By Immunohistochemistry + - Granulosa Cell Tumor, Malignant + - Leukemia, NOS + - Medulloblastoma WHO Grade 4 + - Adenocarcinoma In Situ In Adenomatous Polyp + - Medulloblastoma, SHH-Activated And TP53-Wildtype + - Neurofibroma, NOS + - Malignant Lymphoma, Non-Hodgkin, NOS + - Glial Neoplasm, Astrocytoma + - Acute Promyelocytic Leukaemia, T(15;17)(Q22;Q11-12) + - Embryonal Tumor With Multilayered Rosettes C19MC-Altered + - Hepatosplenic T-Cell Lymphoma, Precursor Cell Lymphoblastic Leukemia, NOS + - Brain Tumor + - Neoplasm, NOS + - Acute Myeloid Leukemia (Megakaryoblastic) With T(1;22)(P13;Q13); RBM15-MKL1 + - Leydig Cell Tumor, Benign + - Oligodendroglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Osteoblastoma, NOS + - Bronchio-Alveolar Carcinoma, Mucinous + - Neoplasm, Uncertain Whether Benign Or Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Arteriovenous Malformation + - Meningeal Melanocytoma + - Precursor B-Cell Acute Lymphoblastic Leukemia With Hyperdiploidy + - Myxoid Spindle Cell Tumor - Adenocarcinoma In Villous Adenoma - - Ganglioneuroblastoma, Nodular; Unfavorable Histology - - Diffuse Midline Glioma H3K27-Altered WHO Grade 4 - - Inflammatory Carcinoma - - Lobular carcinoma NOS - - Low Grade Glial Neoplasm, Histologically Most Consistent With Pilocytic Astrosytoma, CNS WHO Grade 1 - - Epithelioid Hemangioendothelioma, NOS - - '8805/3 : Undifferentiated Sarcoma' - - Dermoid Cyst - - '9181/3 : Chondroblastic Osteosarcoma' - - Perineuroma - - Ulcerated Nodular Melanoma - - Choroid Plexus Carcinoma TP53 Altered CNS WHO Grade 3 - - Residual Pilocytic Astrocytoma (WHO Grade 1) - - Morphologically Consistent With Low Grade Glial Neoplasm - - '8991/3 : Embryonal Sarcoma' - - Embryonal Neoplasm With Focal Dystrophic Calcifications And Microvascular Proliferation - - Carcinoma - - Atypical Teratoid/ Rhabdoid Tumor, CNS WHO Grade 4 - - Polymorphous Low-Grade Neuroepithelial Tumor Of The Young, CNS WHO Grade 1 - - '9392/3 : Ependymoma, Anaplastic' - - '9080/3 : Teratoma, Malignant, NOS' - - Favor Low Grade Glioma - - High-grade Carcinoma - - Epitheloid Neoplasm - - Adrenal Cortical Neoplasm - - '9071/3 : Yolk Sac Tumor, NOS' - - Epithelial - Myoepithelial Carcinoma - - Embryonal CNS Tumor + - Papillary Adenocarcinoma, NOS + - Poorly Differentiated Chordoma + - Adenoid Cystic Carcinoma + - Pigmented Dermatofibrosarcoma Protuberans + - Oligoastrocytoma, NOS + - Myelodysplastic Syndrome With Multilineage Dysplasia + - Astrocytoma, Anaplastic, NOS + - Medulloblastoma, Classic (Biphasic) Histologic Type, Non-SHH/Non-WNT Molecular Group, CNS WHO Grade 4 + - Signet Ring Cell Carcinoma + - B Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34;Q11.2); BCR-ABL1 + - Control + - Adenocarcinoma,NOS, Glioblastoma, NOS + - Adenocarcinoma With Neuroendocrine Differentiation + - Retinoblastoma + - Acute Promyelocytic Leukemia, T(15;17)(Q22;Q11-12) + - Germ Cell Tumor, Nonseminomatous + - Adenocarcinoma + - Malignant Tumor, Spindle Cell Type + - Medulloblastoma, Classic Histology + - Pilocytic Astrocytoma, CNS WHO Grade 1 + - Squamous Cell Carcinoma In Situ, NOS + - Neoplasm + - Composite Hodgkin And Non-Hodgkin Lymphoma + - Adenocarcinoma, Intestinal Type + - Astroblastoma, MN1-Altered. Histologically High-Grade + - Nasopharyngeal Carcinoma + - Glioma, Malignant, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Neoplasm, Uncertain Whether Benign Or Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Central Osteosarcoma, NOS + - Merkel Cell Tumor + - Merkel Cell Carcinoma + - Adenocarcinoma, Endocervical Type + - Serous Cystadenocarcinoma, NOS + - Xanthogranuloma + - Oligodendroglioma, Anaplastic + - Atypical Smooth Muscle Neoplasm + - High Grade Spindle Cell Sarcoma + - Neoplasm, Malignant, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Ductal Carcinoma In Situ, NOS + - Epithelioid Mesothelioma, Malignant + - Brain Tumor, Low Grade Glioma + - Combined Small Cell-Squamous Cell Carcinoma + - Myofibromatosis + - Adamantinomatous Craniopharyngioma, WHO Grade 1 + - Chronic Myeloid Leukemia, BCR-ABL1-Positive + - Basal Cell Adenocarcinoma + - Undifferentiated Nasopharyngeal Carcinoma - Chronic Myelogenous Leukemia - - '8170/3 : Hepatocellular Carcinoma, NOS' - - Low Grade Glioneuronal Neoplasm, Including Ganglioglioma - - Low-Grade Glioma Histologically, Favor Pilocytic Astrocytoma - - Dysembryoplastic Neuroepithelial Tumor (DNET; WHO Grade 1) - - High Grade Neuroepithelial Tumor, With Features Aligning Best With A CNS Embryonal Tumor, CNS WHO Grade 4 - - Precursor T-cell lymphoblastic Leukemia - - Neuroepithelial Tumor Of Pineal Region With Papillary Features - - Invasive Carcinoma - - Atypical Meningioma - - High-grade Serous Carcinoma - - Adenocarcinoma, Metastatic, NOS - - '8430/3 : Mucoepidermoid Carcinoma' - - '8072/3 : Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, NOS' - - Medulloblastoma, Classic Histology, SHH Activated And TP53 Wild-Type, CNS WHO Grade 4 - - Rhabdomyosarcoma With Diffuse Anaplasia - - Hypercellular Cortical Parenchyma, Features Suggestive Of Diffuse Glioma - - Neuroglial Neoplasm + - Medulloblastoma, WHO Grade 4 + - Fibrosarcoma, NOS + - Juvenile Myelomonocytic Leukemia + - Tenosynovial Giant Cell Tumor, NOS + - Acute Myeloid Leukemia With Mutated NPM1 + - Pancreas-Undifferentiated Carcinoma + - Precursor Cell Lymphoblastic Lymphoma, NOS + - Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, NOS + - Large Cell Medulloblastoma, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Ductal Carcinoma NOS + - High Grade Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomyoblastic Differentiation (Malignant Triton Tumor) + - Myxopapillary Ependymoma, Ependymoma + - Retinoblastoma, Grade 3 + - Sarcoma, NOS + - Malignant Peripheral Nerve Sheath Tumor, NOS + - Spindle Cell Rhabdomyosarcoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Serous Adenocarcinoma, NOS + - Neurofibromatosis, NOS + - T-Lymphoblastic Lymphoma + - Neoplasm, Malignant, CNS Embryonal Tumor, NOS Or NEC, Other CNS Embryonal Tumors + - Medulloepithelioma, NOS + - Glioma + - Pineoblastoma, Other CNS Embryonal Tumors + - Ependymoma, NOS + - Adrenal Cortical Adenoma, NOS + - Appearances Consistent With Alveolar Soft Part Sarcoma + - Hypercellular Lesion With Atypia + - Tumor Cells, Uncertain Whether Benign Or Malignant, Other CNS Embryonal Tumors, Pineoblastoma + - Myeloid Leukemia Associated With Down Syndrome + - Rhabdoid Tumor, Malignant + - Carcinoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Astrocytoma, NOS, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Lymphoproliferative Disorder, NOS + - Malignant Tumor + - Embryonal Carcinoma, NOS, Ependymoma, Supratentorial Ependymoma, NOS Or NEC + - Acute Myeloid Leukemia Without Maturation + - Neoplasm, Malignant, ATRT, NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor + - Dysembryoplastic Neuroepithelial Tumor + - Craniopharyngioma, NOS + - Parosteal Osteosarcoma + - Schwannoma, NOS + - Squamous Cell Carcinoma, Keratinizing, NOS + - Craniopharyngioma, Adamantinomatous, Adamantinomatous Craniopharyngioma + - Neuroblastoma, NOS + - Angiocentric Glioma + - Gastrointestinal Stromal Tumor + - Meningothelial Meningioma + - Astrocytoma, NOS, Low-Grade Glioma, Subependymal Giant Cell Astrocytoma + - Metastatic Secondary Tumors + - Mesoblastic Nephroma + - Not Reported + - Rhabdomyoma, NOS + - Favor Posterior Fossa Ependymoma, WHO GRADE 3 + - Clear Cell Meningioma + - Marginal Zone B-Cell Lymphoma, NOS + - Gangliocytoma, NOS + - Acute Monoblastic Leukemia + - Ganglioneuroma + - Glioma, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Malignant Peripheral Nerve Sheath Tumor (Mpnst) + - Anaplastic Ependymoma + - Malignant Sarcoma With DICER1 Mutation, Favor Primary Intracranial Sarcoma, DICER1 Mutant + - Pleomorphic Liposarcoma - Lymphoepithelial Carcinoma - - High Grade Malignant Neoplasm - - Papillary Serous Adenocarcinoma - - Diffuse Midline Glioma H3 K27-altered WHO Grade 4 - - Immature Teratoma - - Not Specified in Data - - Malignant Peripheral Nerve Sheath Tumor, High Grade - - Intraventricular Thalamopeduncular Resection :Diffuse Midline Glioma, H3 K27M Altered WHO Grade 4 - - Myxoid Spindle Cell Tumor - - Neurofibroma - - Cystosarcoma Phyllodes, NOS - - Rhabdoid Tumor - - Malignant Neoplasia - - Thyroid Papillary Carcinoma - - Lung Adenocarcinoma, NOS - - '9384/1 : Subependymal Giant Cell Astrocytoma' - - Glioneuronal Tumor NOS - - Consistent With Meningioma - - Clear Cell Adenocarcinoma - - '9473/3 : CNS Embryonal Tumor, NOS' - - High-grade Fibrosarcoma - - Metastatic Signet Ring Cell Carcinoma - - Periosteal osteosarcoma - - Papillary Tumor - - Adenocarcinoma, NOS - - Micropapillary Carcinoma - - Tumor - - Thymoma - - '8370/3 : Adrenal Cortical Carcinoma' - - Lesional Tissue Present. Cannot Rule Out High Grade Neoplasm - - Brain Neoplasm - - Tubular Adenocarcinoma - - Pineoblastoma, CNS WHO Grade 4 - - Consistent With Neoplasm, Morphologically Favor Low Grade Astrocytoma - - '8814/3 : Infantile Fibrosarcoma' - - Malignant Neoplasm, Most Consistent With Atypical Teratoid/Rhabdoid Tumor, WHO Grade IV - - '8912/3 : Spindle Cell Rhabdomyosarcoma' - - Malignant Small Blue Cell Tumor With Necrosis - - Adenosquamous Carcinoma - - Low Grade Spindle Cell Tumor, Favor Mesenchymal. Differential Chiefly Include STF, Meningiom, Schwannoma And Other Rare Mesenchymal Tumor + - Embryonal Tumor With Multilayered Rosettes With C19MC Alteration + - Ganglioglioma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Mixed-Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified + - Oligoastrocytoma, NOS, Glioneuronal And Neuronal Tumors, Papillary Glioneuronal Tumor + - Supratentorial Ependymoma CNS WHO Grade 3 + - Follicular Adenocarcinoma, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Central Neurocytoma + - Carcinoma, Undifferentiated, NOS + - Papillary Thyroid Carcinoma, Classic Type - Invasive Mammary Carcinoma - - Metastatic Undifferentiated Carcinoma - - Malignant Meoplasm - - Mixed Malignant Germ Cell Tumor - - Acute Leukemia, B/myeloid, NOS - - Ependymoma, Anaplastic - - Atypical Mixed Glioneuronal Lesion - - BRAF V600E Mutant Low Grade Glial Or Glioneuronal Tumor, Ganglioglioma Favored - - Thymic Carcinoma - - Ependymoma, WHO Grade II - - Blue Cell Tumor - - Atypical Choroid Plexus Papilloma WHO Grade 2 - - High-grade Glial or Glioneuronal Neoplasm - - Squamous Cell Carcinoma Nos - - Nasopharyngeal Carcinoma - - '8821/1 : Aggressive Fibromatosis' - - Medulloblastoma, Desmoplastic/Nodular Variant (WHO Grade 4). - - '9540/3 : Malignant Peripheral Nerve Sheath Tumor, NOS' - - Undifferentiated Round Cell Malignancy - - Leomorphic Xanthoastrocytoma - - Epithelioid Cell Tumor - - Hamartomatous Lesion - - Xanthogranuloma - - Sertoli-Leydig Cell Tumor, Moderately Differentiated. Pathologic Stage PT1A, FIGO Stage 1A - - Medulloblastoma, Classic Histology Type, WNT-Activated Molecular Group, CNS WHO Grade 4 - - '9364/3 : Ewing Sarcoma' - - High-grade Glioma - - Retinoblastoma, Poorly Differentiated - - Acute Leukemia, T/myeloid, NOS - - Embryonal Tumor With Multilayered Rosettes CNS WHO Grade 4 - - Papillary Neoplasm - - Adenocarcinoma In Situ, NOS - - Hamartoma - - Choroid Plexus Papilloma, Negative For Atypia And Malignancy - - '9183/3 : Telangiectatic Osteosarcoma' - - Leydig Cell Tumor - - Rhabdomyosarcoma With Focal Anaplasia - - High Grade Mesenchymal Neoplasm - - High-Grade Malignancy With Rhabdomyoblastic Differentiation - - Gastrointestinal Stromal Tumor (GIST) - - Juvenile Myelomonocytic Leukemia, NOS - - Glial Neoplasm, Appearing Pilocytic - - Signet-ring Cell Carcinoma - - Astrocytoma with Pilomyxoid Features - - Myoepithelial Carcinoma - - '8720/3 : Malignant Melanoma, NOS' - - '8920/3 : Alveolar Rhabdomyosarcoma' - - Telangiectatic Osteosarcoma - - Small Cell Carcinoma - - Combined Small Cell Large Carcinoma - - Medulloblastoma, CNS-WHO Grade 4 - - Telangiectatic osteosarcoma - - Choroid Plexus Carcinoma CNS WHO Grade 3 - - Supratentorial Ependymoma, ZFTA-Altered, WHO Grade 2 - - Arteriovenous Malformation - - Non-Germinomatous Germ Cell Tumor - - Low-grade Glial/Neuronal Tumor - - Pleuropulmonary Blastoma, Type 1 - - Small Cell Carcinoma, NOS - - Low Grade Glioma, Favor Pilocytic Astrocytoma, Preliminary WHO Grade 1 - - Morphologically Low Grade Glial Lesion Suggestive Of Pilocytic Astrocytoma - - Primary CNS Neoplasm - - Low-Grade Glioma With Piloid Features. - - Combined Small Cell Adenocarcinoma - - Renal Cell Carcinoma - - Glioblastoma Multiforme - - Hepatocellular Carcinoma, NOS - - Ganglioglioma, WHO Grade I - - Periosteal Osteosarcoma - - '9193/3 : Periosteal Osteosarcoma' - - '9385/3 : Diffuse Midline Glioma, H3 K27M-Mutant' - - Infiltrative Fibromatosis - - Papillary Carcinoma Diffuse Sclerosing Variant With Left Lobe Dominant Nodule And Diffuse Bilateral Intraglandular Spread + - Ganglioglioma, NOS, Other, Other CNS Tumor, NOS Or NEC + - T-Lymphoblastic Leukemia + - Burkitt Lymphoma, NOS + - Intraductal Carcinoma NOS + - Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation + - Glioma, Malignant, Other, Other Low-Grade B-Cell Lymphomas Of The CNS + - "Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And\_TP53-Wildtype" + - Gastrointestinal Stromal Tumor, Benign + - Ependymoma, NOS, Supratentorial Ependymoma, NOS Or NEC - Prostate Cancer - - Lymph Node With Metastatic Melanoma - - EBV-Related Squamous Cell Carcinoma - - 'High Grade Spindle Cell Sarcoma (Clinical: Neurofibromatosis Type 1 (NF-1).' - - Glial/glioneuronal Neoplasm - - Abdominal desmoid - - Abdominal fibromatosis - - Achromic nevus - - Acidophil adenocarcinoma - - Acidophil adenoma - - Acidophil carcinoma - - Acinar adenocarcinoma - - Acinar adenocarcinoma, sarcomatoid - - Acinar adenoma - - Acinar carcinoma - - Acinar cell adenoma - - Acinar cell carcinoma - - Acinar cell cystadenocarcinoma - - Acinar cell tumor - - Acinic cell adenocarcinoma - - Acinic cell adenoma - - Acinic cell tumor - - Acoustic neuroma - - Acquired cystic disease-associated renal cell carcinoma (RCC) - - Acquired tufted hemangioma - - Acral lentiginous melanoma, malignant - - ACTH-producing tumor - - Acute basophilic leukaemia - - Acute bilineal leukemia - - Acute biphenotypic leukemia - - Acute erythremia - - Acute erythremic myelosis - - Acute erythroid leukaemia - - Acute granulocytic leukemia - - Acute leukemia, Burkitt type - - Acute leukemia, NOS - - Acute lymphatic leukemia - - Acute lymphoblastic leukemia-lymphoma, NOS - - Acute lymphoblastic leukemia, L2 type, NOS - - Acute lymphoblastic leukemia, mature B-cell type - - Acute lymphoblastic leukemia, NOS - - Acute lymphoblastic leukemia, precursor cell type - - Acute lymphocytic leukemia - - Acute lymphoid leukemia - - Acute mixed lineage leukemia - - Acute monoblastic and monocytic leukemia - - Acute monocytic leukemia - - Acute myeloblastic leukemia - - Acute myelocytic leukemia - - Acute myelofibrosis - - Acute myelogenous leukemia - - Acute myeloid leukaemia, t(8;21)(q22;q22) - - Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 - - Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants) - - Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 - - Acute myeloid leukemia with maturation - - Acute myeloid leukemia with multilineage dysplasia - - Acute myeloid leukemia with mutated NPM1 - - Acute myeloid leukemia with myelodysplasia-related changes - - Acute myeloid leukemia with prior myelodysplastic syndrome - - Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214 - - Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1 - - Acute myeloid leukemia without prior myelodysplastic syndrome - - Acute myeloid leukemia, AML1(CBF-alpha)/ETO - - Acute myeloid leukemia, CBF-beta/MYH11 - - Acute myeloid leukemia, M6 type - - Acute myeloid leukemia, MLL - - Acute myeloid leukemia, NOS - - Acute myeloid leukemia, PML/RAR-alpha - - Acute myeloid leukemia, t(15:17)(g22;q11-12) - - Acute myelomonocytic leukemia - - Acute myelomonocytic leukemia with abnormal eosinophils - - Acute myelosclerosis, NOS - - Acute myloid leukemia, 11q23 abnormalities - - Acute non-lymphocytic leukemia - - Acute panmyelosis with myelofibrosis - - Acute panmyelosis, NOS - - Acute progressive histiocytosis X - - Acute promyelocytic leukaemia, PML-RAR-alpha - - Acute promyelocytic leukemia, NOS - - Adamantinoma of long bones - - Adamantinoma, malignant - - Adamantinoma, NOS - - Adenoacanthoma - - Adenoameloblastoma - - Adenocarcinoid tumor - - Adenocarcinoma admixed with neuroendocrine carcinoma - - Adenocarcinoma combined with other types of carcinoma - - Adenocarcinoma in a polyp, NOS - - Adenocarcinoma in adenomatous polyp - - Adenocarcinoma in adenomatous polyposis coli - - Adenocarcinoma in multiple adenomatous polyps - - Adenocarcinoma in polypoid adenoma - - Adenocarcinoma in situ in a polyp, NOS - - Adenocarcinoma in situ in adenomatous polyp - - Adenocarcinoma in situ in polypoid adenoma - - Adenocarcinoma in situ in tubular adenoma - - Adenocarcinoma in situ in tubulovillous adenoma - - Adenocarcinoma in situ in villous adenoma - - Adenocarcinoma in situ, mucinous - - Adenocarcinoma in situ, non-mucinous - - Adenocarcinoma in situ, NOS - - Adenocarcinoma in tubolovillous adenoma - - Adenocarcinoma in tubular adenoma - - Adenocarcinoma in villous adenoma - - Adenocarcinoma of anal ducts - - Adenocarcinoma of anal glands - - Adenocarcinoma of rete ovarii - - Adenocarcinoma with apocrine metaplasia - - Adenocarcinoma with cartilaginous and osseous metaplasia - - Adenocarcinoma with cartilaginous metaplasia - - Adenocarcinoma with mixed subtypes - - Adenocarcinoma with neuroendocrine differentiation - - Adenocarcinoma with osseous metaplasia - - Adenocarcinoma with spindle cell metaplasia - - Adenocarcinoma with squamous metaplasia - - Adenocarcinoma, cribriform comedo-type - - Adenocarcinoma, cylindroid - - Adenocarcinoma, diffuse type - - Adenocarcinoma, endocervical type - - Adenocarcinoma, intestinal type - - Adenocarcinoma, metastatic, NOS - - Adenocarcinoma, pancreatobiliary type - - Adenocystic carcinoma - - Adenofibroma, NOS - - Adenoid basal carcinoma - - Adenoid cystic carcinoma - - Adenolipoma - - Adenolymphoma - - Adenoma of nipple - - Adenoma, NOS - - Adenomatoid odontogenic tumor - - Adenomatoid tumor, NOS - - Adenomatosis, NOS - - Adenomatous polyp, NOS - - Adenomatous polyposis coli - - Adenomyoepithelioma - - Adenomyoepithelioma with carcinoma - - Adenomyoma - - Adenosarcoma - - Adenosquamous carcinoma - - Adnexal carcinoma - - Adnexal tumor, benign - - Adrenal cortical adenocarcinoma - - Adrenal cortical adenoma, clear cell - - Adrenal cortical adenoma, compact cell - - Adrenal cortical adenoma, glomerulosa cell - - Adrenal cortical adenoma, mixed cell - - Adrenal cortical adenoma, NOS - - Adrenal cortical adenoma, pigmented - - Adrenal cortical carcinoma - - Adrenal cortical tumor, benign - - Adrenal cortical tumor, malignant - - Adrenal cortical tumor, NOS - - Adrenal medullary paraganglioma - - Adrenal medullary paraganglioma, malignant - - Adrenal rest tumor - - Adult cystic teratoma - - Adult granulosa cell tumor - - Adult rhabdomyoma - - Adult T-cell leukemia - - Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants) - - Adult T-cell lymphoma - - Adult T-cell lymphoma/leukemia - - Adult teratoma, NOS - - Aggressive angiomyxoma - - Aggressive digital papillary adenoma - - Aggressive fibromatosis - - Aggressive NK-cell leukaemia - - Aggressive osteoblastoma - - Aggressive systemic mastocytosis - - Agnogenic myeloid metaplasia - - AIN III - - Aleukemic granulocytic leukemia - - Aleukemic leukemia, NOS - - Aleukemic lymphatic leukemia - - Aleukemic lymphocytic leukemia - - Aleukemic lymphoid leukemia - - Aleukemic monocytic leukemia - - Aleukemic myelogenous leukemia - - Aleukemic myeloid leukemia - - ALK positive large B-cell lymphoma - - Alpha cell tumor, malignant - - Alpha cell tumor, NOS - - Alpha heavy chain disease - - Alveolar adenocarcinoma - - Alveolar adenoma - - Alveolar carcinoma - - Alveolar cell carcinoma - - Alveolar rhabdomyosarcoma - - Alveolar soft part sarcoma - - Amelanotic melanoma - - Ameloblastic carcinoma - - Ameloblastic fibro-odontoma - - Ameloblastic fibro-odontosarcoma - - Ameloblastic fibrodentinoma - - Ameloblastic fibrodentinosarcoma - - Ameloblastic fibroma - - Ameloblastic fibrosarcoma - - Ameloblastic odontosarcoma - - Ameloblastic sarcoma - - Ameloblastoma, malignant - - Ameloblastoma, NOS - - AML M6 - - Anal intraepithelial neoplasia, grade III - - Anal intraepithelial neoplasia, low grade - - Anaplastic astrocytoma, IDH-mutant - - Anaplastic astrocytoma, IDH-wildtype - - Anaplastic large B-cell lymphoma - - Anaplastic large cell lymphoma, ALK negative - - Anaplastic large cell lymphoma, ALK positive - - Anaplastic large cell lymphoma, CD30+ - - Anaplastic large cell lymphoma, NOS - - Anaplastic large cell lymphoma, T cell and Null cell type - - Anaplastic medulloblastoma - - Anaplastic oligoastrocytoma - - Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted - - Anaplastic pleomorphic xanthroastrocytoma - - Ancient schwannoma - - Androblastoma, benign - - Androblastoma, malignant - - Androblastoma, NOS - - Angioblastic meningioma - - Angioblastoma - - Angiocentric glioma - - Angiocentric immunoproliferative lesion - - Angiocentric T-cell lymphoma - - Angioendothelioma - - Angioendotheliomatosis - - Angiofibroma, NOS - - Angioimmunoblastic lymphadenopathy - - Angioimmunoblastic lymphoma - - Angioimmunoblastic T-cell lymphoma - - Angiokeratoma - - Angioleiomyoma - - Angiolipoma, NOS - - Angioma, NOS - - Angiomatoid fibrous histiocytoma - - Angiomatous meningioma - - Angiomyofibroblastoma - - Angiomyolipoma - - Angiomyoma + - Poorly Differentiated Neuroblastoma + - Undiagnosed Spindle Cell Tumor + - Neuroblastoma, Undifferentiated Type + - Schwannoma + - Well Differentiated Neuroendocrince Tumor, Grade 1 + - Seminoma, NOS + - Hepatoblastoma, NOS + - Mesenchymal Chondrosarcoma, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Embryonal Rhabdomyosarcoma, NOS + - Low-Grade Glioneuronal, Neuronal Tumor - Angiomyosarcoma - - Angiomyxoma - - Angiosarcoma - - Angiotropic lymphoma - - Aortic body paraganglioma - - Aortic body tumor - - Aorticopulmonary paraganglioma - - Apocrine adenocarcinoma - - Apocrine adenoma - - Apocrine cystadenoma - - Apudoma - - Argentaffinoma, malignant - - Argentaffinoma, NOS - - Arrhenoblastoma, benign - - Arrhenoblastoma, malignant - - Arrhenoblastoma, NOS - - Arteriovenous hemangioma - - Askin tumor - - Astroblastoma - - Astrocytic glioma - - Astrocytoma, anaplastic - - Astrocytoma, low grade - - Astrocytoma, NOS - - Astroglioma - - Atypical adenoma - - Atypical carcinoid tumor - - Atypical choroid plexus papilloma - - Atypical chronic myeloid leukemia, BCR/ABL negative - - Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative - - Atypical fibrous histiocytoma - - Atypical fibroxanthoma - - Atypical follicular adenoma - - Atypical hyperplasia/Endometrioid intraepithelial neoplasm - - Atypical leiomyoma - - Atypical lipoma - - Atypical medullary carcinoma - - Atypical meningioma - - Atypical polypoid adenomyoma - - Atypical proliferating clear cell tumor - - Atypical proliferating serous tumor - - Atypical proliferative endometrioid tumor - - Atypical proliferative mucinous tumor - - Atypical proliferative papillary serous tumor - - Atypical teratoid/rhabdoid tumor - - B cell lymphoma, NOS - - B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH - - B lymphoblastic leukemia/lymphoma, NOS - - B-ALL - - B-cell lymphocytic leukemia/small lymphocytic lymphoma - - B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma - - B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma - - Balloon cell melanoma - - Balloon cell nevus - - BALT lymphoma - - Basal cell adenocarcinoma - - Basal cell adenoma - - Basal cell carcinoma, desmoplastic type - - Basal cell carcinoma, fibroepithelial - - Basal cell carcinoma, micronodular - - Basal cell carcinoma, morpheic - - Basal cell carcinoma, nodular - - Basal cell carcinoma, NOS - - Basal cell epithelioma - - Basal cell tumor - - Basaloid carcinoma - - Basaloid squamous cell carcinoma - - Basophil adenocarcinoma - - Basophil adenoma - - Basophil carcinoma - - Basosquamous carcinoma - - Bednar tumor - - Bellini duct carcinoma - - Benign cystic nephroma - - Benign fibrous histiocytoma - - Beta cell adenoma - - Beta cell tumor, malignant - - Bile duct adenocarcinoma - - Bile duct adenoma - - Bile duct carcinoma - - Bile duct cystadenocarcinoma - - Bile duct cystadenoma - - Biliary intraepithelial neoplasia, grade 3 - - Biliary intraepithelial neoplasia, high grade - - Biliary intraepithelial neoplasia, low grade - - Biliary papillomatosis - - Biphenotypic sinonasal sarcoma - - Bizarre leiomyoma - - Black adenoma - - Blast cell leukemia - - Blastic NK cell lymphoma - - Blastic plasmacytoid dendritic cell neoplasm - - Blastoma, NOS - - Blue nevus, malignant - - Blue nevus, NOS - - Botryoid sarcoma - - Bowen disease - - Brenner tumor, borderline malignancy - - Brenner tumor, malignant - - Brenner tumor, NOS - - Brenner tumor, proliferating - - Bronchial adenoma, carcinoid - - Bronchial adenoma, cylindroid - - Bronchial adenoma, NOS - - Bronchial-associated lymphoid tissue lymphoma - - Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous - - Bronchio-alveolar carcinoma, mucinous - - Bronchiolar adenocarcinoma - - Bronchiolar carcinoma - - Bronchiolo-alveolar adenocarcinoma, NOS - - Bronchiolo-alveolar carcinoma, Clara cell - - Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type - - Bronchiolo-alveolar carcinoma, goblet cell type - - Bronchiolo-alveolar carcinoma, indeterminate type - - Bronchiolo-alveolar carcinoma, non-mucinous - - Bronchiolo-alveolar carcinoma, NOS - - Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type - - Bronchiolo-alveolar carcinoma; type II pneumocyte - - Brooke tumor - - Brown fat tumor - - Burkitt cell leukemia - - Burkitt lymphoma, NOS (Includes all variants) - - Burkitt tumor - - Burkitt-like lymphoma - - C cell carcinoma - - c-ALL - - Calcifying epithelial odontogenic tumor - - Calcifying epithelioma of Malherbe - - Calcifying nested epithelial stromal tumor - - Calcifying odontogenic cyst - - Canalicular adenoma - - Cancer - - Capillary hemangioma - - Capillary lymphangioma - - Carcinofibroma - - Carcinoid tumor of uncertain malignant potential - - Carcinoid tumor, argentaffin, malignant - - Carcinoid tumor, argentaffin, NOS - - Carcinoid tumor, NOS - - Carcinoid tumor, NOS, of appendix - - Carcinoid, NOS - - Carcinoid, NOS, of appendix - - Carcinoma in a polyp, NOS - - Carcinoma in adenomatous polyp - - Carcinoma in pleomorphic adenoma - - Carcinoma in situ in a polyp, NOS - - Carcinoma in situ in adenomatous polyp - - Carcinoma in situ, NOS - - Carcinoma showing thymus-like differentiation - - Carcinoma showing thymus-like element - - Carcinoma simplex - - Carcinoma with apocrine metaplasia - - Carcinoma with chondroid differentiation - - Carcinoma with neuroendocrine differentiation - - Carcinoma with osseous differentiation - - Carcinoma with osteoclast-like giant cells - - Carcinoma with other types mesenchymal differentiation - - Carcinoma with productive fibrosis - - Carcinoma, anaplastic, NOS - - Carcinoma, diffuse type - - Carcinoma, intestinal type - - Carcinoma, metastatic, NOS - - Carcinoma, NOS - - Carcinoma, undifferentiated, NOS - - Carcinomatosis - - Carcinosarcoma, embryonal - - Carcinosarcoma, NOS - - Carotid body paraganglioma - - Carotid body tumor - - Cartilaginous exostosis - - CASTLE - - Cavernous hemangioma - - Cavernous lymphangioma - - Cellular angiofibroma - - Cellular blue nevus - - Cellular ependymoma - - Cellular fibroma - - Cellular leiomyoma - - Cellular schwannoma - - Cementifying fibroma - - Cemento-ossifying fibroma - - Cementoblastoma, benign - - Cementoma, NOS - - Central neuroblastoma - - Central neurocytoma - - Central odontogenic fibroma - - Central osteosarcoma - - Central primitive neuroectodermal tumor, NOS - - Cerebellar liponeurocytoma - - Cerebellar sarcoma, NOS - - Ceruminous adenocarcinoma - - Ceruminous adenoma - - Ceruminous carcinoma - - Cervical intraepithelial neoplasia, grade III - - Cervical intraepithelial neoplasia, low grade - - Chemodectoma - - Chief cell adenoma - - Chloroma - - Cholangiocarcinoma - - Cholangioma - - Chondroblastic osteosarcoma - - Chondroblastoma, malignant - - Chondroblastoma, NOS - - Chondroid chordoma - - Chondroid lipoma - - Chondroid syringoma - - Chondroma, NOS - - Chondromatosis, NOS - - Chondromatous giant cell tumor - - Chondromyxoid fibroma - - Chondrosarcoma grade 2/3 - - Chordoid glioma - - Chordoid glioma of third ventricle - - Chordoid meningioma - - Chordoma, NOS - - Chorioadenoma - - Chorioadenoma destruens - - Chorioangioma - - Choriocarcinoma combined with embryonal carcinoma - - Choriocarcinoma combined with other germ cell elements - - Choriocarcinoma combined with teratorna - - Choriocarcinoma, NOS - - Chorioepithelioma - - Chorionepithelioma - - Choroid plexus carcinoma - - Choroid plexus papilloma, anaplastic - - Choroid plexus papilloma, malignant - - Choroid plexus papilloma, NOS - - Chromaffin paraganglioma - - Chromaffin tumor - - Chromaffinoma - - Chromophobe adenocarcinoma - - Chromophobe adenoma - - Chromophobe carcinoma - - Chromophobe cell renal carcinoma - - Chronic eosinophilic leukemia, NOS - - Chronic erythremia - - Chronic granulocytic leukemia, BCR/ABL - - Chronic granulocytic leukemia, NOS - - Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive - - Chronic granulocytic leukemia, t(9;22)(q34;q11) - - Chronic idiopathic myelofibrosis - - Chronic leukemia, NOS - - Chronic lymphatic leukemia - - Chronic lymphocytic leukemia - - Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL) - - Chronic lymphoid leukemia - - Chronic lymphoproliferative disorder of NK cells - - Chronic monocytic leukemia - - Chronic myelocytic leukemia, NOS - - Chronic myelogenous leukemia, BCR-ABL positive - - Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive - - Chronic myelogenous leukemia, t(9;22)(q34;q11) - - Chronic myeloid leukemia, NOS - - Chronic myelomonocytic leukemia in transformation - - Chronic myelomonocytic leukemia, NOS - - Chronic myelomonocytic leukemia, Type 1 - - Chronic myelomonocytic leukemia, Type II - - Chronic myeloproliferative disease, NOS - - Chronic myeloproliferative disorder - - Chronic neutrophilic leukemia - - CIN III with severe dysplasia - - Cin III, NOS - - Circumscribed arachnoidal cerebellar sarcoma - - Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis - - Classical Hodgkin lymphoma, lymphocyte depletion, NOS - - Classical Hodgkin lymphoma, lymphocyte depletion, reticular - - Classical Hodgkin lymphoma, lymphocyte-rich - - Classical Hodgkin lymphoma, mixed cellularity, NOS - - Classical Hodgkin lymphoma, nodular sclerosis, cellular phase - - Classical Hodgkin lymphoma, nodular sclerosis, grade 1 - - Classical Hodgkin lymphoma, nodular sclerosis, grade 2 - - Classical Hodgkin lymphoma, nodular sclerosis, NOS - - Clear cell (glycogen-rich) urothelial carcinoma - - Clear cell adenocarcinofibroma - - Clear cell adenocarcinoma, mesonephroid - - Clear cell adenocarcinoma, NOS - - Clear cell adenofibroma - - Clear cell adenofibroma of borderline malignancy - - Clear cell adenoma - - Clear cell carcinoma - - Clear cell chondrosarcoma - - Clear cell cystadenocarcinofibroma - - Clear cell cystadenofibroma - - Clear cell cystadenofibroma of borderline malignancy - - Clear cell cystadenoma - - Clear cell cystic tumor of borderline malignancy - - Clear cell ependymoma - - Clear cell hidradenoma - - Clear cell meningioma - - Clear cell odontogenic carcinoma - - Clear cell odontogenic tumor - - Clear cell sarcoma of kidney - - Clear cell sarcoma, NOS - - Clear cell sarcoma, of tendons and aponeuroses - - Clear cell tumor, NOS - - Cloacogenic carcinoma - - CNS Embryonal tumor with rhabdoid features - - Codman tumor - - Collecting duct carcinoma - - Colloid adenocarcinoma - - Colloid adenoma - - Colloid carcinoma - - Columnar cell papilloma - - Combined carcinoid and adenocarcinoma - - Combined hepatocellular carcinoma and cholangiocarcinoma - - Combined large cell neuroendocrine carcinoma - - Combined small cell carcinoma - - Combined small cell-adenocarcinoma - - Combined small cell-large carcinoma - - Combined small cell-squamous cell carcinoma - - Combined/mixed carcinoid and adenocarcinoma - - Comedocarcinoma, noninfiltrating - - Comedocarcinoma, NOS - - Common ALL - - Common precursor B ALL - - Complete hydatidiform mole - - Complex odontoma - - Composite carcinoid - - Composite Hodgkin and non-Hodgkin lymphoma - - Compound nevus - - Compound odontoma - - Condylomatous carcinoma - - Congenital fibrosarcoma - - Congenital generalized fibromatosis - - Congenital peribronchial myofibroblastic tumor - - Conventional central osteosarcoma - - Cortical T ALL + - CNS Embryonal Tumor, NOS + - Sertoli-Leydig Cell Tumor, Intermediate Differentiation, With Heterologous Elements + - Subependymal Giant Cell Astrocytoma + - Infiltrating Duct Mixed With Other Types Of Carcinoma + - Ganglioneuroblastoma, Nodular Type + - Pancreas-Adenosquamous Carcinoma + - Papillary Serous Adenocarcinoma + - Cavernoma + - Fibrillary Astrocytoma + - Pilocytic Astrocytoma, Low-Grade Glioma, Pleomorphic Xanthoastrocytoma + - Malignant Glioma + - Malignant Peripheral Nerve Sheath Tumor, NOS, CNS Sarcoma, CNS Sarcoma, NOS Or NEC + - Small Round Blue Cell Tumor + - Adenocarcinoma In Adenomatous Polyposis Coli - CPNET - - Craniopharyngioma, adamantinomatous - - Craniopharyngioma, papillary - - Cribriform carcinoma in situ - - Cribriform carcinoma, NOS - - Cribriform comedo-type carcinoma - - Cutaneous histiocytoma, NOS - - Cutaneous lymphoma, NOS - - Cutaneous mastocytosis - - Cutaneous T-cell lymphoma, NOS - - Cylindrical cell carcinoma - - Cylindrical cell papilloma - - Cylindroma of skin - - Cylindroma, NOS - - Cyst-associated renal cell carcinoma - - Cystadenocarcinoma, NOS - - Cystadenofibroma, NOS - - Cystadenoma, NOS - - Cystic astrocytoma - - Cystic hygroma - - Cystic hypersecretory carcinoma - - Cystic lymphangioma - - Cystic mesothelioma, benign - - Cystic mesothelioma, NOS - - Cystic partially differentiated nephroblastoma - - Cystic teratoma, NOS - - Cystic tumor of atrio-ventricular node - - Cystoma, NOS - - Cystosarcoma phyllodes, benign - - Cystosarcoma phyllodes, malignant - - Cystosarcoma phyllodes, NOS - - Dabska tumor - - DCIS, comedo type - - DCIS, NOS - - DCIS, papillary - - Dedifferentiated chondrosarcoma - - Dedifferentiated chordoma - - Dedifferentiated liposarcoma - - Deep histiocytoma - - Degenerated schwannoma - - Dendritic cell sarcoma, NOS - - Dentinoma - - Dermal and epidermal nevus - - Dermal nevus - - Dermatofibroma lenticulare - - Dermatofibroma, NOS - - Dermatofibrosarcoma protuberans, NOS - - Dermatofibrosarcoma, NOS - - Dermoid cyst with malignant transformation - - Dermoid cyst with secondary tumor - - Dermoid cyst, NOS - - Dermoid, NOS - - Desmoid, NOS - - Desmoplastic fibroma - - Desmoplastic infantile astrocytoma - - Desmoplastic infantile ganglioglioma - - Desmoplastic medulloblastoma - - Desmoplastic melanoma, amelanotic - - Desmoplastic melanoma, malignant - - Desmoplastic mesothelioma - - Desmoplastic nodular medulloblastoma - - Desmoplastic small round cell tumor - - Di Guglielmo disease - - Differentiated penile intraepithelial neoplasia - - Differentiated-type vulvar intraepithelial neoplasia - - Diffuse astrocytoma - - Diffuse astrocytoma, IDH-mutant - - Diffuse astrocytoma, IDH-wildtype - - Diffuse astrocytoma, low grade - - Diffuse cutaneous mastocytosis - - Diffuse intraductal papillomatosis - - Diffuse large B-cell lymphoma associated with chronic inflammation - - Diffuse large B-cell lymphoma, NOS - - Diffuse leptomeningeal glioneuronal tumor - - Diffuse melanocytosis - - Diffuse meningiomatosis - - Diffuse midline glioma, H3 K27M-mutant - - Digital papillary adenocarcinoma - - Diktyoma, benign - - Diktyoma, malignant - - DIN 3 - - Duct adenocarcinoma, NOS - - Duct adenoma, NOS - - Duct carcinoma, desmoplastic type - - Duct carcinoma, NOS - - Duct cell carcinoma - - Ductal carcinoma in situ, comedo type - - Ductal carcinoma in situ, cribriform type - - Ductal carcinoma in situ, micropapillary - - Ductal carcinoma in situ, NOS - - Ductal carcinoma in situ, papillary - - Ductal carcinoma in situ, solid type - - Ductal carcinoma, cribriform type - - Ductal carcinoma, NOS - - Ductal intraepithelial neoplasia 3 - - Ductal papilloma - - Dysembryoplastic neuroepithelial tumor - - Dysgerminoma - - Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos) - - Dysplastic nevus - - EBV positive diffuse large B-cell lymphoma of the elderly - - EC cell carcinoid - - Ecchondroma - - Ecchondrosis - - Eccrine acrospiroma - - Eccrine adenocarcinoma - - Eccrine cystadenoma - - Eccrine dermal cylindroma - - Eccrine papillary adenocarcinoma - - Eccrine papillary adenoma - - Eccrine poroma - - Eccrine poroma, malignant - - Eccrine spiradenoma - - ECL cell carcinoid, malignant - - ECL cell carcinoid, NOS - - Ectomesenchymoma - - Ectopic hamartomatous thymoma - - Elastofibroma - - Embryonal adenocarcinoma - - Embryonal adenoma - - Embryonal carcinoma, infantile - - Embryonal carcinoma, NOS - - Embryonal carcinoma, polyembryonal type - - Embryonal hepatoma - - Embryonal rhabdomyosarcoma, NOS - - Embryonal rhabdomyosarcoma, pleomorphic - - Embryonal sarcoma - - Embryonal teratoma - - Embryonal tumor with multilayered rosettes C19MC-altered - - Embryonal tumor with multilayered rosettes, NOS - - Embryonal tumor with rhabdoid features - - Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS) - - Encapsulated papillary carcinoma - - Encapsulated papillary carcinoma with invasion - - Enchondroma - - Endocervical adenocarcinoma usual type - - Endocrine adenomatosis - - Endocrine tumor, functioning, NOS - - Endodermal sinus tumor - - Endolymphatic stromal myosis - - Endometrial sarcoma, NOS - - Endometrial stromal nodule - - Endometrial stromal sarcoma, high grade - - Endometrial stromal sarcoma, low grade - - Endometrial stromal sarcoma, NOS - - Endometrial stromatosis - - Endometrioid adenocarcinoma, ciliated cell variant - - Endometrioid adenocarcinoma, NOS - - Endometrioid adenocarcinoma, secretory variant - - Endometrioid adenocarcinoma, villoglandular - - Endometrioid adenofibroma, borderline malignancy - - Endometrioid adenofibroma, malignant - - Endometrioid adenofibroma, NOS - - Endometrioid adenoma, borderline malignancy - - Endometrioid adenoma, NOS - - Endometrioid carcinoma with squamous differentiation - - Endometrioid carcinoma, NOS - - Endometrioid cystadenocarcinoma - - Endometrioid cystadenofibroma, borderline malignancy - - Endometrioid cystadenofibroma, malignant - - Endometrioid cystadenofibroma, NOS - - Endometrioid cystadenoma, borderline malignancy - - Endometrioid cystadenoma, NOS - - Endometrioid tumor of low malignant potential - - Endotheliomatous meningioma - - Endovascular papillary angioendothelioma - - Enteric adenocarcinoma - - Enterochromaffin cell carcinoid - - Enterochromaffin-like cell carcinoid, NOS - - Enterochromaffin-like cell tumor, malignant - - Enteroglucagonoma, malignant - - Enteroglucagonoma, NOS - - Enteropathy associated T-cell lymphoma - - Enteropathy type intestinal T-cell lymphoma - - Eosinophil adenocarcinoma - - Eosinophil adenoma - - Eosinophil carcinoma - - Eosinophilic granuloma - - Eosinophilic leukemia - - Ependymoblastoma - - Ependymoma, anaplastic - - Ependymoma, RELA fusion-positive - - Epidermoid carcinoma in situ with questionable stromal invasion - - Epidermoid carcinoma in situ, NOS - - Epidermoid carcinoma, keratinizing - - Epidermoid carcinoma, large cell, nonkeratinizing - - Epidermoid carcinoma, NOS - - Epidermoid carcinoma, small cell, nonkeratinizing - - Epidermoid carcinoma, spindle cell - - Epithelial ependymoma - - Epithelial tumor, benign - - Epithelial tumor, malignant - - Epithelial-myoepithelial carcinoma - - Epithelioid and spindle cell nevus - - Epithelioid cell melanoma - - Epithelioid cell nevus - - Epithelioid cell sarcoma - - Epithelioid glioblastoma - - Epithelioid hemangioendothelioma, malignant - - Epithelioid hemangioendothelioma, NOS - - Epithelioid hemangioma - - Epithelioid leiomyoma - - Epithelioid leiomyosarcoma - - Epithelioid malignant peripheral nerve sheath tumor - - Epithelioid mesothelioma, benign - - Epithelioid mesothelioma, malignant - - Epithelioid mesothelioma, NOS - - Epithelioid MPNST - - Epithelioid sarcoma - - Epithelioma adenoides cysticum - - Epithelioma, benign - - Epithelioma, malignant - - Epithelioma, NOS - - Erythremic myelosis, NOS - - Erythroleukemia - - Esophageal glandular dysplasia (intraepithelial neoplasia), high grade - - Esophageal glandular dysplasia (intraepithelial neoplasia), low grade - - Esophageal intraepithelial neoplasia, high grade - - Esophageal squamous intraepithelial neoplasia (dysplasia), high grade - - Esophageal squamous intraepithelial neoplasia (dysplasia), low grade - - Essential hemorrhagic thrombocythaemia - - Essential thrombocythemia - - Esthesioneuroblastoma - - Esthesioneurocytoma - - Esthesioneuroepithelioma - - Ewing sarcoma - - Ewing tumor - - Extra-abdominal desmoid - - Extra-adrenal paraganglioma, malignant - - Extra-adrenal paraganglioma, NOS - - Extracutaneous mastocytoma - - Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue - - Extranodal NK/T-cell lymphoma, nasal type - - Extraosseous plasmacytoma - - Extraventricular neurocytoma - - FAB L2 - - FAB L3 - - FAB Ll - - FAB M1 - - FAB M2, AML1(CBF-alpha)/ETO - - FAB M2, NOS - - FAB M2, t(8;21)(q22;q22) - - FAB M3 (includes all variants) - - FAB M4 - - FAB M4Eo - - FAB M5 (includes all variants) - - FAB M6 - - FAB M7 - - FAB MO - - Familial polyposis coli - - Fascial fibroma - - Fascial fibrosarcoma - - Fetal adenocarcinoma - - Fetal adenoma - - Fetal fat cell lipoma - - Fetal lipoma, NOS - - Fetal lipomatosis - - Fetal rhabdomyoma - - Fibrillary astrocytoma - - Fibro-osteoma - - Fibroadenoma, NOS - - Fibroameloblastic odontoma - - Fibroblastic liposarcoma - - Fibroblastic meningioma - - Fibroblastic osteosarcoma - - Fibroblastic reticular cell tumor - - Fibrochondrosarcoma - - Fibroepithelial basal cell carcinoma, Pinkus type - - Fibroepithelioma of Pinkus type - - Fibroepithelioma, NOS - - Fibrofolliculoma - - Fibroid uterus - - Fibrolipoma - - Fibroliposarcoma - - Fibroma, NOS - - Fibromatosis-like metaplastic carcinoma - - Fibromyoma - - Fibromyxolipoma - - Fibromyxoma - - Fibromyxosarcoma - - Fibrosarcoma, NOS - - Fibrosarcomatous dermatofibrosarcoma protuberans - - Fibrous astrocytoma - - Fibrous histiocytoma of tendon sheath - - Fibrous histiocytoma, NOS - - Fibrous meningioma - - Fibrous mesothelioma, benign - - Fibrous mesothelioma, malignant - - Fibrous mesothelioma, NOS - - Fibrous papule of nose - - Fibroxanthoma, malignant - - Fibroxanthoma, NOS - - Flat adenoma - - Flat intraepithelial glandular neoplasia, high grade - - Flat intraepithelial neoplasia, high grade - - Florid osseous dysplasia - - Follicular adenocarcinoma, moderately differentiated - - Follicular adenocarcinoma, NOS - - Follicular adenocarcinoma, trabecular - - Follicular adenocarcinoma, well differentiated - - Follicular adenoma - - Follicular adenoma, oxyphilic cell - - Follicular carcinoma, encapsulated - - Follicular carcinoma, minimally invasive - - Follicular carcinoma, moderately differentiated - - Follicular carcinoma, NOS - - Follicular carcinoma, oxyphilic cell - - Follicular carcinoma, trabecular - - Follicular carcinoma, well differentiated - - Follicular dendritic cell sarcoma - - Follicular dendritic cell tumor - - Follicular fibroma - - Follicular lymphoma, grade 1 - - Follicular lymphoma, grade 2 - - Follicular lymphoma, grade 3 - - Follicular lymphoma, grade 3A - - Follicular lymphoma, grade 3B - - Follicular lymphoma, NOS - - Follicular lymphoma, small cleaved cell - - Follicular thyroid carcinoma (FTC), encapsulated angioinvasive - - Folliculome lipidique - - Franklin disease - - G cell tumor, malignant - - G cell tumor, NOS - - Gamma heavy chain disease - - Gangliocytic paraganglioma - - Gangliocytoma - - Ganglioglioma, anaplastic - - Ganglioglioma, NOS - - Ganglioneuromatosis - - GANT - - Gastrin cell tumor - - Gastrin cell tumor, malignant - - Gastrinoma, malignant - - Gastrinoma, NOS - - Gastrointestinal autonomic nerve tumor - - Gastrointestinal pacemaker cell tumor - - Gastrointestinal stromal sarcoma - - Gastrointestinal stromal tumor, benign - - Gastrointestinal stromal tumor, malignant - - Gastrointestinal stromal tumor, NOS - - Gastrointestinal stromal tumor, uncertain malignant potential - - Gelatinous adenocarcinoma - - Gelatinous carcinoma - - Gemistocytic astrocytoma - - Gemistocytoma - - Genital rhabdomyoma - - Germ cell tumor, nonseminomatous - - Germ cell tumor, NOS - - Germ cell tumors with associated hematological malignancy - - Ghost cell odontogenic carcinoma - - Giant cell and spindle cell carcinoma - - Giant cell angiofibroma - - Giant cell carcinoma - - Giant cell fibroblastoma - - Giant cell glioblastoma - - Giant cell sarcoma - - Giant cell sarcoma of bone - - Giant cell tumor of bone, malignant - - Giant cell tumor of bone, NOS - - Giant cell tumor of soft parts, NOS - - Giant cell tumor of tendon sheath - - Giant cell tumor of tendon sheath, malignant - - Giant fibroadenoma - - Giant osteoid osteoma - - Giant pigmented nevus, NOS - - Gigantiform cementoma - - GIST, benign - - GIST, malignant - - GIST, NOS - - Glandular intraepithelial neoplasia, grade I - - Glandular intraepithelial neoplasia, grade II - - Glandular intraepithelial neoplasia, grade III - - Glandular intraepithelial neoplasia, high grade - - Glandular intraepithelial neoplasia, low grade - - Glandular papilloma - - Glassy cell carcinoma - - Glioblastoma multiforme - - Glioblastoma with sarcomatous component - - Glioblastoma, IDH wildtype - - Glioblastoma, IDH-mutant - - Gliofibroma - - Glioma, malignant - - Glioma, NOS - - Gliomatosis cerebri - - Glioneuroma - - Gliosarcoma - - Glomangioma - - Glomangiomyoma - - Glomangiosarcoma - - Glomoid sarcoma - - Glomus jugulare tumor, NOS - - Glomus tumor, malignant - - Glomus tumor, NOS - - Glucagon-like peptide-producing tumor - - Glucagonoma, malignant - - Glucagonoma, NOS - - Glycogen-rich carcinoma - - Glycogenic rhabdomyoma - - Goblet cell carcinoid - - Gonadal stromal tumor, NOS - - Gonadoblastoma - - Gonocytoma - - Granular cell adenocarcinoma - - Granular cell carcinoma - - Granular cell myoblastoma, malignant - - Granular cell myoblastoma, NOS - - Granular cell tumor of the sellar region - - Granular cell tumor, malignant - - Granular cell tumor, NOS - - Granulocytic leukemia, NOS - - Granulocytic sarcoma - - Granulosa cell carcinoma - - Granulosa cell tumor, adult type - - Granulosa cell tumor, juvenile - - Granulosa cell tumor, malignant - - Granulosa cell tumor, NOS - - Granulosa cell tumor, sarcomatoid - - Granulosa cell-theca cell tumor - - Grawitz tumor - - Gynandroblastoma - - Haemangioblastoma - - Haemangiosarcoma - - Hairy cell leukaemia variant - - Hairy cell leukemia - - Hairy cell leukemia variant - - Hairy nevus - - Halo nevus - - Hand-Schuller-Christian disease - - Heavy chain disease, NOS - - Hemangioblastic meningioma - - Hemangioendothelial sarcoma - - Hemangioendothelioma, benign - - Hemangioendothelioma, malignant + - Pilocytic Astrocytoma WHO Grade 1 + - Low Grade Glioma + - Tumor Cells, Malignant, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors + - Endometrioid Adenocarcinoma, NOS + - Carcinoma, Metastatic, NOS + - Alveolar Soft Part Sarcoma + - Papillary Tumor Of Pineal Region + - Favor Pilocytic Astrocytoma, CNS WHO Grade 1 + - Acute Leukemia, NOS - Hemangioendothelioma, NOS - - Hemangioma simplex - - Hemangioma, NOS - - Hemangiopericytic meningioma - - Hemangiopericytoma, benign - - Hemangiopericytoma, malignant - - Hemangiopericytoma, NOS - - Hemolymphangioma - - Hepatoblastoma, epithelioid - - Hepatoblastoma, mixed epithelial-mesenchymal - - Hepatocarcinoma - - Hepatocellular adenoma - - Hepatocellular carcinoma, clear cell type - - Hepatocellular carcinoma, fibrolamellar - - Hepatocellular carcinoma, NOS - - Hepatocellular carcinoma, pleomorphic type - - Hepatocellular carcinoma, sarcomatoid - - Hepatocellular carcinoma, scirrhous - - Hepatocellular carcinoma, spindle cell variant - - Hepatocholangiocarcinoma - - Hepatoid adenocarcinoma - - Hepatoid carcinoma - - Hepatoid yolk sac tumor - - Hepatoma, benign - - Hepatoma, malignant - - Hepatoma, NOS - - Hepatosplenic gamma-delta cell lymphoma - - Hepatosplenic T-cell lymphoma - - Hereditary leiomyomatosis & RCC-associated renal cell carcinoma - - Hibernoma - - Hidradenocarcinoma - - Hidradenoma papilliferum - - Hidradenoma, NOS - - Hidrocystoma - - High grade surface osteosarcoma - - High-grade neuroendocrine carcinoma - - Hilar cell tumor - - Hilus cell tumor - - Histiocyte-rich large B-cell lymphoma - - Histiocytic medullary reticulosis - - Histiocytic sarcoma - - Histiocytoid hemangioma - - Histiocytoma, NOS - - Histiocytosis X, NOS - - Hodgkin disease, lymphocyte predominance, diffuse - - Hodgkin disease, lymphocyte predominance, NOS - - Hodgkin disease, lymphocytic-histiocytic predominance - - Hodgkin disease, nodular sclerosis, lymphocyte depletion - - Hodgkin disease, nodular sclerosis, lymphocyte predominance - - Hodgkin disease, nodular sclerosis, mixed cellularity - - Hodgkin disease, nodular sclerosis, NOS - - Hodgkin disease, nodular sclerosis, syncytial variant - - Hodgkin disease, NOS - - Hodgkin granuloma - - Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis - - Hodgkin lymphoma, lymphocyte depletion, NOS - - Hodgkin lymphoma, lymphocyte depletion, reticular - - Hodgkin lymphoma, lymphocyte predominance, nodular - - Hodgkin lymphoma, lymphocyte-rich - - Hodgkin lymphoma, mixed cellularity, NOS - - Hodgkin lymphoma, nodular lymphocyte predominance - - Hodgkin lymphoma, nodular sclerosis, cellular phase - - Hodgkin lymphoma, nodular sclerosis, grade 1 - - Hodgkin lymphoma, nodular sclerosis, grade 2 - - Hodgkin lymphoma, nodular sclerosis, NOS - - Hodgkin lymphoma, NOS - - Hodgkin paragranuloma, nodular - - Hodgkin paragranuloma, NOS - - Hodgkin sarcoma - - Hurthle cell adenocarcinoma - - Hurthle cell adenoma - - Hurthle cell carcinoma - - Hurthle cell tumor - - Hutchinson melanotic freckle, NOS - - Hyalinizing trabecular adenoma - - Hydatid mole - - Hydatidiform mole, NOS - - Hydroa vacciniforme-like lymphoma - - Hygroma, NOS - - Hypereosinophilic syndrome - - Hypernephroid tumor - - Hypernephroma - - Idiopathic hemorrhagic thrombocythaemia - - Idiopathic thrombocythemia - - Immature teratoma, malignant - - Immature teratoma, NOS - - Immunoblastic sarcoma - - Immunocytoma - - Immunoglobulin deposition disease - - Immunoproliferative disease, NOS - - Immunoproliferative small intestinal disease - - Indeterminate dendritic cell tumor - - Indolent systemic mastocytosis - - Infantile fibrosarcoma - - Infantile hemangioma - - Infantile myofibromatosis - - Infiltrating and papillary adenocarcinoma - - Infiltrating angiolipoma - - Infiltrating basal cell carcinoma, non-sclerosing - - Infiltrating basal cell carcinoma, NOS - - Infiltrating basal cell carcinoma, sclerosing - - Infiltrating duct adenocarcinoma - - Infiltrating duct and colloid carcinoma - - Infiltrating duct and cribriform carcinoma - - Infiltrating duct and lobular carcinoma in situ - - Infiltrating duct and tubular carcinoma - - Infiltrating duct carcinoma, NOS - - Infiltrating duct mixed with other types of carcinoma - - Infiltrating ductular carcinoma - - Infiltrating lipoma - - Infiltrating lobular carcinoma and ductal carcinoma in situ - - Infiltrating lobular carcinoma, NOS - - Infiltrating lobular mixed with other types of carcinoma - - Infiltrating papillary adenocarcinoma - - Inflammatory adenocarcinoma - - Inflammatory carcinoma - - Inflammatory liposarcoma - - Inflammatory myofibroblastic tumor - - Insular carcinoma - - Insulinoma, malignant - - Insulinoma, NOS - - Interdigitating cell sarcoma - - Interdigitating dendritic cell sarcoma - - Intermediate and giant congenital nevus - - Interstitial cell tumor, benign - - Interstitial cell tumor, malignant - - Interstitial cell tumor, NOS - - Intestinal T-cell lymphoma - - Intestinal-type adenocarcinoma - - Intimal sarcoma - - Intracanalicular fibroadenoma - - Intracortical osteosarcoma - - Intracystic carcinoma, NOS - - Intracystic papillary adenocarcinoma - - Intracystic papillary adenoma - - Intracystic papillary neoplasm with associated invasive carcinoma - - Intracystic papillary neoplasm with high grade intraepithelial neoplasia - - Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia - - Intracystic papillary neoplasm with low grade intraepithelial neoplasia - - Intracystic papillary tumor with high grade dysplasia - - Intracystic papillary tumor with high grade entraepithelial neoplasia - - Intracystic papillary tumor with high grade intraepithelial neoplasia - - Intracystic papilloma - - Intradermal nevus - - Intraductal adenocarcinoma, noninfiltrating, NOS - - Intraductal and lobular carcinoma - - Intraductal carcinoma and lobular carcinoma in situ - - Intraductal carcinoma, clinging - - Intraductal carcinoma, noninfiltrating, NOS - - Intraductal carcinoma, NOS - - Intraductal carcinoma, solid type - - Intraductal micropapillary carcinoma - - Intraductal papillary adenocarcinoma with invasion - - Intraductal papillary adenocarcinoma, NOS - - Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma - - Intraductal papillary mucinous neoplasm with an associated invasive carcinoma - - Intraductal papillary mucinous neoplasm with high grade dysplasia - - Intraductal papillary neoplasm with associated invasive carcinoma - - Intraductal papillary neoplasm with high grade dysplasia - - Intraductal papillary neoplasm with high grade intraepithelial neoplasia - - Intraductal papillary neoplasm with intermediate grade neoplasia - - Intraductal papillary neoplasm with low grade intraepithelial neoplasia - - Intraductal papillary neoplasm, NOS - - Intraductal papillary tumor with high grade dysplasia - - Intraductal papillary tumor with high grade intraepithelial neoplasia - - Intraductal papillary-mucinous adenoma - - Intraductal papillary-mucinous carcinoma, invasive - - Intraductal papillary-mucinous carcinoma, non-invasive - - Intraductal papillary-mucinous neoplasm with low grade dysplasia - - Intraductal papillary-mucinous neoplasm with moderate dysplasia - - Intraductal papillary-mucinous tumor with intermediate dysplasia - - Intraductal papillary-mucinous tumor with low grade dysplasia - - Intraductal papillary-mucinous tumor with moderate dysplasia - - Intraductal papilloma - - Intraductal papilloma with ductal carcinoma in situ - - Intraductal papilloma with lobular carcinoma in situ - - Intraductal papillomatosis, NOS - - Intraductal tubular-papillary neoplasm, high grade - - Intraductal tubular-papillary neoplasm, low grade - - Intraductal tubulopapillary neoplasm - - Intraepidermal carcinoma, NOS - - Intraepidermal epithelioma of Jadassohn - - Intraepidermal nevus - - Intraepidermal squamous cell carcinoma, Bowen type - - Intraepithelial carcinoma, NOS - - Intraepithelial squamous cell carcinoma - - Intraglandular papillary neoplasm with low grade intraepithelial neoplasia - - Intramuscular hemangioma - - Intramuscular lipoma - - Intraneural perineurioma - - Intraosseous low grade osteosarcoma - - Intraosseous well differentiated osteosarcoma - - Intratubular germ cell neoplasia - - Intratubular malignant germ cells - - Intravascular B-cell lymphoma - - Intravascular bronchial alveolar tumor - - Intravascular large B-cell lymphoma - - Intravascular leiomyomatosis - - Invasive carcinoma of no special type - - Invasive carcinoma, NST - - Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC) - - Invasive fibroma - - Invasive hydatidiform mole - - Invasive lobular carcinoma, alveolar type - - Invasive lobular carcinoma, solid type - - Invasive lobular carcinoma, tubulolobular variant - - Invasive mammary carcinoma - - Invasive micropapillary carcinoma - - Invasive mole, NOS - - Invasive mucinous adenocarcinoma - - Involuting nevus - - Islet cell adenocarcinoma - - Islet cell adenoma - - Islet cell adenomatosis - - Islet cell carcinoma - - Islet cell tumor, benign - - Islet cell tumor, NOS - - Jadassohn blue nevus - - Jugular paraganglioma - - Jugulotympanic paraganglioma - - Junction nevus - - Junctional nevus, NOS - - Juvenile angiofibroma - - Juvenile astrocytoma - - Juvenile carcinoma of breast - - Juvenile chronic myelomonocytic leukemia - - Juvenile fibroadenoma - - Juvenile hemangioma - - Juvenile histiocytoma - - Juvenile melanoma - - Juvenile myelomonocytic leukemia - - Juvenile nevus - - Juxtacortical chondroma - - Juxtacortical chondrosarcoma - - Juxtacortical osteosarcoma - - Juxtaglomerular tumor - - Kaposi sarcoma - - Kaposiform hemangioendothelioma - - Keratotoc papilloma - - Klatskin tumor - - Krukenberg tumor - - Kupffer cell sarcoma - - L-cell tumor - - Lactating adenoma - - Langerhans cell granulomatosis - - Langerhans cell granulomatosis, unifocal - - Langerhans cell histiocytosis, disseminated - - Langerhans cell histiocytosis, generalized - - Langerhans cell histiocytosis, mono-ostotic - - Langerhans cell histiocytosis, multifocal - - Langerhans cell histiocytosis, NOS - - Langerhans cell histiocytosis, poly-ostotic - - Langerhans cell histiocytosis, unifocal - - Langerhans cell sarcoma - - Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease - - Large cell (Ki-1+) lymphoma - - Large cell calcifying Sertoli cell tumor - - Large cell carcinoma with rhabdoid phenotype - - Large cell carcinoma, NOS - - Large cell medulloblastoma - - Large cell neuroendocrine carcinoma - - Large granular lymphocytosis, NOS - - LCIS, NOS - - Leiomyoblastoma - - Leiomyofibroma - - Leiomyoma, NOS - - Leiomyomatosis, NOS - - Lennert lymphoma - - Lentigo maligna - - Lentigo maligna melanoma - - Lepidic adenocarcinoma - - Lepidic predominant adenocarcinoma - - Leptomeningeal sarcoma - - Letterer-Siwe disease - - Leukemia, NOS - - Leukemic reticuloendotheliosis - - Leydig cell tumor, benign - - Leydig cell tumor, malignant - - Leydig cell tumor, NOS - - Linitis plastica - - Lipid cell tumor of ovary - - Lipid-rich carcinoma - - Lipid-rich Sertoli cell tumor - - Lipid-rich urothelial carcinoma - - Lipoadenoma - - Lipoblastoma - - Lipoblastomatosis - - Lipoid cell tumor of ovary - - Lipoleiomyoma - - Lipoma-like liposarcoma - - Lipoma, NOS - - Lipomatous medulloblastoma - - Liposarcoma, differentiated - - Liposarcoma, NOS - - Liposarcoma, well differentiated - - Liver cell adenoma - - Liver cell carcinoma - - Lobular adenocarcinoma - - Lobular and ductal carcinoma - - Lobular carcinoma in situ, NOS - - Lobular carcinoma, noninfiltrating - - Lobular carcinoma, NOS - - Localized fibrous tumor - - Low grade adenosquamous carcinoma - - Low grade appendiceal mucinous neoplasm - - Low grade cribriform cystadenocarcinoma (LGCCC) - - Low-grade central osteosarcoma - - Low-grade intramedullary osteosarcoma - - Low-grade myofibroblastic sarcoma - - Low-grade serous carcinoma - - Luteinoma - - Luteoma, NOS - - Lymphangioendothelial sarcoma - - Lymphangioendothelioma, malignant - - Lymphangioendothelioma, NOS - - Lymphangioleiomyomatosis - - Lymphangioma, NOS - - Lymphangiomyoma - - Lymphangiomyomatosis - - Lymphangiosarcoma - - Lymphatic leukemic, NOS - - Lymphoblastic leukemia, NOS - - Lymphoblastoma - - Lymphocytic leukemia, NOS - - Lymphoepithelial carcinoma - - Lymphoepithelioid lymphoma - - Lymphoepithelioma - - Lymphoepithelioma-like carcinoma - - Lymphoid leukemia, NOS - - Lymphomatoid granulomatosis - - Lymphomatoid papulosis - - Lymphoplasmacyte-rich meningioma - - Lymphoproliferative disease, NOS - - Lymphoproliferative disorder, NOS - - Lymphosarcoma cell leukemia - - Lymphosarcoma, diffuse - - Lymphosarcoma, NOS - - M6A - - M6B - - Macrofollicular adenoma - - Magnocellular nevus - - Malignancy - - Malignant chondroid syringoma - - Malignant cystic nephroma - - Malignant eccrine spiradenoma - - Malignant fibrous histiocytoma - - Malignant fibrous histiocytoma (MFH) of bone - - Malignant giant cell tumor of soft parts - - Malignant histiocytosis - - Malignant hydatidiform mole - - Malignant lymphoma, centroblastic, diffuse - - Malignant lymphoma, centroblastic, follicular - - Malignant lymphoma, centroblastic, NOS - - Malignant lymphoma, centroblasticcentrocytic, diffuse - - Malignant lymphoma, centroblasticcentrocytic, follicular - - Malignant lymphoma, centroblasticcentrocytic, NOS - - Malignant lymphoma, centrocytic - - Malignant lymphoma, cleaved cell, NOS - - Malignant lymphoma, convoluted cell - - Malignant lymphoma, diffuse, NOS - - Malignant lymphoma, follicle center, follicular - - Malignant lymphoma, follicle center, NOS - - Malignant lymphoma, follicular, NOS - - Malignant lymphoma, histiocytic, diffuse - - Malignant lymphoma, histiocytic, nodular - - Malignant lymphoma, histiocytic, NOS - - Malignant lymphoma, Hodgkin - - Malignant lymphoma, immunoblastic, NOS - - Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS - - Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS - - Malignant lymphoma, large B-cell, diffuse, NOS - - Malignant lymphoma, large B-cell, NOS - - Malignant lymphoma, large cell, cleaved and noncleaved - - Malignant lymphoma, large cell, cleaved, diffuse - - Malignant lymphoma, large cell, cleaved, NOS - - Malignant lymphoma, large cell, diffuse, NOS - - Malignant lymphoma, large cell, follicular, NOS - - Malignant lymphoma, large cell, immunoblastic - - Malignant lymphoma, large cell, noncleaved, diffuse - - Malignant lymphoma, large cell, noncleaved, follicular - - Malignant lymphoma, large cell, noncleaved, NOS - - Malignant lymphoma, large cell, NOS - - Malignant lymphoma, large cleaved cell, follicular - - Malignant lymphoma, large cleaved cell, NOS - - Malignant lymphoma, lymphoblastic, NOS - - Malignant lymphoma, lymphocytic, diffuse, NOS - - Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse - - Malignant lymphoma, lymphocytic, intermediate differentiation, nodular - - Malignant lymphoma, lymphocytic, nodular, NOS - - Malignant lymphoma, lymphocytic, NOS - - Malignant lymphoma, lymphocytic, poorly differentiated, diffuse - - Malignant lymphoma, lymphocytic, poorly differentiated, nodular - - Malignant lymphoma, lymphocytic, well differentiated, diffuse - - Malignant lymphoma, lymphocytic, well differentiated, nodular - - Malignant lymphoma, lymphoplasmacytic - - Malignant lymphoma, lymphoplasmacytoid - - Malignant lymphoma, mixed cell type, diffuse - - Malignant lymphoma, mixed cell type, follicular - - Malignant lymphoma, mixed cell type, nodular - - Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse - - Malignant lymphoma, mixed lymphocytic-histiocytic, nodular - - Malignant lymphoma, mixed small and large cell, diffuse - - Malignant lymphoma, mixed small cleaved and large cell, follicular - - Malignant lymphoma, nodular, NOS - - Malignant lymphoma, non-cleaved cell, NOS - - Malignant lymphoma, non-Hodgkin, NOS - - Malignant lymphoma, noncleaved cell, follicular, NOS - - Malignant lymphoma, noncleaved, diffuse, NOS - - Malignant lymphoma, noncleaved, NOS - - Malignant lymphoma, NOS - - Malignant lymphoma, plasmacytoid - - Malignant lymphoma, small B lymphocytic, NOS - - Malignant lymphoma, small cell diffuse - - Malignant lymphoma, small cell, noncleaved, diffuse - - Malignant lymphoma, small cell, NOS - - Malignant lymphoma, small cleaved cell, diffuse - - Malignant lymphoma, small cleaved cell, follicular - - Malignant lymphoma, small cleaved cell, NOS - - Malignant lymphoma, small lymphocytic, diffuse - - Malignant lymphoma, small lymphocytic, NOS - - Malignant lymphoma, small noncleaved, Burkitt type - - Malignant lymphoma, undifferentiated cell type, NOS - - Malignant lymphoma, undifferentiated cell, non-Burkitt - - Malignant lymphoma, undifferentiated, Burkitt type - - Malignant lymphomatous polyposis - - Malignant mast cell tumor - - Malignant mastocytoma - - Malignant mastocytosis - - Malignant melanoma in congenital melanocytic nevus - - Malignant melanoma in giant pigmented nevus - - Malignant melanoma in Hutchinson melanotic freckle - - Malignant melanoma in junctional nevus - - Malignant melanoma in precancerous melanosis - - Malignant melanoma, NOS - - Malignant melanoma, regressing - - Malignant midline reticulosis - - Malignant mucinous adenofibroma - - Malignant mucinous cystadenofibroma - - Malignant multilocular cystic nephroma - - Malignant myelosclerosis - - Malignant myoepithelioma - - Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation - - Malignant perivascular epithelial cell tumor - - Malignant reticulosis, NOS - - Malignant rhabdoid tumor - - Malignant schwannoma with rhabdomyoblastic differentiation - - Malignant schwannoma, NOS - - Malignant serous adenofibroma - - Malignant serous cystadenofibroma - - Malignant tenosynovial giant cell tumor - - Malignant teratoma, anaplastic - - Malignant teratoma, intermediate - - Malignant teratoma, trophoblastic - - Malignant teratoma, undifferentiated - - Malignant tumor, clear cell type - - Malignant tumor, fusiform cell type - - Malignant tumor, giant cell type - - Malignant tumor, small cell type - - Malignant tumor, spindle cell type - - MALT lymphoma - - Mammary carcinoma, in situ - - MANEC - - Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell) - - Mantle zone lymphoma - - Marginal zone B-cell lymphoma, NOS - - Marginal zone lymphoma, NOS - - Masculinovoblastoma - - Mast cell leukaemia - - Mast cell sarcoma - - Mast cell tumor, NOS - - Mastocytoma, NOS - - Matrical carcinoma - - Mature T ALL - - Mature T-cell lymphoma, NOS - - Mature teratoma - - Mediastinal (thymic) large B-cell lymphoma - - Mediterranean lymphoma - - Medullary adenocarcinoma - - Medullary carcinoma with amyloid stroma - - Medullary carcinoma with lymphoid stroma - - Medullary carcinoma, NOS - - Medullary osteosarcoma - - Medulloblastoma with extensive nodularity - - Medulloblastoma, group 3 - - Medulloblastoma, group 4 - - Medulloblastoma, non-WNT/non-SHH - - Medulloblastoma, NOS - - Medulloblastoma, SHH-activated and TP53-mutant - - Medulloblastoma, SHH-activated and TP53-wildtype - - Medulloblastoma, WNT-activated - - Medullocytoma - - Medulloepithelioma, benign - - Medulloepithelioma, NOS - - Medullomyoblastoma - - Megakaryocytic leukemia - - Megakaryocytic myelosclerosis - - Melanoameloblastoma - - Melanocytic nevus - - Melanocytoma, eyeball - - Melanocytoma, NOS - - Melanoma in situ - - Melanoma, malignant, of soft parts - - Melanoma, NOS - - Melanotic medulloblastoma - - Melanotic MPNST - - Melanotic neuroectodermal tumor - - Melanotic neurofibroma - - Melanotic progonoma - - Melanotic psammomatous MPNST - - Melanotic schwannoma - - Meningeal melanocytoma - - Meningeal melanoma - - Meningeal melanomatosis - - Meningeal sarcoma - - Meningeal sarcomatosis - - Meningioma, anaplastic - - Meningioma, malignant - - Meningioma, NOS - - Meningiomatosis, NOS - - Meningothelial meningioma - - Meningothelial sarcoma - - Merkel cell carcinoma - - Merkel cell tumor - - Mesenchymal chondrosarcoma - - Mesenchymal tumor, malignant - - Mesenchymoma, benign - - Mesenchymoma, malignant - - Mesenchymoma, NOS - - Mesenteric fibromatosis - - Mesoblastic nephroma - - Mesodermal mixed tumor - - Mesonephric adenocarcinoma - - Mesonephric adenoma - - Mesonephric tumor, NOS - - Mesonephroma, benign - - Mesonephroma, malignant - - Mesonephroma, NOS - - Mesothelial papilloma - - Mesothelioma, benign - - Mesothelioma, biphasic, malignant - - Mesothelioma, biphasic, NOS - - Mesothelioma, malignant - - Mesothelioma, NOS - - Metanephric adenoma - - Metaplastic carcinoma of no special type - - Metaplastic carcinoma with chondroid differentiation - - Metaplastic carcinoma with osseous differentiation - - Metaplastic carcinoma with other types mesenchymal differentiation - - Metaplastic carcinoma, NOS - - Metaplastic meningioma - - Metastasizing leiomyoma - - Metastatic signet ring cell carcinoma - - Metatypical carcinoma - - MGUS - - Microcystic adenoma - - Microcystic adnexal carcinoma - - Microcystic meningioma - - Microcystic urothelial carcinoma - - Microfollicular adenoma, NOS - - Microglioma - - Micropapillary adenocarcinoma - - Micropapillary carcinoma, NOS - - Micropapillary serous carcinoma - - Midline carcinoma of children and young adults with NUT rearrangement - - Minimally invasive adenocarcinoma, mucinous - - Minimally invasive adenocarcinoma, non-mucinous - - Minimally invasive adenocarcinoma, NOS - - MiT family translocation renal cell carcinoma - - Mixed acidophil-basophil adenoma - - Mixed acidophil-basophil carcinoma - - Mixed acinar-ductal carcinoma - - Mixed acinar-endocrine carcinoma - - Mixed acinar-endocrine-ductal carcinoma - - Mixed adenocarcinoma and epidermoid carcinoma - - Mixed adenocarcinoma and squamous cell carcinoma - - Mixed adenomatous and hyperplastic polyp - - Mixed adenoneuroendocrine carcinoma - - Mixed basal-squamous cell carcinoma - - Mixed carcinoid-adenocarcinoma - - Mixed cell adenocarcinoma - - Mixed cell adenoma - - Mixed ductal-endocrine carcinoma - - Mixed embryonal carcinoma and teratoma - - Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma - - Mixed endocrine and exocrine adenocarcinoma - - Mixed epithelioid and spindle cell melanoma - - Mixed germ cell sex cord-stromal tumor, unclassified - - Mixed germ cell tumor - - Mixed glioma - - Mixed hepatocellular and bile duct carcinoma - - Mixed invasive mucinous and non-mucinous adenocarcinoma - - Mixed islet cell and exocrine adenocarcinoma - - Mixed liposarcoma - - Mixed medullary-follicular carcinoma - - Mixed medullary-papillary carcinoma - - Mixed meningioma - - Mixed mesenchymal sarcoma - - Mixed mesenchymal tumor - - Mixed pancreatic endocrine and exocrine tumor, malignant - - Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1 - - Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged - - Mixed phenotype acute leukemia, B/myeloid, NOS - - Mixed phenotype acute leukemia, T/myeloid, NOS - - Mixed pineal tumor - - Mixed pineocytoma-pineoblastoma - - Mixed small cell carcinoma - - Mixed squamous cell and glandular papilloma - - Mixed subependymoma-ependymoma - - Mixed teratoma and seminoma - - Mixed tumor, malignant, NOS - - Mixed tumor, NOS - - Mixed tumor, salivary gland type, malignant - - Mixed tumor, salivary gland type, NOS - - Mixed type rhabdomyosarcoma - - Monoblastic leukemia, NOS - - Monoclonal gammopathy of undetermined significance - - Monoclonal gammopathy, NOS - - Monocytic leukemia, NOS - - Monocytoid B-cell lymphoma - - Monomorphic adenoma - - Monstrocellular sarcoma - - MPNST with glandular differentiation - - MPNST with mesenchymal differentiation - - MPNST with rhabdomyoblastic differentiation - - MPNST, NOS - - Mu heavy chain disease - - Mucin-producing adenocarcinoma - - Mucin-producing carcinoma - - Mucin-secreting adenocarcinoma - - Mucin-secreting carcinoma - - Mucinous adenocarcinofibroma - - Mucinous adenocarcinoma - - Mucinous adenocarcinoma, endocervical type - - Mucinous adenofibroma of borderline malignancy - - Mucinous adenofibroma, NOS - - Mucinous adenoma - - Mucinous carcinoid - - Mucinous carcinoma - - Mucinous carcinoma, gastric type - - Mucinous carcinoma, intestinal type - - Mucinous cystadenocarcinofibroma - - Mucinous cystadenocarcinoma, non-invasive - - Mucinous cystadenocarcinoma, NOS - - Mucinous cystadenofibroma of borderline malignancy - - Mucinous cystadenofibroma, NOS - - Mucinous cystadenoma, borderline malignancy - - Mucinous cystadenoma, NOS - - Mucinous cystic neoplasm with an associated invasive carcinoma - - Mucinous cystic neoplasm with high-grade dysplasia - - Mucinous cystic neoplasm with high-grade intraepithelial neoplasia - - Mucinous cystic neoplasm with intermediate-grade dysplasia - - Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia - - Mucinous cystic neoplasm with low-grade dysplasia - - Mucinous cystic neoplasm with low-grade intraepithelial neoplasia - - Mucinous cystic tumor of borderline malignancy - - Mucinous cystic tumor with an associated invasive carcinoma - - Mucinous cystic tumor with high-grade dysplasia - - Mucinous cystic tumor with intermediate dysplasia - - Mucinous cystic tumor with low grade dysplasia - - Mucinous cystic tumor with moderate dysplasia - - Mucinous cystoma - - Mucinous tubular and spindle cell carcinoma - - Mucinous tumor, NOS, of low malignant potential - - Mucocarcinoid tumor - - Mucoepidermoid tumor - - Mucoid adenocarcinoma - - Mucoid carcinoma - - Mucoid cell adenocarcinoma - - Mucoid cell adenoma - - Mucosal lentiginous melanoma - - Mucosal-associated lymphoid tissue lymphoma - - Mucous adenocarcinoma - - Mucous carcinoma - - Mullerian adenosarcoma - - Mullerian mixed tumor - - Multicentric basal cell carcinoma - - Multicystic mesothelioma, benign - - Multifocal superficial basal cell carcinoma - - Multiple adenomatous polyps - - Multiple endocrine adenomas - - Multiple hemorrhagic sarcoma - - Multiple meningiomas - - Multiple myeloma - - Multiple neurofibromatosis - - Mycosis fungoides - - Myelocytic leukemia, NOS - - Myelodysplastic syndrome with 5q deletion (5q-) syndrome - - Myelodysplastic syndrome with isolated del (5q) - - Myelodysplastic syndrome, NOS - - Myelodysplastic syndrome, unclassifiable - - Myelodysplastic/myeloproliferative neoplasm, unclassifiable - - Myelofibrosis as a result of myeloproliferative disease - - Myelofibrosis with myeloid metaplasia - - Myelogenous leukemia, NOS - - Myeloid and lymphoid neoplasms with FGFR1 abnormalities - - Myeloid and lymphoid neoplasms with PDGFRA rearrangement - - Myeloid leukemia, NOS - - Myeloid neoplasms with PDGFRB rearrangement - - Myeloid sarcoma - - Myelolipoma - - Myeloma, NOS - - Myelomatosis - - Myelomonocytic leukemia, NOS - - Myeloproliferative disease, NOS - - Myeloproliferative neoplasm, NOS - - Myelosclerosis with myeloid metaplasia - - Myloproliferative neoplasm, unclassifiable - - Myoepithelial adenoma - - Myoepithelial carcinoma - - Myoepithelial tumor - - Myoepithelioma - - Myofibroblastic sarcoma - - Myofibroblastic tumor, NOS - - Myofibroblastic tumor, peribronchial - - Myofibroblastoma - - Myofibromatosis - - Myoma - - Myosarcoma - - Myxofibroma, NOS - - Myxoid chondrosarcoma - - Myxoid fibroma - - Myxoid leiomyosarcoma - - Myxoid liposarcoma - - Myxoinflammatory fibroblastic sarcoma (MIFS) - - Myxolipoma - - Myxoliposarcoma - - Myxoma, NOS - - Myxopapillary ependymoma - - Myxosarcoma - - Neoplasm, benign - - Neoplasm, malignant - - Neoplasm, malignant, uncertain whether primary or metastatic - - Neoplasm, metastatic - - Neoplasm, NOS - - Neoplasm, secondary - - Neoplasm, uncertain whether benign or malignant - - Nephroblastoma, NOS - - Nephrogenic adenofibroma - - Nephroma, NOS - - Nerve sheath myxoma - - Nesidioblastoma - - Nested urothelial carcinoma - - Neurilemoma, malignant - - Neurilemoma, NOS - - Neurilemosarcoma - - Neurinoma - - Neurinomatosis - - Neuroastrocytoma - - Neuroblastoma, NOS - - Neuroectodermal tumor, NOS - - Neuroendocrine carcinoma, low grade - - Neuroendocrine carcinoma, moderately differentiated - - Neuroendocrine carcinoma, NOS - - Neuroendocrine carcinoma, poorly differentiated - - Neuroendocrine carcinoma, well-differentiated - - Neuroendocrine tumor, grade 1 - - Neuroendocrine tumor, grade 2 - - Neuroendocrine tumor, well differentiated - - Neuroepithelioma, NOS - - Neurofibroma, NOS - - Neurofibromatosis, NOS - - Neurofibrosarcoma - - Neurogenic sarcoma - - Neurolipocytoma + - Mucinous Carcinoma + - Myelodysplastic Syndrome, NOS + - Desmoplastic/Nodular Medulloblastoma + - Angiomatoid Fibrous Histiocytoma + - Gastrointestinal Stromal Tumor, NOS + - Neoplasm, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Small Cell Carcinoma, NOS + - Small Cell Neuroendocrine Carcinoma + - Secretory Carcinoma - Neuroma, NOS - - Neuronevus - - Neurosarcoma - - Neurothekeoma - - Neurotropic melanoma, malignant - - Nevus, NOS - - NK-cell large granular lymphocytic leukemia - - NK/T-cell lymphoma, nasal and nasal-type - - Nodal marginal zone lymphoma - - Nodular hidradenoma - - Nodular hidradenoma, malignant - - Nodular melanoma - - Non-Hodgkin lymphoma, NOS - - Non-invasive EFVPTC - - Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC) - - Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) - - Non-invasive FTP - - Non-invasive low grade serous carcinoma - - Non-invasive mammary carcinoma - - Non-lymphocytic leukemia, NOS - - Non-small cell carcinoma - - Nonchromaffin paraganglioma, malignant - - Nonchromaffin paraganglioma, NOS - - Nonencapsulated sclerosing adenocarcinoma - - Nonencapsulated sclerosing carcinoma - - Nonencapsulated sclerosing tumor - - Noninfiltrating intracystic carcinoma - - Noninfiltrating intraductal papillary adenocarcinoma - - Noninfiltrating intraductal papillary carcinoma - - Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia - - Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia - - Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia - - Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia - - Nonlipid reticuloendotheliosis - - Nonpigmented nevus - - NUT carcinoma - - NUT midline carcinoma - - Oat cell carcinoma - - Odontoameloblastoma - - Odontogenic carcinoma - - Odontogenic carcinosarcoma - - Odontogenic fibroma, NOS - - Odontogenic fibrosarcoma - - Odontogenic ghost cell tumor - - Odontogenic myxofibroma - - Odontogenic myxoma - - Odontogenic sarcoma - - Odontogenic tumor, benign - - Odontogenic tumor, malignant - - Odontogenic tumor, NOS - - Odontoma, NOS - - Olfactory neuroblastoma - - Olfactory neurocytoma - - Olfactory neuroepithelioma - - Olfactory neurogenic tumor - - Oligoastrocytoma - - Oligodendroblastoma - - Oligodendroglioma, anaplastic - - Oligodendroglioma, IDH-mutant and 1p/19q-codeleted - - Oligodendroglioma, NOS - - Oncocytic adenocarcinoma - - Oncocytic adenoma - - Oncocytic carcinoma - - Oncocytic Schneiderian papilloma - - Oncocytoma - - Orchioblastoma - - Ossifying fibroma - - Ossifying fibromyxoid tumor - - Ossifying fibromyxoid tumor, malignant - - Ossifying renal tumor - - Osteoblastic sarcoma - - Osteoblastoma, malignant - - Osteoblastoma, NOS - - Osteocartilaginous exostosis - - Osteochondroma - - Osteochondromatosis, NOS - - Osteochondrosarcoma - - Osteofibroma - - Osteofibrosarcoma - - Osteogenic sarcoma, NOS - - Osteoid osteoma, NOS - - Osteoma, NOS - - Osteosarcoma in Paget disease of bone - - Ovarian stromal tumor - - Oxyphilic adenocarcinoma - - Oxyphilic adenoma - - Pacinian tumor - - Paget disease and infiltrating duct carcinoma of breast - - Paget disease and intraductal carcinoma of breast - - Paget disease of breast - - Paget disease, extramammary - - Paget disease, mammary - - Pagetoid reticulosis - - Pancreatic endocrine tumor, benign - - Pancreatic endocrine tumor, malignant - - Pancreatic endocrine tumor, nonfunctioning - - Pancreatic endocrine tumor, NOS - - Pancreatic microadenoma - - Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor - - Pancreatobiliary neoplasm, non-invasive - - Pancreatobiliary-type carcinoma - - Pancreatoblastoma - - Papillary adenocarcinoma, follicular variant - - Papillary adenocarcinoma, NOS - - Papillary adenofibroma - - Papillary adenoma, NOS - - Papillary and follicular adenocarcinoma - - Papillary and follicular carcinoma - - Papillary carcinoma in situ - - Papillary carcinoma, columnar cell - - Papillary carcinoma, diffuse sclerosing - - Papillary carcinoma, encapsulated - - Papillary carcinoma, follicular variant - - Papillary carcinoma, NOS - - Papillary carcinoma, oxyphilic cell - - Papillary carcinoma, tall cell - - Papillary cystadenocarcinoma, NOS - - Papillary cystadenoma lymphomatosum - - Papillary cystadenoma, borderline malignancy - - Papillary cystadenoma, NOS - - Papillary cystic tumor - - Papillary ependymoma - - Papillary epidermoid carcinoma - - Papillary glioneuronal tumor - - Papillary hidradenoma - - Papillary meningioma - - Papillary microcarcinoma - - Papillary mucinous cystadenocarcinoma - - Papillary mucinous cystadenoma, borderline malignancy - - Papillary mucinous cystadenoma, NOS - - Papillary mucinous tumor of low malignant potential - - Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia - - Papillary pseudomucinous cystadenocarcinoma - - Papillary pseudomucinous cystadenoma, borderline malignancy - - Papillary pseudomucinous cystadenoma, NOS - - Papillary renal cell carcinoma - - Papillary serous adenocarcinoma - - Papillary serous cystadenocarcinoma - - Papillary serous cystadenoma, borderline malignancy - - Papillary serous cystadenoma, NOS - - Papillary serous tumor of low malignant potential - - Papillary squamous cell carcinoma - - Papillary squamous cell carcinoma in situ - - Papillary squamous cell carcinoma, non-invasive - - Papillary syringadenoma - - Papillary syringocystadenoma - - Papillary transitional cell carcinoma - - Papillary transitional cell carcinoma, non-invasive - - Papillary transitional cell neoplasm of low malignant potential - - Papillary tumor of the pineal region - - Papillary urothelial carcinoma - - Papillary urothelial carcinoma, non-invasive - - Papillary urothelial neoplasm of low malignant potential - - Papillocystic adenocarcinoma - - Papilloma of bladder - - Papilloma, NOS - - Papillomatosis, glandular - - Papillomatosis, NOS - - Papillotubular adenocarcinoma - - Papillotubular adenoma - - Parachordoma - - Parafollicular cell carcinoma - - Paraganglioma, benign - - Paraganglioma, malignant - - Paraganglioma, NOS - - Parasympathetic paraganglioma - - Parietal cell adenocarcinoma - - Parietal cell carcinoma - - Parosteal osteosarcoma - - Partial hydatidiform mole - - PEComa, malignant - - Periapical cemental dysplasia - - Periapical cemento-osseous dysplasia - - Pericanalicular fibroadenoma - - Periductal stromal tumor, low grade - - Perifollicular fibroma - - Perineural MPNST - - Perineurioma, malignant - - Perineurioma, NOS - - Periosteal chondroma - - Periosteal chondrosarcoma - - Periosteal fibroma - - Periosteal fibrosarcoma - - Periosteal sarcoma, NOS - - Peripheral neuroectodermal tumor - - Peripheral odontogenic fibroma - - Peripheral primitive neuroectodermal tumor, NOS - - Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia) - - Peripheral T-cell lymphoma, large cell - - Peripheral T-cell lymphoma, NOS - - Peripheral T-cell lymphoma, pleomorphic medium and large cell - - Peripheral T-cell lymphoma, pleomorphic small cell - - Perivascular epithelioid cell tumor, malignant - - Pheochromoblastoma - - Pheochromocytoma, malignant - - Pheochromocytoma, NOS - - Phosphaturic mesenchymal tumor, malignant - - Phyllodes tumor, benign - - Phyllodes tumor, borderline - - Phyllodes tumor, malignant - - Phyllodes tumor, NOS - - Pick tubular adenoma - - Pigmented adenoma - - Pigmented basal cell carcinoma - - Pigmented dermatofibrosarcoma protuberans - - Pigmented nevus, NOS - - Pigmented schwannoma - - Pigmented spindle cell nevus of Reed - - Pilar tumor - - Pilocytic astrocytoma - - Piloid astrocytoma - - Pilomatricoma, malignant - - Pilomatricoma, NOS - - Pilomatrix carcinoma - - Pilomatrixoma, malignant - - Pilomatrixoma, NOS - - Pilomyxoid astrocytoma - - PIN III - - Pindborg tumor - - Pineal parenchymal tumor of intermediate differentiation - - Pinealoma - - Pineocytoma - - Pinkus tumor - - Pituicytoma - - Pituitary adenoma, NOS - - Pituitary carcinoma, NOS - - Placental site trophoblastic tumor - - Plasma cell leukemia - - Plasma cell myeloma - - Plasma cell tumor - - Plasmablastic lymphoma - - Plasmacytic leukemia - - Plasmacytic lymphoma - - Plasmacytoma of bone - - Plasmacytoma, extramedullary - - Plasmacytoma, NOS - - Pleomorphic adenoma - - Pleomorphic carcinoma - - Pleomorphic cell sarcoma - - Pleomorphic leiomyoma - - Pleomorphic lipoma - - Pleomorphic liposarcoma - - Pleomorphic lobular carcinoma - - Pleomorphic lobular carcinoma in situ - - Pleomorphic rhabdomyosarcoma, adult type - - Pleomorphic rhabdomyosarcoma, NOS - - Pleomorphic xanthoastrocytoma - - Pleuropulmonary blastoma - - Plexiform fibrohistiocytic tumor - - Plexiform fibromyxoma - - Plexiform hemangioma - - Plexiform leiomyoma - - Plexiform neurofibroma - - Plexiform neuroma - - Plexiform schwannoma - - PNET, NOS - - Pneumoblastoma - - Polar spongioblastoma - - Polycythemia rubra vera - - Polycythemia vera - - Polyembryoma - - Polygonal cell carcinoma - - Polymorphic post transplant lymphoproliferative disorder - - Polymorphic reticulosis - - Polymorphous low grade adenocarcinoma - - Polypoid adenoma - - Polyvesicular vitelline tumor - - Poorly cohesive carcinoma - - Porocarcinoma - - Post transplant lymphoproliferative disorder, NOS - - PP/PYY producing tumor - - PPNET - - Pre-B ALL - - Pre-pre-B ALL - - Pre-T ALL - - Precancerous melanosis, NOS - - Precursor B-cell lymphoblastic leukemia - - Precursor B-cell lymphoblastic lymphoma - - Precursor cell lymphoblastic leukemia, NOS - - Precursor cell lymphoblastic leukemia, not phenotyped - - Precursor cell lymphoblastic lymphoma, NOS - - Precursor T-cell lymphoblastic leukemia - - Precursor T-cell lymphoblastic lymphoma - - Preleukemia - - Preleukemic syndrome - - Primary amyloidosis - - Primary cutaneous anaplastic large cell lymphoma - - Primary cutaneous CD30+ large T-cell lymphoma - - Primary cutaneous CD30+ T-cell lymphoproliferative disorder - - Primary cutaneous CD4-positive small/medium T-cell lymphoma - - Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma - - Primary cutaneous DLBCL, leg type - - Primary cutaneous follicle centre lymphoma - - Primary cutaneous gamma-delta T-cell lymphoma - - Primary cutaneous neuroendocrine carcinoma - - Primary diffuse large B-cell lymphoma of the CNS - - Primary effusion lymphoma - - Primary intraosseous carcinoma - - Primary myelofibrosis - - Primary serous papillary carcinoma of peritoneum - - Primitive neuroectodermal tumor, NOS - - Primitive polar spongioblastoma - - Pro-B ALL - - Pro-T ALL - - Prolactinoma - - Proliferating trichilemmal cyst - - Proliferating trichilemmal tumor - - Proliferative dermal lesion in congenital nevus - - Proliferative polycythemia - - Prolymphocytic leukemia, B-cell type - - Prolymphocytic leukemia, NOS - - Prolymphocytic leukemia, T-cell type - - Prostatic intraepithelial neoplasia, grade III - - Protoplasmic astrocytoma - - Psammomatous meningioma - - Psammomatous schwannoma - - Pseudomucinous adenocarcinoma - - Pseudomucinous cystadenocarcinoma, NOS - - Pseudomucinous cystadenoma, borderline malignancy - - Pseudomucinous cystadenoma, NOS - - Pseudomyxoma peritonei - - Pseudomyxoma peritonei with unknown primary site - - Pseudosarcomatous carcinoma - - PTLD, NOS - - Pulmonary adenomatosis - - Pulmonary artery intimal sarcoma - - Pulmonary blastoma - - Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation - - Queyrat erythroplasia - - Racemose hemangioma - - RAEB - - RAEB I - - RAEB II - - RAEB-T - - RARS - - Rathke pouch tumor - - Recklinghausen disease - - Refractory anemia - - Refractory anemia with excess blasts - - Refractory anemia with excess blasts in transformation - - Refractory anemia with ring sideroblasts associated with marked thrombocytosis - - Refractory anemia with ringed sideroblasts - - Refractory anemia with sideroblasts - - Refractory anemia without sideroblasts - - Refractory cytopenia of childhood - - Refractory cytopenia with multilineage dysplasia - - Refractory neutropenia - - Refractory thrombocytopenia - - Regressing nevus - - Renal carcinoma, collecting duct type - - Renal cell adenocarcinoma - - Renal cell carcinoma, chromophobe type - - Renal cell carcinoma, sarcomatoid - - Renal cell carcinoma, spindle cell - - Renal cell carcinoma, unclassified - - Reninoma - - Renomedullary fibroma - - Renomedullary interstitial cell tumor - - Reserve cell carcinoma - - Reticulohistiocytoma - - Reticulosarcoma, diffuse - - Reticulosarcoma, NOS - - Reticulum cell sarcoma, diffuse - - Reticulum cell sarcoma, NOS - - Retinal anlage tumor - - Retinoblastoma, differentiated - - Retinoblastoma, diffuse - - Retinoblastoma, NOS - - Retinoblastoma, spontaneously regressed - - Retinoblastoma, undifferentiated - - Retinocytoma - - Retroperitoneal fibromatosis - - Rhabdoid meningioma - - Rhabdoid sarcoma - - Rhabdoid tumor, NOS - - Rhabdomyoma, NOS - - Rhabdomyosarcoma with ganglionic differentiation - - Rhabdomyosarcoma, NOS - - Rhabdosarcoma - - Rodent ulcer - - Rosette-forming glioneuronal tumor - - Round cell carcinoma - - Round cell liposarcoma - - Round cell osteosarcoma - - Round cell sarcoma - - Salivary duct carcinoma - - SALT lymphoma - - Sarcoma botryoides - - Sarcoma, NOS - - Sarcomatoid carcinoma - - Sarcomatoid mesothelioma - - Sarcomatosis, NOS - - Schmincke tumor - - Schneiderian carcinoma - - Schneiderian papilloma, inverted - - Schneiderian papilloma, NOS - - Schwannoma, NOS - - Scirrhous adenocarcinoma - - Scirrhous carcinoma - - Sclerosing epithelioid fibrosarcoma - - Sclerosing hemangioma - - Sclerosing hepatic carcinoma - - Sclerosing liposarcoma - - Sclerosing rhabdomyosarcoma - - Sclerosing stromal tumor - - Sclerosing sweat duct carcinoma - - Sebaceous adenocarcinoma - - Sebaceous adenoma - - Sebaceous carcinoma - - Sebaceous epithelioma - - Secondary carcinoma - - Secretory carcinoma of breast - - Secretory meningioma - - Seminoma with high mitotic index - - Seminoma, anaplastic - - Seminoma, NOS - - Seromucinous carcinoma - - Serotonin producing carcinoid - - Serous adenocarcinofibroma - - Serous adenocarcinoma, NOS - - Serous adenofibroma of borderline malignancy - - Serous adenofibroma, NOS - - Serous borderline tumor-micropapillary variant - - Serous carcinoma, NOS - - Serous cystadenocarcinofibroma - - Serous cystadenocarcinoma, NOS - - Serous cystadenofibroma of borderline malignancy - - Serous cystadenofibroma, NOS - - Serous cystadenoma, borderline malignancy - - Serous cystadenoma, NOS - - Serous cystoma - - Serous endometrial intraepithelial carcinoma - - Serous microcystic adenoma - - Serous papillary cystic tumor of borderline malignancy - - Serous surface papillary carcinoma - - Serous surface papillary tumor of borderline malignancy - - Serous surface papilloma - - Serous tubal intraepithelial carcinoma - - Serous tumor, NOS, of low malignant potential - - Serrated adenocarcinoma - - Serrated adenoma - - Sertoli cell adenoma - - Sertoli cell carcinoma - - Sertoli cell tumor with lipid storage - - Sertoli cell tumor, NOS - - Sertoli-Leydig cell tumor of intermediate differentiation - - Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements - - Sertoli-Leydig cell tumor, NOS - - Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements - - Sertoli-Leydig cell tumor, retiform - - Sertoli-Leydig cell tumor, retiform, with heterologous elements - - Sertoli-Leydig cell tumor, sarcomatoid - - Sertoli-Leydig cell tumor, well differentiated - - Sessile serrated adenoma - - Sessile serrated polyp - - SETTLE - - Sex cord tumor with annular tubules - - Sex cord tumor, NOS - - Sex cord-gonadal stromal tumor, incompletely differentiated - - Sex cord-gonadal stromal tumor, mixed forms - - Sex cord-gonadal stromal tumor, NOS - - Sezary disease - - Sezary syndrome - - Sialoblastoma - - Signet ring cell adenocarcinoma - - Signet ring cell carcinoma - - Sinonasal papilloma, exophytic - - Sinonasal papilloma, fungiform - - Sinonasal papilloma, NOS - - Skin appendage adenoma - - Skin appendage carcinoma - - Skin appendage tumor, benign - - Skin-associated lymphoid tissue lymphoma - - Small cell carcinoma pulmonary type - - Small cell carcinoma, fusiform cell - - Small cell carcinoma, hypercalcemic type - - Small cell carcinoma, intermediate cell - - Small cell carcinoma, NOS - - Small cell neuroendocrine carcinoma - - Small cell osteosarcoma - - Small cell sarcoma - - Small congenital nevus - - Smooth muscle tumor of uncertain malignant potential - - Smooth muscle tumor, NOS - - Soft tissue perineurioma - - Soft tissue sarcoma - - Soft tissue tumor, benign - - Soft tissue tumor, malignant - - Solid adenocarcinoma with mucin formation - - Solid and cystic tumor - - Solid and papillary epithelial neoplasm - - Solid carcinoma with mucin formation - - Solid carcinoma, NOS - - Solid papillary carcinoma in situ - - Solid papillary carcinoma with invasion - - Solid pseudopapillary carcinoma - - Solid pseudopapillary tumor - - Solid teratoma - - Solitary fibrous tumor - - Solitary fibrous tumor, malignant - - Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS) - - Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS) - - Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS) - - Solitary mastocytoma of skin - - Solitary myeloma - - Solitary plasmacytoma - - Somatostatin cell tumor, malignant - - Somatostatin cell tumor, NOS - - Somatostatinoma, malignant - - Somatostatinoma, NOS - - Spermatocytic seminoma - - Spermatocytoma - - Spindle cell angioendothelioma - - Spindle cell carcinoma, NOS - - Spindle cell hemangioendothelioma - - Spindle cell lipoma - - Spindle cell melanoma, NOS - - Spindle cell melanoma, type A - - Spindle cell melanoma, type B - - Spindle cell nevus, NOS - - Spindle cell oncocytoma - - Spindle cell rhabdomyosarcoma - - Spindle cell sarcoma - - Spindle epithelial tumor with thymus-like differentiation - - Spindle epithelial tumor with thymus-like element - - Spindled mesothelioma - - Spiradenoma, NOS - - Spitz nevus - - Splenic B-cell lymphoma/leukemia, unclassifiable - - Splenic diffuse red pulp small B-cell lymphoma - - Splenic lymphoma with villous lymphocytes - - Splenic marginal zone B-cell lymphoma - - Splenic marginal zone lymphoma, NOS - - Spongioblastoma multiforme - - Spongioblastoma polare - - Spongioblastoma, NOS - - Spongioneuroblastoma - - Squamotransitional cell carcinoma - - Squamous carcinoma - - Squamous cell carcinoma in situ with questionable stromal invasion - - Squamous cell carcinoma in situ, NOS - - Squamous cell carcinoma with horn formation - - Squamous cell carcinoma, acantholytic - - Squamous cell carcinoma, adenoid - - Squamous cell carcinoma, clear cell type - - Squamous cell carcinoma, HPV-negative - - Squamous cell carcinoma, HPV-positive - - Squamous cell carcinoma, keratinizing, NOS - - Squamous cell carcinoma, large cell, keratinizing - - Squamous cell carcinoma, large cell, nonkeratinizing, NOS - - Squamous cell carcinoma, metastatic, NOS - - Squamous cell carcinoma, microinvasive - - Squamous cell carcinoma, nonkeratinizing, NOS - - Squamous cell carcinoma, NOS - - Squamous cell carcinoma, pseudoglandular - - Squamous cell carcinoma, sarcomatoid - - Squamous cell carcinoma, small cell, nonkeratinizing - - Squamous cell carcinoma, spindle cell - - Squamous cell epithelioma - - Squamous cell papilloma, inverted - - Squamous cell papilloma, NOS - - Squamous intraepithelial neoplasia, grade I - - Squamous intraepithelial neoplasia, grade II - - Squamous intraepithelial neoplasia, grade III - - Squamous intraepithelial neoplasia, high grade - - Squamous intraepithelial neoplasia, low grade - - Squamous odontogenic tumor - - Squamous papilloma - - Squamous papillomatosis - - Stem cell leukemia - - Steroid cell tumor, malignant - - Steroid cell tumor, NOS - - Stromal endometriosis - - Stromal myosis, NOS - - Stromal sarcoma, NOS - - Stromal tumor with minor sex cord elements - - Stromal tumor, benign - - Stromal tumor, NOS - - Struma ovarii and carcinoid - - Struma ovarii, malignant - - Struma ovarii, NOS - - Strumal carcinoid - - Subacute granulocytic leukemia - - Subacute leukemia, NOS - - Subacute lymphatic leukemia - - Subacute lymphocytic leukemia - - Subacute lymphoid leukemia - - Subacute monocytic leukemia - - Subacute myelogenous leukemia - - Subacute myeloid leukemia - - Subareolar duct papillomatosis - - Subcutaneous panniculitis-like T-cell lymphoma - - Subependymal astrocytoma, NOS - - Subependymal giant cell astrocytoma - - Subependymal glioma - - Subependymoma - - Subepidermal nodular fibrosis - - Superficial spreading adenocarcinoma - - Superficial spreading melanoma - - Superficial well differentiated liposarcoma - - Supratentorial PNET - - Sweat gland adenocarcinoma - - Sweat gland adenoma - - Sweat gland carcinoma - - Sweat gland tumor, benign - - Sweat gland tumor, malignant - - Sweat gland tumor, NOS - - Sympathetic paraganglioma - - Sympathicoblastoma - - Symplastic leiomyoma - - Syncytial meningioma - - Synovial sarcoma, biphasic - - Synovial sarcoma, epithelioid cell - - Synovial sarcoma, monophasic fibrous - - Synovial sarcoma, spindle cell - - Synovioma, benign - - Synovioma, malignant - - Synovioma, NOS - - Syringadenoma, NOS - - Syringocystadenoma papilliferum - - Syringofibroadenoma - - Syringoma, NOS - - Syringomatous carcinoma - - Systemic EBV positive T-cell lymphoproliferative disease of childhood - - Systemic light chain disease - - Systemic mastocytosis with AHNMD - - Systemic mastocytosis with associated hematological clonal non-mast cell disorder - - Systemic tissue mast cell disease - - T lymphoblastic leukemia/lymphoma - - T-cell large granular lymphocytic leukemia - - T-cell large granular lymphocytosis - - T-cell lymphoma, NOS - - T-cell rich large B-cell lymphoma - - T-cell rich/histiocyte-rich large B-cell lymphoma - - T-gamma lymphoproliferative disease - - T-zone lymphoma - - T/NK-cell lymphoma - - Tanycytic ependymoma - - Tenosynovial giant cell tumor - - Teratoblastoma, malignant + - Ependymoma, Anaplastic + - Myxopapillary Ependymoma (CNS WHO Grade II) + - Nodular Melanoma + - Transient Abnormal Myelopoiesis + - Choriocarcinoma, NOS + - Choroid Plexus Papilloma, NOS, Other CNS Embryonal Tumors, Pineoblastoma + - Desmoplastic/Nodular Medulloblastoma (Histologically Defined), CNS WHO Grade 4 + - Histologically Low-Grade Glioma + - Infiltrating Duct And Lobular Carcinoma + - Juvenile Granulosa Cell Tumor + - Astrocytoma, NOS, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Central Neurocytoma, Glioneuronal And Neuronal Tumors + - Giant Cell Tumor Of Bone, Malignant + - High Grade Carcinosarcoma + - Malignant Neoplasm With Rhabdomyoblastic Differentiation, High Grade + - Glioma, Malignant, Diffuse Hemispheric Glioma, H3 G34-Mutant, High-Grade Glioma + - Glioblastoma Multiforme + - Acute Myeloid Leukemia, NOS, Juvenile Myelomonocytic Leukemia, NOS + - Glial Neoplasm Showing High-Grade Features + - Sertoli-Leydig Cell Tumor Of Intermediate Differentiation, NOS + - Glioma, Malignant, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Chronic Myeloid Leukemia, NOS + - Lung Adenocarcinoma, NOS + - Acute Myeloid Leukemia, T(16;16)(P 13;Q 11) + - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Subcutaneous Panniculitis-Like T-Cell Lymphoma + - Chondrosarcoma, NOS + - Non-Germinomatous Germ Cell Tumor + - Dysembryoplastic Neuroepithelial Tumor, Angiocentric Glioma, Low-Grade Glioma + - Neuroepithelial Tumor + - Serous Carcinoma, NOS + - CNS Embryonal Tumor, NOS, CNS Embryonal Tumor, NOS Or NEC, Other CNS Embryonal Tumors + - Sertoli-Leydig Cell Tumor, Poorly Differentiated + - Solid Pseudopapillary Tumor Of Ovary + - Rhabdomyosarcoma + - Astrocytoma, NOS, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Extra Adrenal Paraganglioma + - Melanoma In Situ + - Tumor Cells, Malignant, Other, Pineal Parenchymal Tumor Of Intermediate Differentiation + - Glioma, Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Pituitary Adenoma, NOS + - Neoplasm, Uncertain Whether Benign Or Malignant, CNS Germ Cell Tumors, CNS Germinoma + - Basaloid Squamous Cell Carcinoma + - Embryonal Carcinoma, NOS + - Mixed Germ Cell Tumor + - Sertoli Cell Tumor, NOS + - Tumor Cells, Benign + - Pineoblastoma, CNS Germ Cell Tumors, CNS Germinoma + - Periosteal Osteosarcoma + - Lobular And Ductal Carcinoma + - Carcinosarcoma NOS + - Unknown + - Thymic Carcinoma, NOS + - Pleomorphic Rhabdomyosarcoma, Adult Type + - Papillary Transitional Cell Carcinoma + - Ependymoma, NOS, Posterior Fossa Ependymoma, Group PFA + - Ependymoma, NOS, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Malignant Rhabdoid Tumor + - Medulloblastoma, NOS, Medulloblastoma, WNT-Activated + - Tumor Cells, Malignant, Medulloblastoma, Medulloblastoma, NOS Or NEC + - Ganglioneuroma, Other, Schwannoma + - Lymphangioma, NOS + - Neoplasm, Malignant, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation + - Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, Group 4 + - Glioblastoma, NOS, High-Grade Glioma, High-Grade Glioma, NOS Or NEC + - Lymphoma, NOS + - Precursor B-Cell Lymphoblastic Leukemia + - Inflammatory Carcinoma + - Neoplasm, Malignant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype And IDH-Wildtype, High-Grade Glioma + - Solid Pseudopapillary Neoplasm Of Pancreas + - Squamous Cell Carcinoma, NOS - Teratocarcinoma - - Teratoid medulloepithelioma - - Teratoid medulloepithelioma, benign - - Teratoma with malignant transformation - - Teratoma, benign - - Teratoma, differentiated - - Teratoma, NOS - - Terminal duct adenocarcinoma - - Testicular adenoma - - Testicular stromal tumor - - Theca cell tumor - - Theca cell-granulosa cell tumor - - Thecoma, luteinized - - Thecoma, malignant - - Thecoma, NOS - - Therapy related myeloid neoplasm - - Therapy-related acute myeloid leukemia, alkylating agent related - - Therapy-related acute myeloid leukemia, epipodophyllotoxin-related - - Therapy-related acute myeloid leukemia, NOS - - Therapy-related myelodysplastic syndrome, alkylating agent related - - Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related - - Therapy-related myelodysplastic syndrome, NOS - - Thymic carcinoma with adenoid cystic carcinoma-like features - - Thymic carcinoma, NOS - - Thymic large B-cell lymphoma - - Thymoma, atypical, malignant - - Thymoma, atypical, NOS - - Thymoma, benign - - Thymoma, cortical, malignant - - Thymoma, cortical, NOS - - Thymoma, epithelial, malignant - - Thymoma, epithelial, NOS - - Thymoma, lymphocyte-rich, malignant - - Thymoma, lymphocyte-rich, NOS - - Thymoma, lymphocytic, malignant - - Thymoma, lymphocytic, NOS - - Thymoma, malignant, NOS - - Thymoma, medullary, malignant - - Thymoma, medullary, NOS - - Thymoma, mixed type, malignant - - Thymoma, mixed type, NOS - - Thymoma, NOS - - Thymoma, organoid, malignant - - Thymoma, organoid, NOS - - Thymoma, predominantly cortical, malignant - - Thymoma, predominantly cortical, NOS - - Thymoma, spindle cell, malignant - - Thymoma, spindle cell, NOS - - Thymoma, type A, malignant - - Thymoma, type A, NOS - - Thymoma, type AB, malignant - - Thymoma, type AB, NOS - - Thymoma, type B1, malignant - - Thymoma, type B1, NOS - - Thymoma, type B2, malignant - - Thymoma, type B2, NOS - - Thymoma, type B3, malignant - - Thymoma, type B3, NOS - - Thymoma, type C - - Tibial adamantinoma - - Trabecular adenocarcinoma - - Trabecular adenoma - - Trabecular carcinoma - - Traditional serrated adenoma - - Traditional sessile serrated adenoma - - Transient abnormal myelopoiesis - - Transitional carcinoma - - Transitional cell carcinoma - - Transitional cell carcinoma in situ - - Transitional cell carcinoma, micropapillary - - Transitional cell carcinoma, sarcomatoid - - Transitional cell carcinoma, spindle cell - - Transitional cell papilloma, benign - - Transitional cell papilloma, inverted, benign - - Transitional cell papilloma, inverted, NOS - - Transitional cell papilloma, NOS - - Transitional meningioma - - Transitional papilloma - - Transitional papilloma, inverted, benign - - Transitional papilloma, inverted, NOS - - Transitional pineal tumor - - Trichilemmal carcinoma - - Trichilemmocarcinoma - - Trichilemmoma - - Trichodiscoma - - Trichoepithelioma - - Trichofolliculoma - - Triton tumor, malignant - - Trophoblastic tumor, epithelioid - - True histiocytic lymphoma - - Tubular adenocarcinoma - - Tubular adenoma, NOS - - Tubular androblastoma with lipid storage - - Tubular androblastoma, NOS - - Tubular carcinoid - - Tubular carcinoma - - Tubulo-papillary adenoma - - Tubulocystic renal cell carcinoma - - Tubulolobular carcinoma - - Tubulopapillary adenocarcinoma - - Tubulovillous adenoma, NOS - - Tumor cells, benign - - Tumor cells, malignant - - Tumor cells, NOS - - Tumor cells, uncertain whether benign or malignant - - Tumor embolus - - Tumor, benign - - Tumor, malignant, NOS - - Tumor, metastatic - - Tumor, NOS - - Tumor, secondary - - Tumorlet, benign - - Tumorlet, NOS - - Turban tumor - - Typical carcinoid - - Unclassified tumor, benign - - Unclassified tumor, borderline malignancy - - Unclassified tumor, malignant - - Unclassified tumor, malignant, uncertain whether primary or metastatic - - Unclassified tumor, uncertain whether benign or malignant - - Undifferentiated epithelioid sarcoma - - Undifferentiated high-grade pleomorphic sarcoma - - Undifferentiated pleomorphic sarcoma - - Undifferentiated round cell sarcoma - - Undifferentiated spindle cell sarcoma - - Undifferentiated uterine sarcoma - - Urachal carcinoma - - Urothelial carcinoma in situ - - Urothelial carcinoma with divergent differentiation - - Urothelial carcinoma with squamous differentiation - - Urothelial carcinoma with trophoblastic differentiation - - Urothelial carcinoma, NOS - - Urothelial papilloma, NOS - - Urticaria pigmentosa - - Vaginal intraepithelial neoplasia, grade III - - VAIN III - - Vascular leiomyoma - - Venous hemangioma - - Verrucous carcinoma, NOS - - Verrucous epidermoid carcinoma - - Verrucous keratotic hemangioma - - Verrucous papilloma - - Verrucous squamous cell carcinoma - - Villoglandular adenoma - - Villoglandular carcinoma - - Villous adenocarcinoma - - Villous adenoma, NOS - - Villous papilloma - - VIN III - - Vipoma, malignant - - Vipoma, NOS - - Von Recklinghausen disease - - Vulvar intraepithelial neoplasia, grade III - - Waldenstrom macroglobulinemia - - Warthin tumor - - Warty carcinoma - - Water-clear cell adenocarcinoma - - Water-clear cell adenoma - - Water-clear cell carcinoma - - Well differentiated liposarcoma of superficial soft tissue - - Well differentiated papillary mesothelioma, benign - - Well differentiated thymic carcinoma - - Wilms tumor - - Wolffian duct adenoma - - Wolffian duct carcinoma - - Wolffian duct tumor - - Xanthofibroma - - Yolk sac tumor - - 'Source Data Not Available ' + - Papillary Urothelial Carcinoma, Non-Invasive + - Meningioangiomatosis + - High-Grade Neuroepithelial Tumor + - Mixed Germ Cell Tumor, CNS Germ Cell Tumors, CNS Germinoma + - Neoplasm, Benign + - Atypical Teratoid-Rhabdoid Tumor, CNS WHO Grade 4 + - Acute Myelomonocytic Leukemia, NOS + - Subependymoma + - Rhabdomyosarcoma, Embryonal Subtype Is Favored + - Schawannoma + - Therapy-Related Myeloid Neoplasms + - Papillary Carcinoma, NOS + - Infantile Fibrosarcoma + - Sertoli Leydig Cell Tumor + - Central Primitive Neuroectodermal Tumor + - Medulloblastoma, Group 3 Subtype (WHO Grade 4) + - Choroid Plexus Carcinoma, WHO Grade 3 + - Papillary Carcinoma, Columnar Cell + - Yolk Sac Tumor, NOS, CNS Germ Cell Tumors, CNS Non-Germinomatous Germ Cell Tumor + - Ependymoma WHO Grade 3 + - Neuroepithelial Tumor With Glioneuronal-Like Features + - Sex Cord Stromal Tumor NOS + - Sex Cord-Gonadal Stromal Tumor, NOS + - Spindle Cell Sarcoma + - Acral Lentiginous Melanoma, Malignant + - Chondroid Chordoma + - Unknown, To Be Completed Later, Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH + - Glioblastoma, NOS + - Embryonal Tumor + - Paratesticular Rhabdomyosarcoma With Diffuse Anaplasia + - Olfactory Neurocytoma + - Astrocytoma, Benign + - Mixed Germ Cell Tumor, Myelodysplastic Syndrome With Excess Blasts + - Large Cell Medulloblastoma + - Adenocarcinoma In Situ, Non-Mucinous + - Rasmussen Encephalitis + - Acute Myeloid Leukemia, NOS, Myeloproliferative Neoplasm, Unclassifiable + - Epithelioid Cell Melanoma + - Craniopharyngioma, NOS, Adamantinomatous Craniopharyngioma + - Giant Cell Tumor Of Soft Parts, NOS + - Undifferentiated Leukaemia + - Neoplasm, Uncertain Whether Benign Or Malignant, Dysembryoplastic Neuroepithelial Tumor, Glioneuronal And Neuronal Tumors + - Follicular Carcinoma, Minimally Invasive + - Spindled And Epithelioid Tumor With Features Of Intracranial Mesenchymal Tumor + - Infiltrating Duct And Mucinous Carcinoma + - Cutaneous T-Cell Lymphoma, NOS + - Clear Cell Adenocarcinoma, NOS + - Diffuse Midline Glioma, H3 K27 Altered, WHO Grade 4 + - Metastatic Signet Ring Cell Carcinoma + - Micropapillary Carcinoma, NOS + - Subependymal Giant Cell Astrocytoma, Glioneuronal And Neuronal Tumors, Glioneuronal And Neuronal Tumors, NOS Or NEC + - Desmoplastic Small Round Cell Tumor + - Mixed Phenotype Acute Leukemia With T(V;11q23); MLL Rearranged + - B Lymphoblastic Leukemia/Lymphoma With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1) + - Dysembryoplastic Neuroepithelial Tumor, Low-Grade Glioma, Low-Grade Glioma, NOS Or NEC + - Glioma, Malignant + - Proliferative Dermal Lesion In Congenital Nevus + - Pinealoma + - Transitional Cell Carcinoma + - Adenosarcoma + - Medulloblastoma, NOS, Medulloblastoma, Group 4 + - B Lymphoblastic Leukemia/Lymphoma With T(12;21)(P13;Q22); TEL-AML1 (ETV6-RUNX1) + - Meningothelial Meningioma, Meningioma, Other + - Germinoma, CNS Germ Cell Tumors, CNS Germinoma + - Leiomyosarcoma, NOS + - Low Grade Glial Neoplasm + - Adamantinomatous Craniopharyngioma, CNS WHO Grade 1 + - Infiltrating Ductal Carcinoma + - Acute Myeloid Leukemia, T(8;21)(Q22;Q22) + - Adenosquamous Carcinoma + - Anaplastic Large Cell Lymphoma, ALK Positive + - Ganglioglioma, NOS, Malignant Peripheral Nerve Sheath Tumor, NOS + - Schwannoma, NOS, Other + - Mesenchymal Lesion + - Granulosa Cell Tumor, Juvenile + - Poorly Differentiated, Intermediate Mitotic-Karyorrhectic Index + - Nuclear Protein In Testis (NUT)-Associated Carcinoma + - Neoplasm, Uncertain Whether Benign Or Malignant, Astrocytoma, IDH-Mutant, Low-Grade Glioma + - Sex Cord-Gonadal Stromal Tumor, Incompletely Differentiated + - Meningioma, NOS, Embryonal Tumor With Multilayered Rosettes, NOS, Other CNS Embryonal Tumors + - Chordoma, NOS + - Carcinoma In Situ, NOS + - Acute Megakaryoblastic Leukemia + - Oligoastrocytoma, NOS, Other, Other CNS Tumor, NOS Or NEC + - Kidney Clear Cell Renal Carcinoma + - Medulloblastoma, Classic Histologic Type, CNS WHO Grade 4 + - Malignant Melanoma, NOS Req: true Term: - Origin: caDSR @@ -7533,8 +5014,8 @@ PropDefinitions: Term: - Origin: caDSR Original Source: CCDI (DDE) - Code: '13594090' - Value: Disease Morphology ICD-O-3 Code Label Text + Code: '14714127' + Value: Diagnosis Disease Text Version: '1.00' tumor_grade: Desc: Numeric value to express the degree of abnormality of cancer cells, a measure of differentiation and aggressiveness. @@ -7880,7 +5361,7 @@ PropDefinitions: - Origin: caDSR Original Source: CDS Code: '12445832' - Value: Specimen Material Category + Value: Specimen Material Biospecimen Category Version: '1.00' biosample_accession: Desc: NCBI BioSample accession ID (SAMN) for this sample @@ -8331,93 +5812,57 @@ PropDefinitions: treatment_outcome: Desc: Text term that describes the patient's final outcome after the treatment was administered Enum: - - Complete Response + - Complete Remission + - Minor Response - Mixed Response - - No Measurable Disease - - No Response + - No Evidence of Disease + - Non-Response + - Not Applicable + - Not Done + - Not Evaluable - Not Reported - Partial Response - - Persistent Disease - Progressive Disease - Stable Disease - - Treatment Ongoing - - Treatment Stopped Due to Toxicity - Unknown - Very Good Partial Response Term: - Origin: caDSR Original Source: TCGA - Code: '5102383' - Value: Treatment Outcome Type + Code: '13383448' + Value: Disease Response Assessment Outcome Version: '1.00' treatment_type: Desc: Text term that describes the kind of treatment administered Enum: - - Ablation, Cryo - - Ablation, Ethanol Injection - - Ablation, Microwave - - Ablation, NOS - - Ablation, Radiofrequency - - Ablation, Radiosurgical - - Ancillary Treatment - - Antiseizure Treatment - - Bisphosphonate Therapy - - Blinded Study, Treatment Unknown - - Brachytherapy, High Dose - - Brachytherapy, Low Dose - - Brachytherapy, NOS - - Chemoembolization - - Chemoprotectant + - 3-Dimensional Conformal Radiation Therapy + - Allogeneic Hematopoietic Stem Cell Transplantation + - Autologous Stem Cell Transplantation + - Brachytherapy + - Cellular Therapy - Chemotherapy - Concurrent Chemoradiation - - Cryoablation - - Embolization - - Ethanol Injection Ablation - - External Beam Radiation + - Conventional Radiotherapy + - Electron Beam Radiation Therapy + - External Beam Radiation Therapy + - High-Dose Rate Brachytherapy - Hormone Therapy - - I-131 Radiation Therapy - - Immunotherapy (Including Vaccines) - - Internal Radiation - - Isolated Limb Perfusion (ILP) - - Organ Transplantation - - Other - - Pharmaceutical Therapy, NOS - - Pleurodesis - - Pleurodesis, Talc - - Pleurodesis, NOS - - Radiation Therapy, NOS - - Radiation, 2D Conventional - - Radiation, 3D Conformal - - Radiation, Combination - - Radiation, Cyberknife - - Radiation, External Beam - - Radiation, Hypofractionated - - Radiation, Implants - - Radiation, Intensity-Modulated Radiotherapy - - Radiation, Internal - - Radiation, Mixed Photon Beam - - Radiation, Photon Beam - - Radiation, Proton Beam - - Radiation, Radioisotope - - Radiation, Stereotactic/Gamma Knife/SRS - - Radiation, Systemic - - Radioactive Iodine Therapy - - Radioembolization - - Radiosensitizing Agent - - Stem Cell Transplantation, Allogeneic - - Stem Cell Transplantation, Autologous - - Stem Cell Transplantation, Double Autologous - - Stem Cell Transplantation, Haploidentical - - Stem Cell Transplantation, Non-Myeloablative - - Stem Cell Transplantation, NOS - - Stem Cell Transplantation, Syngenic - - Stem Cell Treatment + - Immunotherapy + - Intensity-Modulated Radiation Therapy + - Low-Dose Rate Brachytherapy + - Not Reported + - Pharmacotherapy + - Photon Beam Radiation Therapy + - Proton Beam Radiation Therapy + - Radiation Therapy + - Radiofrequency Ablation + - Radiopharmaceutical + - Stem Cell Transplant + - Stereotactic Body Radiation Therapy - Stereotactic Radiosurgery - - Steroid Therapy - - Surgery + - Surgical Procedure - Targeted Molecular Therapy - Unknown - - Not Reported Term: - Origin: caDSR Original Source: TCGA diff --git a/model-desc/cds-model.yml b/model-desc/cds-model.yml index f240376..69bc20e 100644 --- a/model-desc/cds-model.yml +++ b/model-desc/cds-model.yml @@ -1,5 +1,5 @@ Handle: CDS -Version: v4.0.1 +Version: v4.0.2 Nodes: program: Desc: "Program in the Cancer Data Service refer to a broad framework of goals under which related projects or other research activities are grouped. Example - Clinical Proteomic Tumor Analysis Consortium (CPTAC)" From 3689e407cefe833ac97c89eb3cb1d3a5d344815c Mon Sep 17 00:00:00 2001 From: Fuyuan Wang <60631776+wfy1997@users.noreply.github.com> Date: Mon, 26 Aug 2024 11:22:07 -0400 Subject: [PATCH 2/5] replace \_ --- model-desc/cds-model-props.yml | 20 ++++++++++---------- 1 file changed, 10 insertions(+), 10 deletions(-) diff --git a/model-desc/cds-model-props.yml b/model-desc/cds-model-props.yml index 92d225d..42a81cb 100644 --- a/model-desc/cds-model-props.yml +++ b/model-desc/cds-model-props.yml @@ -770,7 +770,7 @@ PropDefinitions: Value: Imaging Assay Technology Type Version: '1.00' objective: - Desc: "An\_objective\_is an optical element that gathers light from an object being observed and\_focuses\_the\_light rays\_from it to produce a\_real image\_of the object." + Desc: "An objective is an optical element that gathers light from an object being observed and focuses the light rays from it to produce a real image of the object." Type: string Term: - Origin: caDSR @@ -2856,7 +2856,7 @@ PropDefinitions: - Neurocytoma - Ependymoma WHO Grade 2 - Desmoplastic Melanoma, NOS - - "Neoplasm, Malignant, CNS Neuroblastoma,\_FOXR2-Activated, Other CNS Embryonal Tumors" + - "Neoplasm, Malignant, CNS Neuroblastoma, FOXR2-Activated, Other CNS Embryonal Tumors" - Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation - Carcinoid Tumor Of Uncertain Malignant Potential - Choroid Plexus Carcinoma, Choroid Plexus Tumors @@ -2880,7 +2880,7 @@ PropDefinitions: - Giant Cell Tumor Of Bone, NOS - Pilocytic Astrocytoma, Low-Grade Glioma - Embryonal Carcinoma, NOS, Embryonal Tumor With Multilayered Rosettes, C19MC Altered, Other CNS Embryonal Tumors - - "Astroblastoma, Astroblastoma,\_MN1-Altered, High-Grade Glioma" + - "Astroblastoma, Astroblastoma, MN1-Altered, High-Grade Glioma" - Adenoma, NOS - Combined Small Cell-Adenocarcinoma - Combined Small Cell-Large Carcinoma @@ -2963,7 +2963,7 @@ PropDefinitions: - Langerhans Cell Histiocytosis, Disseminated - Epithelial-Myoepithelial Carcinoma - Ependymoma (WHO Grade 2) - - "Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And\_TP53-Mutant" + - "Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And TP53-Mutant" - Neurofibroma, NOS, Other, Solitary Fibrous Tumor - Adenoma - Clear Cell Sarcoma, NOS @@ -3072,7 +3072,7 @@ PropDefinitions: - Craniopharyngioma - Mesothelioma, Biphasic, Malignant, B Lymphoblastic Leukemia/Lymphoma, NOS - Neoplasm, Uncertain Whether Benign Or Malignant, Low-Grade Glioma, Oligodendroglioma, IDH-Mutant, And 1p/19q-Codeleted - - 'B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy ' + - 'B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy' - Glioblastoma - Leydig Cell Tumor, NOS - Mixed Type Rhabdomyosarcoma @@ -3119,13 +3119,13 @@ PropDefinitions: - Pilocytic Astrocytoma, Diffuse Leptomeningeal Glioneuronal Tumor, Glioneuronal And Neuronal Tumors - Diffuse Glioma - B Lymphoblastic Leukemia/Lymphoma With T(V;11q23); MLL Rearranged - - "Ependymoma, NOS, Supratentorial Ependymoma,\_ZFTA\_Fusion-Positive" + - "Ependymoma, NOS, Supratentorial Ependymoma, ZFTA Fusion-Positive" - Acinar Cell Carcinoma - Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Juvenile Myelomonocytic Leukemia, NOS - - "Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, SHH-Activated And\_TP53-Wildtype" + - "Neoplasm, Uncertain Whether Benign Or Malignant, Medulloblastoma, Medulloblastoma, SHH-Activated And TP53-Wildtype" - Anaplastic Ganglioglioma - Squamous Cell Carcinoma, Small Cell, Nonkeratinizing - - "Ganglioglioma, NOS, Diffuse Astrocytoma,\_MYB- Or\_MYBL1-Altered, Low-Grade Glioma" + - "Ganglioglioma, NOS, Diffuse Astrocytoma, MYB- Or MYBL1-Altered, Low-Grade Glioma" - Unclassified Sarcoma With Round Cell Morphology - Pilomyxoid Astrocytoma - Lung Squamous Cell Carcinoma, NOS @@ -3174,7 +3174,7 @@ PropDefinitions: - Infiltrating Duct Carcinoma NOS - Squamous Cell Carcinoma NOS - Posterior Fossa Ependymoma, CNS WHO Grade 2 - - "Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, SHH-Activated And\_TP53-Wildtype" + - "Desmoplastic Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma, SHH-Activated And TP53-Wildtype" - Choroid Plexus Neoplasm - Chordoma, NOS, Ganglioneuroblastoma - Colon Adenocarcinoma @@ -3385,7 +3385,7 @@ PropDefinitions: - Intraductal Carcinoma NOS - Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation - Glioma, Malignant, Other, Other Low-Grade B-Cell Lymphomas Of The CNS - - "Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And\_TP53-Wildtype" + - "Medulloblastoma, NOS, Medulloblastoma, SHH-Activated And TP53-Wildtype" - Gastrointestinal Stromal Tumor, Benign - Ependymoma, NOS, Supratentorial Ependymoma, NOS Or NEC - Prostate Cancer From 3290e720db81acfa05df7eb83a7894610d66166c Mon Sep 17 00:00:00 2001 From: Fuyuan Wang <60631776+wfy1997@users.noreply.github.com> Date: Wed, 2 Oct 2024 15:14:51 -0400 Subject: [PATCH 3/5] Update sample node definition --- model-desc/cds-model.yml | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/model-desc/cds-model.yml b/model-desc/cds-model.yml index 69bc20e..c2140d0 100644 --- a/model-desc/cds-model.yml +++ b/model-desc/cds-model.yml @@ -139,7 +139,7 @@ Nodes: - crdc_id sample: # aka subspecimen (CMB) - Desc: "An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process." + Desc: "Specimen tissue type collected from the participant." Tags: Category: case Assignment: core From 991b48e25fd5939204a73ab3a437a7ae5687da03 Mon Sep 17 00:00:00 2001 From: Fuyuan Wang <60631776+wfy1997@users.noreply.github.com> Date: Wed, 2 Oct 2024 15:36:09 -0400 Subject: [PATCH 4/5] Update model version to 4.0.3 --- model-desc/cds-model.yml | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/model-desc/cds-model.yml b/model-desc/cds-model.yml index c2140d0..40b305e 100644 --- a/model-desc/cds-model.yml +++ b/model-desc/cds-model.yml @@ -1,5 +1,5 @@ Handle: CDS -Version: v4.0.2 +Version: v4.0.3 Nodes: program: Desc: "Program in the Cancer Data Service refer to a broad framework of goals under which related projects or other research activities are grouped. Example - Clinical Proteomic Tumor Analysis Consortium (CPTAC)" From ed7af0bade11a95e4fb6194f2df6818b207544fa Mon Sep 17 00:00:00 2001 From: wfy1997 <60631776+wfy1997@users.noreply.github.com> Date: Thu, 10 Oct 2024 14:19:11 -0400 Subject: [PATCH 5/5] To further support data model auto-update, we include following information in data model's model-desc folder README.md: README used in data model navigator cds-file-examples.zip: example metadata files navigator-icon.png: An ~100x100px optional icon to display in the header of Model Navigator. If not included, a default icon will be shown --- model-desc/README.md | 54 +++++++++++++++++++++++++++++++ model-desc/cds-file-examples.zip | Bin 0 -> 90143 bytes model-desc/navigator-icon.png | Bin 0 -> 7798 bytes 3 files changed, 54 insertions(+) create mode 100644 model-desc/README.md create mode 100644 model-desc/cds-file-examples.zip create mode 100644 model-desc/navigator-icon.png diff --git a/model-desc/README.md b/model-desc/README.md new file mode 100644 index 0000000..4637e14 --- /dev/null +++ b/model-desc/README.md @@ -0,0 +1,54 @@ +### The Graph-Based Data Model + +The CDS data model is graph-based, where nodes correspond functionally to tables in a traditional relational database. Each node contains properties that represent columns or fields in the respective table, with relationships stored at the level of individual records. This flexible data model is developed to accommodate genomic and imaging cancer data submitted to CDS, enabling the exploration of biological questions in basic cancer research. Nodes are designed to capture specific information relevant to each study and data type, recognizing variations between submissions. + +### Node Categories + +All nodes are categorized into several groups, each representing a family of interconnected nodes that collectively define higher-level entities within the data model. For example, the **Participant** category encompasses a small set of nodes that comprehensively describe CDS study participants/subjects. The **Study** category includes nodes that collectively define various aspects of studies. Meanwhile, the **Sequencing** category contains nodes where genomic experimental observations related to various cancer conditions can be represented + +### Assignment: Core nodes versus Extended nodes + +CDS is data type agnostic, and within its data model, there are nodes that are consistently or frequently populated with data, irrespective of the study type. These nodes, positioned at the core of the data model, are classified as 'Core' nodes. Surrounding the core is the extended data model, which includes numerous nodes that currently have lower data density. This division aims to guide users, especially data submitters, towards focusing on the nodes and properties crucial for defining any study, regardless of its specific nature. + +### Class: Required nodes versus Optional nodes + +Within the core data model and its extended counterpart, certain nodes are more crucial and therefore more densely populated. These nodes include fields designated as 'Required,' distinguishing them from less populated nodes with 'Optional' fields. Core nodes are essential components that form the backbone of any study, containing numerous required properties. It's important to note that each node contains both required and optional fields. Optional fields may contain valuable accessory data relevant to some studies but not necessarily all. + + + +### Facet-Based Filtering + +The facet-based filtering options available in the left-hand sidebar of the Data Model Navigator allow users to filter nodes based on several criteria: Category, Assignment, and Class designations; properties marked as Required, or Optional; and properties displayed in the application’s user interface (UI). Using these filtering criteria, users can efficiently segment the data model into smaller sets of nodes and identify nodes of specific interest. It's important to note that these filters apply to both the Graph View and the Table View, and selected filters remain active when switching between these viewing modes. + +### Graph View + +In Graph View mode, the Data Model Navigator offers users an interactive, graphical representation of the data model. Users can apply filters, as described previously, to pinpoint nodes and their associated properties that are most relevant or interesting. Selecting a node activates a Properties Dialogue box, which displays the node’s Assignment and Class designations and quantifies the number of properties categorized as Required, and Optional. + +### Table View + +In Table View mode, the Data Model Navigator displays detailed tabular views of each node, which fully-define the properties within them, inclusive of the applicable controlled vocabularies of acceptable terms for enumerated properties. The tabular views also clearly identify which properties are Required versus those that are Preferred or Optional; the acceptable data type for each property; which properties are displayed within the application’s UI; and the labels via which such properties are displayed. Note that many properties displayed within the UI are renamed with labels which are more intuitive than the property names themselves, and that some properties are displayed via more than one label. As described below, comprehensive documentation of the data model’s nodes and property requirements can be downloaded in PDF format via the Table View, alongside node-specific data loading templates into which data submitters can insert the relevant data values and thereby create loading-ready data files. + +### Required, Preferred and Optional Properties + +Each property is assigned one of three requirement levels - Required, or Optional. + +- **Required** properties are largely self-explanatory, i.e. data destined for a node which contains required properties must include values for all such properties, and values must be compliant with the acceptable values for properties which are both required and enumerated. Controlled vocabularies for such properties typically include terms such as “Not Applicable”, “Not Reported” and “Unknown” to accommodate situations where data values aren’t relevant or weren’t collected, either by design or otherwise. Notably, for nodes into which a data submitter is not propagating any data values, required fields are no longer relevant, and can be ignored. +- **Optional** properties are precisely that and null values are allowed. + + + +### Key Properties + +Many nodes contain a single property visually identified as a Key Property by a **blue key icon** displayed next to the name of the appropriate property. In addition to several nodes that require one in support of data updates, all nodes which act as parents of child nodes will likewise have a single property within them identified as a Key Property. During data loading, **_child records_** are associated with their correct **_parents_** by virtue of data loading files which contain the appropriate values for the property identified as their parents’ Key Property. For example, files via which sample records are loaded will contain a column into which values of "Participant ID" must be inserted, such that samples can be associated with the appropriate participant from which they were derived, with “Participant ID” being designated as the Key Property within the **Participant** node. Key Properties are therefore functionally equivalent to foreign keys in traditional relational databases. + +### PDF Documentation + +Detailed documentation of the data model’s nodes and property requirements can be downloaded as PDF exports, either in the form of a comprehensive data dictionary inclusive of all nodes, invoked via the upper-level “Available Downloads” option, or from within the Table View, and invoked on a node-by-node basis. Used alongside the corresponding data loading templates described below, these node-specific PDF exports function as user guides for data preparation and submission. See the associated [Data Submission Guidelines](/#/submit) + +### Data Loading Templates + +In support of data submission, data loading templates can be downloaded, either in the form of a zip file containing copies of all available templates, invoked via the upper-level “Available Downloads” option, or from within the Table View, and invoked on a node-by-node basis. Templates include columns into which the data values required to associate child records with their parents can be inserted. Notably, each template will include a **mapping column** for each potential parent, but although \*all child records must be mapped to **at least one parent\***, submitters are not required to provide a mapping value for each and every potential parent, _only the_ **_most appropriate parent(s)_**. Guided by the corresponding node-specific PDF exports described above, data submitters can insert the relevant data values into these data loading templates, and thereby create loading-ready data files that can be handed off to the CDS Data Team. + +### Controlled Vocabularies + +In the interests of data quality and consistency, the CDS data model makes extensive use of enumerated properties and controlled vocabularies of acceptable terms. All such controlled vocabularies can be viewed via Table View mode, and value sets are included in full in the appropriate PDF exports. Furthermore, in support of data submitters pre-validating their templated data, all controlled vocabularies can be exported in machine readable JSON and TSV formats, either in the form of a zip file containing copies of controlled vocabularies for all enumerated properties, invoked via the upper-level “Available Downloads” option, or from within the Table View, and invoked on a property-by-property basis. As more studies are added to the CDS, many of these controlled vocabularies will continue to evolve, and will be updated by the CDS Data Team during study on-boarding, in order to accommodate additional terms not yet encountered. diff --git a/model-desc/cds-file-examples.zip b/model-desc/cds-file-examples.zip new file mode 100644 index 0000000000000000000000000000000000000000..0008d6f510ec0716215097530ed5d616af0cb00c GIT binary patch literal 90143 zcmd41V~l6tx9_PKkXlYNu@Kj*$UE14@R znaLV+JoCvMW975tBtbw?0RLQ}Ruby}_VDjF8UO)6NLW!xsSISo3$lS(MSIOAg z&Pw0O*iqMog^q!aS=Y(ISl`Lo*v5%oSqT;Z5sLt6`ag!V+YbN`XhGpMEa(|LuDsm8 zMS=uC{!fumfB*p2zmarxr3Hj!71ikJbpM5*|5MD2zp?+9n1*_&hNgN3dNlq}u^1ra2-rZk#021Xm?9XVz|n++0tjeo!)OFD{EB^`sLy(OJF-*Li;^@HBjStW z(o$3YBi}#}s zIqF*58d~Za{oN{BQ)3%jYjZNkt|-;pdjJ(k4%0P6NMQ znI95=(vsYn?ho3!%9bA;G<@H*=v9{=i$_fqb#>{kRw}k8_~`j&Q%*g6>i<+HTQPQP z$u7BOv#viHY5I0~e*9j%^w8k*(WE~!e?e!97=5y6>@vA0{mfrK_h|ie>P%n!(bU;q zs{WF8e_H%{XYpvxYp8lJqP>UQ)tYH_2CKQHqq}r2TV5`E?!mNPGkTrf|Lv`@Fh0Fb zZ`JnJsUyqF_jNOPVB_5WdHwC->GB}L`LxbA72)cda{gMu-u>Meo-yjBJq>qu7>Vo6 z@#T?@VPBVC=KHBRAlj9uc-TR8 zf^Bf}^39~N6rRrZIKsMC8#Uqd0WHQ|z?Ucgn61<#TDb z)^k*zob^E?Z7rE4MTLY(`auir%r4Hn?^ccKs))g}?ZG>jwvy8j>7oazde+Bon^7aXno+0DHLDZ!?HNxOPicBUC*5~nG~Lwdphw*X z=Cn*LS^c2Jn=I$;S>4u*Y}e{m)%jlAmXG@6N_jK+arO7Je5uT_+?dQ72@=VlN2&2} zN*#}>iupo?>BiG{6JcBVc+^fl`a~5DYcVo02mQ1n_$v2O(EXt#8 zmtAO|64!%myMn&{ZzrJQhB%G|yk+smg=sELO38ob)zKb%y*SFhOZIUYK0klo^Qh0w zZ!LgT9Hd!yY|N*Fil3*F^If-41{n=SD2&ev2AdEbyGnAhbdp0{tBy}Yn4;)juaBK( zn7Tgwm>3`v8-pf?}Wx(z13)50i{V3EuDz zX&s5@4w$K8>AEM>#pUDJ+cI{4IV)h-rKRW}b5qMEIPEZuSCvwWMj5h)=H$YE$_qv& z_hf$)Boi&Fp@~+JJjm>&3D4I~{e0;-U%gBmm_EyJ?j)3DG>;@;I&e}BFHys-B-jrRGx(c@R_kU!w%t>&GiTalkhu=dX0F@DV9=1m}#7Xk_5j zvJ5Z!BgFupjUYz0NG$ORFet7~trLG_kvm={VkwIL;;6lIejnjojXtp-*l=Ocs56h9 zK72fAsz_o%&4eJ?8jMotIN_lfUmDpu)RTCON4cSxQ{SJz{7_R=eN?{p@o+&D13Xw< zMk29hK)D<{molP(7#g+4%yRjvQMtODbyUJjTr#zUvOgCq5jDob zVB98~m~mC7WANf8<|kbEQ%b?BxPcaNi&OI~cx|FYm`^nf(7~&kGhfj~j;Bp1Uyg$u zzLz6G0ASLI8mt65n-tpb&AKD#_Q{IuEWp8m7mh0_r9c2)v#>t(7k-_4m-h@V;yJF~ z?*1CCrwG+CbpF$rM1bc^BwvUiph!mMOo?(Ij58Bz0H@&V!{y;(38rU@t3;8R{^hO1 zmpGFm=y5<*MBUr4Q#fBBS$1G}XlLi~aJ#I#eLXV(X+5T4j($5r879%6MgoQee(4}M zs!*o&*yvh}Kb>A%og!31geOQUZ^}{cvW%)Wo0~+fEop4cl9_GEK0L{=a(YY1mA)~7 z9%1V#t!qSnOF$Jyb=TMj6vkG_6zQmb7JPI4{;O^kaI)@YNY>6I)W6H5CeA%2nx_Sn zdMlOhn(Sb8$dz^baPf#NYUlLw6vNrvukAsu(Z{yjHZo@0Equ^{+FI9^M#%VHuf16SQqnI*CJakK z<>aqACD_5$20C+ZzuAoT!3P`3w$4CntK*b%bv|MpCVgHJCJ}rjp52Gg&nl7l7>bLX zk3oAgav#y{*ijm``^%5#*C#sb8|vpuntenNq@*Gu$FczAT+LNWbrr+;i5-+n-lNs! zit9jL%;P*G?nwSTl^mc1uheJKR%3_|9$@+3N|i$rNWX~cxQg6jgN1{Bp-1(Vn24u= zxK_1a=;9OQSe!GOBZThEYY4!G|AH`88=|%r)uF=U09hRUBE? zbil85aiX){Oh@1RH{lyMZkyv-zuX4_OuI=RJNO(@(Y*P6!RyQaN ztv+f8-6WR|n-J4)+w4`}YVoLOQBW}yKfh-qV%Cj{yu=RVk9VAV_xTWz(CIgErP;|6 zT2dx5hKbz>+;(ILa}w(b_;y0X4YJl-`9J)_C24zd#KR-QdqWLai7okLuyP4~BA;*l z_WLulAZ*H0yFYPbYGX?(C{W}B(#CRyrdxZ&=6}9;3;=Zvu6c$^?a2dBjs?8V1zL&y zfXztl7hpa+@Kx45MF^G8AeiQFODV(pC@C}e~GKQ1S1a> zr;|`ERBgx3D;}WG+NpCUkpFtAwN57E6(y1vN&8J!eT|w$tuf~=De^OK`XDdJuX&hE z138;IuB0vzF`jcin@GIwfs|fgON1|mg;yUKzu5%onY~&91~FoZWBL{j--rdH?y6%n zK1?=QOo>oYFr^bxWlu`^4AB|80GdaK^}^!z{gg>5JB)9s_89r&IBdm<2&Ogey*e&gmbEx^bI$Pv9gpa14YvNx&7b zsAG64ZMAYdQW@?!p*}LdUE&fVM+T0INzVQl2gC5k28sD)V?DU%1H;PsYZPh9Y#Y(# zq`g#R3y;nQRhb*J6Bt+Z!;GtWV5Z(>ZqHasp+T(kdDtc}-ljr_QFWh-vXlwtH$4>X zqk7kVg!zR>K`4nWm`!%L=E4w@-Y4N%oA|NL&tz|{fz3l8Rz(e0(y;1K9rdn}0;kpO z!A&G$J{igTIcy1KTJ8f;BmL9`GSN&zbxRTEK>Gu3&NBHsestYH*MRkwA1zFS5E#Wm zN*Q{r*eIwI3wQF!&9>Xr&?>vvY0n-NsWE=uy1xNlnf1z;x*}dDDBLJ<+V0?`V>?d) z=n2EB8FHg+C_TEcMEmv>%27Qg2pT*4Er9}~qO~Mdq3qz`+kcNuDgRdp`%9(&wsTCH zy?REC+D!bToKrOETHoK(*mU7X(^X*;?sqH{6?XP*JcVd=Kn{BZv0^Q7Ww0Ry6aV;o zIwGrG$kE0uX7*(~MbjVlFtA`8YMr1XyUqM*ywszHCAJzL%4Rl~+ZCWNED?O2>!EP= zc@-CuSC6G~yu6H$xQvKt197DUWehv!a%jiWx%rfo`?QO`7Cd4$^y~@F18l%1&xw@8 z25A&8!Jkn5YSN17{h?wtwMh^iNd{=cd#*nkNllI)H#R_;XUm$JgjgC6x_h(x34ae2xD&Se=oEd34$I4e*Dm)BdLPe;Y1^~WE0e<25?zy z{5rsvE436sj;HHaQ5Ac}U$V&&{y1I0cJ!*4z|sf!gy+U@V^H&@-qSfvO1YZ=*drFCB4SW zy`%+xe|KS>H*}y&(Le2vjXH)s3*CQpPI6d5{E}51J5J%*0&i z$cp0K&u{ zPPp-^AuKhMo!jQ*acui>Km?dys16PyA9Av!#*$xAFo$b8g2%XiRTSPsus|3%nn18L z7IOjqPoIUwzVj&;zMHS0N67f|4vGk{jo;=TXCkhVnJcPFBV13EjeTlCr*w&zY?6GO zA3?2!9Z(!@zU>hOlJds}uoSJDYWd zn{jQbpj-XH#RP)!Z}XG=XiU(!Jo|bJrvpeY{OAt_*Ui;fL1JP(Jsk$K^wZp6*hYM7 z<>)hgSHp@?_k-RKT;qWg{3={cY9Ht-)m+EvVu8QD8D>`Zdg>MxSxAxR=ou2!psHAp zYVp?s&WiW<4oqDw6+u^p+9;9h=;M`93p4QeO;KmCbknCsRVB&a=d~)Pqm|QQ6a5nc zk(hsHp_$sjhe`mHPwHrnUa7|L5jn>Kh5e0SH$8zfI+WzBqZJH~O*`SUKls0J>5vsb zoJcjHGcIj{VIp9uf3JOF2*BM0pQxF5CpR5v*^e6w29q&Uu1xtw`i!CVvDk))h5_J`aE~7%u zF^I?fUn7bYCuS3gJDu{z18Jn+{O&cOIWKI=+lnPAk(t%@J+fiQ3Xl|-;+->@fkMZ) zULa4?;n=Ze2vj4z;U6YFy2}D#U_nQ4f{D{uajY?uukd){pI{W)1=(y9d~iEC+)}#J zE07d)!G_GyS|=M)u?G=c)3!SAldd78`Jk zVx*ilPa@J$be*7~R6tdP>XSUiF^Q5EVFzP&o1C|6`g*sXY+l(6e{f*SXvz&26apT zVxA>lrvPyuBj7|o!oZb)cmgP`GzEMs<9X|XW?UCnugnRw@>4#6H&=Dr5mRtI8oTdG zlh1fx$E4WP_=@CQk7>|V`lnP##qipgH@?&G$byuKao`bW;4S_-otB;^I?Bvq&Hgg< z3TLk^@I{5~lk$UVWCw$I5%uBNcEm&&;`+FzMhGjGS|FrVRyhk3n}k`YR>oA~Oz5bO zF$We@&K%c2A*fH(n6j4nJPoO*fjH4dv}iEM5t)g+mSY3_q(H3ovohc&+MbrHdrR22m#b76JBK}BZTuS{6e z{OD?+GV#UU)vZDepl<#~0z*`%Cp+gi5tYqxvvy!lK-gkBzMqMb< zzzDzUH2h*CyQr`iqVgszqz)m9EoiMpD=%!_B|pf3{vHUnHQv!sn5p!}K~=Bv`QSzJ z*0@Ca4HV=+9pXJ`j8^(E_W?NZ@_te$j>lHdqht@AxnsNu+6jLCm{uN}`g$15aa=_< z+og5y2OXlea8sUimg%4rkw%RW#j+<7JuQtZu-0 zq{31`A%_4ygx^P~$ZY{Jis|`B+!~`j6$L?399Aq-;-ltBa;Wi*;GY6yG-wW4=9V?n zwhLMQ=CVQ@h2|h8e1oVNeoe6zp!l)*)hhgjQu}hVC31XeWQR4gxQ~ve>!2T?o*V7f)0s(UWMFadYdbFnd>xxaeUaA*RxH0vknfb@VQJfRf`FJ1LfzNxYe$)jVsMj; zbSwQ?38lfZ^IRT)&_IK@mDd=eR%i3NCzY{F{XDpw1fRkM+ljPYUrHo~19$lShx7UY z^!-a7o-J_9=*U)rz>;;~rGH3lM^PyvE0v;*ry-k;V^w0~`kScYS zh>edmqE4m()~4vn58cE)WCx8T=co|pZ1Wz=GUrB=!yPVmYY7Z+X*|^SQ0BCw7FLEi zmVZ1evWgJAFSu}X1RGJDGm2;&(GIi(gC*-EEXM4_3#nKj?Q8@*pZjvhvIpZX{?;UP z3l11bL0Hn~00%E(xwTWfr)z}I&sQr0_?k}1kpS`JJ0LQavP2-#`CogNBLX0vbsxC4 z;{In=vd-Kov4?w4gFcKjM9<*x>r}dJQ^ZiTEx&Bf{`_-P1j{%Igz?ZvsErpmVGmsmJO-|peS75g|Jo*oJ|Fv$Z1(NN_OwsChdWS zoS%^ipo+4~WeE~NARc}9O%@DFj+n4GK&}CeN8Ml$wa+b>n6@~o8FgRC%Qcr5nisJ= zZApQm%=V+w)AlR2jLt-9@#%n;oUkfRtSelu3=sk11>z=9r$Jak)0PDGbgO72C_Ia2 z;Ul!(Y4Ln2HMGVj3j$w;u z%uIwx6RD&a3Z3krKt|sC@(w0*{SxP|6H~bhR}y6ucumN)8x+@D%%{i7p$Z~QB2!t* zB!$cNGmNv+%j;DU(@gSD9BQyJ#aKKhX9nTEx{W?zoVrLvnxU@fV^aH5+|#M!5mPFL zVmRDxt%tQZr~N_B6GlIm3#u1uL>WU+Ja8f_xv-5QDrumq(i&pz5Q7`WNaMkw5CM7+ zZdB_zo?27GZ+M;j%Pci2Eq-rn-p3*;FFZtrfSQy{i=)18H}F?mvGd|L#6J*lXNzRk z8XExk2lf5e5U}PiB2@m*Q1o9wqJIJEf0GCP!%P1qW@?X%@cRY(-;t>tnb-YLA!twx0O04p2tw)p;%Y@FTLA%Cj8@0x5utgELZT&t#x(Qa&pK%UB{b5Od#rBNItHqv&GDstlAou&?OCVyJqjf4y zYQGx@C3_Tkw!Nt@ba7=ajX!p+XI(9qAI;FdA65IbpTSR_o_EiQJpa)AG@}gbZ#D_j{~bqq}Cm7yGjC zJ!iK|Z+9T9XBIZf`d-oV`Fu*;`?zZ0ynSBTovEVV7PX3LcC1$|9e3lwuQ?6NZti)z zYJAVLbuUdZ&`-Iw^JaCMc6y=QkG~!_w~vcAz2574pJl+W?|11|@m0MqmMFaoo`qZ% zUtWzr5smRg5IwjqYv~RvWl9J^S{GDf?Kb zX{M(YBMF%(vR^Mb4?SSNKuFo3XO~Fv)25%3iFiZot9N6&p&|oQiUT~6%+TMzA&qiB zz$^W*zp!@S#&|fs`&{xCWYK4H~QR9UQgT`7YxfTQ|QVSCXf% zUfSZzY}}#+1?5!DfEZcQN@0LY@=z?}+!!Veqyk2EIiAd!6m2kqYi7tfmfl3CUHZ{S zY5Md+Iw*u1hzvi+A4{JA(`ZWfom~ckin7hl*$AysMkY{3Do|L-(c%8Ip>U1h21 zjjn!cXMJw7OyfP-oeX|+|9xy>*s>1W(#cjh|9#!=pF`nTt0gEI~&2PrsTY5or;yZ#0pM!Eh!47t`Y4s|f;i163~f>740-gQ;6Kb%~m zE(=7%?nc-IaUTuS^bakueE|68iNCmPS0Ye%hA>Ure{+71h|>Bj{-Ow1q0#Ra<}k&FI3C-<;P%#r2`OW!E^F;uQv2$Yq0J}3NKF)AIN zA4XM>P^T@Oq%H^DJejIs%#yel;ZlP|s%YF9AI}*_V!@ec;%7jWtER;}ttD=XmF#ZR zELfU+h{ZWwYdz^;nUTaknIxRiJ$S=9F56mjbM;AxgE~=ygl!mo;l;)b- zT4y^tR>W3cihTT?or~;^(%%WGG4qoa9EL<4Hh&B=$4%6X{Gr}#wE{XT0W>_}uTeQP zz@^m$J>M6gL3HB1#=sT=XKpJzr>yQnq#E`hF-e_E6&`X6{bBxo=Xv@M*^fFKL4}H-|1LM_!==6v$s-0@ zfnv_lz6Y>KNSF72`x%i)7P*!(uz*I{G=>8Oi6vK*d+QH)!%b8~D5WB0)xm*!$12CD zxAujeCc(m+bQA~8J~Uu3#2#djZ*D<>fX9D86QPGS@%MCzuy-jNTsGDu3gW zy!&S&DF9#dWo9XM_cTdU!>vp%c~$Y}@qH5TD!O@!9ZQ@oP&V0MD3G~CVEuI4ZHXx_ z@9!Kd6NnFr+b*E`U)E{lL3->e%-}R7eT)H%GO*x*0QaCp2 zBLPIBgah*0WxEUv)C7Ty7jw{z*jjdF#YO!cD4OQ9SR$>iv7 zzOUxOymBhpAS8ma8-=F{IXEkN`5#c4N@c(L+9!C96?>|4nGR-t;`6OXnF%@%Opd%Y zwd(j>1)Dnw(f9bAi7dpJ;m4|9+B{YWZ+f;n}uSZN`-6yzG^aT-PmhuWltf`7R>7bT@Ernm;Mv zU*Al8N8pFO>&nNabv%8SeT;SS!b!TRZSHx;ocxrz}2!f0=00#5hN7%c#8ee;vt1 zd7J;ahG*L@du)5VZ;_nH?y@cCYi8R-YdDAV>3R)2;`%=4>!@tmEcUxTV|Ps?_%$tgW)S&F^WJi7$T-X$w%CCz9UMCdU`Q3p*G^)g%iq zJ}^#S7%XCWkM}A=>T~Whg8se&@)3y6&In(jGHZtZW1d!bpy{Kzzy@~F{{<=e`dqv5 z{jSzSwiL3@N*~Y6j{KtaF4Cnji9( ziZGG%8lz&5^)-<$%ew6G^!_0Hh-Fq|K4pT>^qy_{<|ce`uS_GeUjS`fNRULfKq7%Y z%9<>2bOlCxe;gVJXFbxnd|6S>ee7cAa%~ET3 z#}$Sy4e!zUoz0KtE0R}@EwapngH39+^|^}5k7^fVJv+`y|86$dOTT|VBb%pDPF2o%QX=Z_y4?qtM6CJ zII)-ettVVJEc#1fiDb=$biDlL3SmY3CYh>UWH{o_>k~CHq(bAnw!l9tcxW}`KU{5f z-@1XWl&p}2o1x+n1VtP&mYZKEk-naguC|!AapBoC??Vo(-8K8$;1=z#FMo4Puw|^j z<*xM|b_j+fdg%mUi^R0Jfju+qmRiZ6Tx}r1Cy+?UgQrwIMkt;uVbUbIiKdUTG-0h) z{-Pw*_icLhfii_|g3K=4z&X#b-65Wop0MrxPI9%wU~4yMr-GX_UAf#Dxm$Oh)hKP8 zG%=<}OKEp#*FcZBH-Ie%OL;S}|2lQBhZ?ql<9Pwm+88|cxILYG6~Aj*Ik{19}GfjkRD8dz139Q}I*ek2pW;R-SzI z1z;x6>aaZSKP}+!gKZi-7q>Hnzxp7yt9mfPw|Lm6eNld5`QGWjS5Bpze~5Yl@hVfl z=-XYNG*)d6f5JXu>7uyN)%=jhyFxcb;AE`p^3vVfWP@mM)8y9^f_Sdg%H`=8Jr9(?yb9qG z(W2HRm54>eXLacZ69-irh{UF2##%?P-ltZ?@j3U_p|LGDrv`9P~` zaUOeTJ!wFET6|OMQTb%Q0h1W7AMRE ziB1)8P$xx>@_pp>|Onw1A1Q#esGCCF#xttlK39&5a%JPP$gQ z>I~ZM#rmA3d4Fejac@t5|8qse{sT^OM3+@}>mUlb&70}9mOE}?UCQlpMZzLxY=c+&e6T{;t{x77Ed=&8p12i-X#7&flydHyH zbaKG@J#ioZ%d1e9S1;J{B%(`*E&YNrP&P{b;57&69=HBZMGxKY7(=2Upk}+C#5hRc z13v&ILB6VSV@C)sXiO*I!MrY86_*&IAXhddJv~}BVNxX!;*uV`o)`Ke?Tb<2$Kvx9Ke9ur z1>7>(3G%FxNoad}odVByA*&GiuXL!(FOc^H#&pob&bhlHVhlxVN3?6}xVhZoUhc9TWyi`{ z3xDkdObu{ODAGr;`H+$kGS1|ded}bg8pv$t#QYm;)Xhk!1WZAYL41)yr|aXHaeK%A zX@aX`uX-1_r`1;o#4M%T4;4S!&)|+$_@jBtb%s}FXG70*$(?BD$Qy89%4UaEBcOvc zkd7stLL7M!tVfkg!vKs+Yb^JpAvF(LiUK^0{0HFaV|wRJbv$IK-P`T+>tX*^Zv(q1 zz_;UjgA4{|3cp9S3p@f=hVLflBRESHgpj}|iZUbaD> z)yey9_lk213Oi=ax(X68WfTi)WKIK>gBEKp!;z5R#HHYCk&s@0h)6SO)MQtKduGv- zoPC}AdaC*xRwd&8-OE$ekMjHZ79#N0`F&YmbQZvUvDB++E6RXrmo_km!>NZQ&Abr} zh$2P00vREW2&5pq?B|GRzDvSL4co)tWXK9nf&w7{688E#wsWby=F}{OA zdfXknw)ealz&gZklD?n8e0X>v!WY8s|9x@%nQI5Ph4VnV^>ye?q_mdSDPRP46vlnC z4<)WlPK4g%+4a}IwM7O$N{Z+Gy(~L@ErtKrt5`Qmu*KKD|GKyEM& z5}>?Hc{}x@y^QEz&)3;=X$M9V*$UX&RYL}DCVol!bIYcK6Od@7AEx^Rs6U1RV!l}? zrSkAW3$agQgtX3A9>xU!to?vWUby&Gjh7^VazS-b1?d_!5-xJ5E9L@_G5UHm;!H+n zQjLhGMDH&Xt*+UyK2^(xCIbb6he`#G2CDWNj zFE5a#OUytyl6?V<7}u_)=}t29@kfTVPY{AiSy56urk|F!$9Vb;xuhIatt~^Y)=kNF z#?Hh}Irxz@eu8U=hA9sTo*s#^!dhZ;^Cc4n5kCxp{ z`=wmfG$?e(bunSD{f7t+_&Q5Y%nky~(@NeyMXa9T8`zhq_fT@1QP^@}VlkW`MA;#) zUb|0U0Iq=+!Q;hwBSz%2Q|(#ciMk?5FPsm_k@9H?U}o|==f`+23ei0eXjE1(^;Zqb zdRaekyZCX38FQR~7TxuI(?{G#)9(bW%tZvV9!+P_BRVnF^L81Q*$!J-XgMOrwEM^g zRZ+{MZK< zQvE ze3v4`hkv<@D%6`>%o%bT`gAJ&t<;k~>qom3C4(}YSAi$D$zGcYvi zrL2^tifUf6b_MEU5iZ;9P$$b1SpdIevyMx&I!g*O#|!(N)6?5b3^> zfE#^xNMTqxMr@wtx;&~XJb4y<<1{?fPw#^z=}xx)f!05;VGs|)&GAw&&8B(?^oj7% zP0c=)0fMs&yEJ;2(GNmmp!sps7D$^;*ZR|C-(f|+5taI+*d(P#?9Rg$lftjS6KvUK z8wOLPxVB3HobI>Z;>Vm1kX+Pd3K(DH?-UGrW9fM`8Q$vgc4%G%wWZCri=TDf8^@N4 z%@QqUVxr4Y2|JRZ_3Hio?um{hO38Y+z2mn=C@BsRz9@Q8i9Av6GZoY&l`ekmqj6J& z-t62Ym~Qwtew%S$He+zylfh9)s=N?}IYfagcFl&8_5(z;p+v})HCJQp;fNJx@UC5@ zj_WkG1uWbn;eklfF?f!AB+>#V5=z-?A-u5j*))#ayke&YlD8gOT0Jt{hbGZZ44x;w zM0Zn)o++_2h#rw)-DV*yR$5rLu%%H7KtB>{F%FKTJ5zt8N$tV$--y9T`Lx=1?{8RUwUoWwNZaz(;5z~gsJ%A zKEU){^@?%5fjw(JI|i;r18T$7y;Xl1YI6wSm?$BAJy4*QfOSvqd0X0OPSG(m4c5)l zzj}#u)cxQWKl0@}a@PKYdSwzaJx5~QPqRTLRal%}YT1E;z+ot+#&4ewXuHEA^-~a~ zW<~zlR6W?Gg)1G?3Hz0c+VHE!&1I3{gA+reDyx5yBK&&CH+8wmoSv7CBfnu9YZ(EL zGEP7bQU0saE|W+i&Tv)|E+G6$>Bd#+Y+KLtTu8?T-FE}sjcqM8EadE#4t&?_2F!1> z*w?GgBkbGr_3KkyEoC5Yos0E=;w6c8lqgi9pUik?!y5+=wkLo~w4?;zk32$%{1`s8 zS>Ilid)6?c6WzHch@8&VEiyPMH47pKf_1CB%bJ;{o_h=L!{JTM_u(5Tp9yMud!`a#V<;q8j!t(+Z;m4dvI>hUD|eWuGq-r zb&xek&T9@w4)rE?g>1=#dvK3uyZKZ_SPemeU@}uXLZ<~pMOrGePn{vs^YSudM?WLE z)BV!Kxdd?Z8LleyPo%-E7IYS-uE3HzxN!Jw20U!?QnBT{NTYI(5FJEIC_bZzJ05rB z6-qvReGc7QB%TN4x`)@Iu~2?rO+T%pP1B`hcECq)Y^mY#t_=kaPp7fAkW(0Eq%=u+ z$L|!3dd46Ws-p<8z#@A6grc+wX6p$8YsK}as<-pb!fu~pBo=(UPeyMWu z3BuAfp0|SSWxp_@YZ(&^DGc_VjY}!eUOR#T^NgxAv@nKLlLUC85ik7N2{KdA{Y1*5M%ilX;_l4fNGx+kQ$DKLKaRgR4BEOnW6;Mi z#Kn%-q?z!__ryfS<`l#^PeA#mnmz83ulo0_z&z8cC-t{~S{qzs`9m-Ced~&^Wzmv+fb9WOvoDuQx4k->E%0`t-@# z(7}*f+P47$8#?G660X1x_BRe%VF)MnWH@j<2XAf*W~1gtBvYOGxN zH2Pbn46g(4p7(=We;L-&N80K(5gS#c5ju7x7DbLTKq(Vn!l^!vo5jmtJKmp^vU`CS z<*sfoC|!?S6?a>!>T^5dZZTJw@2mfOpo(+WhC5Ko6@ZrJp{rp0C5G%I;q@Y(r>H-N zI!0h#7&A>heG$wm01^N>n;rhlqHw65+`HB|KBNm{sh^cutFSXMi- zV94zon|m9r6ZuHdo=)hO8*Q~%`FMq+w{!)4UB?lj)O2)A>_lJA@1|3){$ppGS-et1 zZTd^!m`KT4Dbj$#dovcLq4n*`;efw8J<%EP~pK+~7e`3|JaDTJ+uPJ2! zU_DoC@A368P0#T~f;<-^;TkVci9%1Ib=abqrEXX-OGODKh>D_i!ON5%-ZV1Fz;d~< zc}8{Oyk($WJl(+$!KN{M-T zQCC^<$F05dTjwsTX{|MA=4mesTPw;pQ|m;TTh!2tUu)q&;cgO|g+^sMfz0I;LUmFq zxTvBV1hac2@+KN5;s&4!QZK}licXZRRHK9>bXvkhQmCbDcjsz%c$-Mkqy%22NU`h+ zjH*QEXwGtQd6C2CixFjyippVsVG^%iPi7?)gFv@+GkwJk#Zw&` zImEv0&TgSHn6yn(Q*$gN*^b5uUHQzEFf9g}k$6UPIuEQhebG8P71^({?K$j=SxjTQ zz)5&W4PaG`dvO-A@;`);c%Amq7T!TNaP?k+&x4|dA~#zgdd*VCof9TYI&<8+gKSpd zwKBQ_tWiWH8OIvM&3_qrmDradaLAch%z$h_RR{FU@3c88+Rgz2q>a7B^psbAnhMbV z8A**$L^FaCK`s0&I@#CrU|4W%+EyJWn`Lb|`{~6rK5$QfU4TNG%q~37-s4iO87fEY zXhnP__4{*=){#zIcocpN_SzVybX2xA%SI{pJ#)5oXg{|!%hw;_5t9i0DAx=Jz<@qY z2Mrlyix++ztZ4Kw_`xsT0v+QPPWel`Pne%vSzf7%XDSmz56$clrYc?MV%^RAi1F6X)30jtN)KN^Vyn8GbOy=+XAdX3s^`jz82GmCW^ zbof_x6dF5n;^UQqGTgF&kz4gWfgL46%pW+BNVC5kFv1!6O^DSu63avkZ7YL1dSq{* zy}C|acRJhr)|J0W0|qrO3>RXf!I=(t6pS^3> zuBsCzIT8}=O}Oj>KsuJLZ-$*1$}Za>#PD+q=vMNfNd44l)MR8vX1{GD6B+!sLuE}i zjnc<0SzqjWw1EgN9981eJ&bt?_?;8tZ;8SjjOxk&^vP^^YNXy#ssqc=81;>UxPiP+ zO&0x&e0Z-7D#n({W}bJ6dsL14F#T(aO=qAaq4C>^N9dX2xQw8rBH>f#rw1J@r)bqr zoPd7UI%E=N;nHo$Q5W%SB{PgLQ)i6aRPJO_@sf14?Reg0tSu22BFYV{fgztU(?r&i zRI|7~LS>ay=RJJ3O!(B_7CUM8ZM?@NpmY}s03|Nka-+v2H<0JL18PFUd62R8A{G!N zaR2^1tBh%@WI(4e>Btr#Ih)}kyx;EHKzN}GbOt#?6Gc)j+{vu(4pZNwfx;dPOFB+c z;j~Jo>Bo-3_Ol~wN2>UpG+?+=f_>o3afrN0)L2b4PQGI|Xs}Aragm=5=E=XgMH9wK zU+@s-JUGhO-zooo;FVy+vR0G6x*&R7w$RU0J>ldMT*CF>-)q0_d&6SSHsk#qIcids zQ931PFH!g-1?zlSCOM+S9Awv9y;_)$MOlVD7sc0Kyo{yN4I!pD>7;1Gxs_3lO$#QN zKdV(fnLjB)cqJ}ua3-~WEqO#8x@m9|)jrJ3i08PPL~$^`D)9#(&5%(pY68fsSn?ii zlvHgmppR!k0`l1D#{&(!h2Drkdy4!33~mZc zqVJI^?>)}@Y!Lrad^o=-HE;GjH>dlRvm&AONkiLm-POB0L;A<6(n3Y3{F^jlJ{HaO@feJr94BO&bV6H^J zKWD`$=>78`zKpC#xY~JY+Dq^H$@{j)voZP4NM^fb(hPV+rH6Shq-iGu!fv20da3z7 z?f9p`;uzmb(#W|tBSq|TcQhb?DvpMbtx)T-TKC~~{aV6Sptuj2G5;4;i9FVXFB%PH zyG|Qid0HHsChj{!8t|dAla#VwgrCQYCTVuN!gO{X+b1tL0FQOPfjM)#B&{*MyS`|-5$8Xb{)c;d)N zCmLmm8fW(KN0fAC4!66fbpIV>BrYC{h{Pg7OT1G3#;aLTZ!E4YHbssjyUK{e#=&~z zwTnN*oa5JlYt3y8&)~U^M($*t2H%JuKM`S}!(FzLuKXk$H^q1`f2e|0vc_T0zHzQc2Ybq_*E486GH<8wvk+yANFFJFdYolw z`2zm~`q&8HkJ#`4>)H?1(KI3mA$G{<-a+ltAqcZva*VE3_AdG{R&?C~1)rb6o)#ao z3f%5>YlENisW}042~l-%q^-Wn5+17w7W}4WdDoM zgS#AcV%2HntOmmTx}5BKkao?ZDJZcUxbfG;H?@2>D@Y!weF~pvE*jmco>0kL>=JT7 zwoz0MN6I>0U_I}@tdhBZ;f3Ffg35DD6Jx<04Wxo#pE|PAwmW^IFu;+}%UEq@kR$z< z?3L+T=EYFD5Bieg%$o7W4f%=?)QI2EhN$<+t#x$iAQVnp7fqO)^2ed{2;;_^TCI8? zA;@bDCo#j8AJ;qlr*&ch7fp^(tqM02{QT0iM8F!CnM|H1K0*w2zM@S%32FPCtPDYJ z8moY0ApW=8Mkwx{UGc4by}a+>%wEaL&yds5v2Kb{K7 z-J^AMFrIk^r(OQilth1^@`fuDR;clxybqI#q~Y<~VVY?m`&2XRObk!dv19VR72>J; z9RS0rcTmX_6Mv+uhppQiA75UIAe&Px^ivF;WuN^3ps|qSKeqS#L!6Yx zMGE;GhL{o{sTrwziN{)IXqzq`i>er1K$|j9ND7=+s=91*71>lnz)i5&1Ct)=6Buj9 zc0xwa*0G0+Td)vTPUtQ?z<~(Tfh|ff+{|Ma?I-?zST3G?*}Qj}rEnmIYsJ>%7!9{E z@eyli{0;`Z&)4z%}gx9WlS%jQn@t8JYF<8NdTwnw3hb1b1 z@tBR(a|6%uoCtfMb`U}_bid_cU`S>_!4U-2%a>d&!&zNg?;$E_s*PhL8mIn_VkQWd zbX%D;`7ElNbV>ixAF6x!pC49cPF8)k_Um{W74ZA|&x+2C*2g{2bZk3^YEAD2MoeXN z8n|g$hr&oi7`C^N+{MGAw#Mc2=IO z(ZVy{(hR#0h}K!Q5`!3N=407*|FB@yz;IXjl}1%nD8&2u;lSy0hgbdTA4;WDcyNC6 zcecS`)$JrYvVoqQ^#*7TEt~}llQa`K%W~`~j-v5ZG%K-2AEv5s0AQe-XmavoUc!Efm{{mcM;=;N+8~pSlQCg6L{W zn?EA(hueoxoB7Scir$ZF0(xredP`*`lL#hR4{V7wNi-ysHfCHc_|>XzW-Kc2Bxp^w zsL5Z^(dL~YJ8i)g}wy?rIih{O}*0T>;m1cw;udFVp^_eqwTd zhhSycNb2Ahlq?CU&{iUyY;uFB^(bg_l&{I^@C3zB6kd?}^O%e#!p2HSmzsq(vD&ig zh(+(U)8%VCK7E%R{sgTKzOHDJgBTEkk$O%3H$MoWRdKA~Jiw&dw&kn*9w7JiRA(}3 zY968p0%w;j&z9gU)o-rCu^8jrM4>=pjljqj^tx8SeUXcTPdqM;Xr$hKRLe>AUb6oS zBtSI#LK61?k^2^40RsEcWWLG%yc?L){87p37sJDzpM&{Kw-89 zbpY@S_AUn)PH4EOybLNb%Y)Q9rRl z_|@bPdaz}QElGX@npj8p=SW~p$Bb?FM%VCOv{$*+7c8joGvm|3&h z2DEJ6a83JcD36s8*gkhaWqnXCOq2aw3iFd ztryu_8nCMF8J(6Iv;0yb^~2(a8;FPJRovEiT2ji}n15^2P_`+|fQ5?fKo~0zVIxFwf>*0?AWCg}DccQJ;+4^tP^&rHgP#8z9>t!^ zDwk%n93)|hU!Q=Mm^UeS43~VXCO$#sc<$C3SfpI3@r2)TNR$RM&BlAxVv&af+EjFc zNk_t+{UKi(*VLqi`qlNR^Cb{G$1#}L_F_~xERs}Y&PiI9u#dCb_lP3uM?D>VCYBMR z-f`zq{dHlRDTF07v&`eKWe;3dHar;eSeJFHCGu$i%f{|?jrwKe@7~JGsgOMt`SEKl z%bo@OTeZZvNs?adEt;dKWu@XP3kYIFUrr}i6fk5{7_cL&jTTW|bQr8L{pjJxf89Uu z9F8@LDeg>g$h&EidBfd%G=2jxLUuRE)OQn0o7K`V3M9jhe=f(VU4a%97MvBFnihns z7a|iC{EsY^h_7WdJ03!LtuRkLs-aa^*`q)w|5Pi zQ2KmWcXF02g;&!gk6G`zzyndNp7b$&q0_hr-r~f%B%ww&sJbDT$^GyK!Fx3lXBO+m zV1LWZ+}_y>D2Mg5{)V2={xVLLX8{hXF?ZmJH7nljbhj!{ojO%a`)(Ai1CO5Yr$LJ& zNo~st8Bwey!tWHuLk)Me|+l0E$bNWl=f#0hv%juP!h=azA&+o9gtk^BCJTkSkO19*O zSM1~|C0E&bP~c7@Za)l&&UjKB9%0{sf3w~0_J8n@r6F6PT_{#abD^&JcUS}hXgNGieo=N8m7}sI_ zf}p!=5+U@*eTS{C{I+TI(rnN}c^}KW%bUKv*N^!#ZK-2+d9GFs*T}>1oaWEzfDx)C_IlDrvv-Thim+A*01zAi%WY8xhQ4e*06rvJ203Uc(^@>4rm8F_y zKLPe2ysIW=5#{$Iuz;?dOgc}y8w<`*@nYx`b;Gg-?4j-_(RBCocJb~nD?&Yo2|qRb zstnmMip?}22`yeKG{sV5-}{*JB95?&%{_<^IXAG9dj>|wo4b|mzMl)64tRoIpPV2K z<*pdMct%?E^K1>AWB7c?w(4%VE!)Myc>u65CQ~37_3y-~uSo%xrXwHW`1(o(EAkCR zy%h=Gtm$erdO%JF=G|Ox&5mf}hpCdg<@2ktVOAVKkbsx+dFQvW9hQ&7Z^FIYHgo{^ zyZ#+v?xg@pyvI>Wxu57X$|<7Pg_)Zh9z2ucKmGC(#Mug?m?mMD~hYIY* zC{~IuukE9UxMpP~yFpZ^HME(4yK^!$+aq3FZ%|MbWH%SnO){h?P!Z@RyAU;E^t_2yUE3yTs;GOy$NkEFw1)^4iv9(e*HJ#OMzQOzB2n*cYFQBn zKBmO^J*w=a03=L`SKj=WI2e4J0JIB2xVrUYL^+-K14&>2ne1bN_HXbq<36ez3??dB z4@rYvLpSyptpcnNNy6#r+uKY7m-pD7%T*@^`ZBKz2AHoVGDvNs0}7a^<4LP(_djA1 zaix1{XFL~KrQobu?2&)F+KHx?@pd!XRgxJ#C0f*gap)fS2Ccm_NlKlC2}jqlC}Bv1 zM-nP(m~Cq0iS;7_1q^KL$yCeUqf`3!cVz0*HtKauaPOtkMtluz*LIxmGekyrf^W*M z%YlNVH?pLOe;B!YAYkVoQKfL{R(M-|GA`s5xY9-&z4WLW*IgUx7Wsn`L^(<<)&V%u zEddO}fstCkq%%SW6I!KM^=xR8bm^dmeb~gCY@-3+6&_{^M%%c5?CV6jS9Bf-C zh5dxS4k_FpUX$#WM|Y=`QWIC#RZLe&HwW(=a&^xe2a~6A2xi;WcsE-VTLah5z{MXW zSm)#Xn6^PyGq{&BDBvN2S!A(EpoDfj;%^NJ6f&{pQGJpaQN`>n*-!7OLdxZ%ONX5 z!N6sGQf~*|xOcZFMlRzH%=8_1m}sl5y}$nGClAHzVEKl@`=(`t<7|=x0RQkDH`J^Q zqZd#8JQ5Ff4y?F-^d<(8USQxC7;Y>zEtXfHG_Y5rNwO8;R)5>$5}wxDdH%-N8Wm>5 zlE6|4ve8D=ELQceJn*+o7bZ}0-Q}+g9v1szH@3TT zwR0BG{~Y=o{VB$ZmVi-(5I~eI&NVK|ykvc762it^Hu7;dz(m&hYDq^R2S`fx-#&qa z6@0RSK}c-MB1u2K#}1cwyXsUv2s?sQqKK!%kq6$t0lblg1Y`q->{(|D?x_^96KKmh zFS_tW1>~SFCKzQ#$ElX5u{2A2W%K`aE0d?PEFV>wE%fNO?XF#zM4s#g4p`DFcMdo; zjA3s}H`$Jifp&qwOAtUAdMZYLA^&G;Iqt`e5n%xV`OmxYzc;n0{=YJ{{I3lj|9{(B z#&MxR#Qv{rE!OtNmgfH_mX_%rYu8QLHilyDE?Ax|x`(_HuH(zXcytC~CYYV9K?nX!6t=qPyLuM|otOYkA zfSKn{>qq7f{QA@FHxELmQ#YyWeLE)&Oz&!xOn~Ff_H)3ay?|cLXSYuQ15$&d=5B!E zYRgcc;cCtGg>@^8=H(6G*sQg{?lgC1lin-8uCH!|spWKHzwRNi($R9-@n2kE{bO~- z`Kz~}zmK1x;D>fY2Jovo@YL(^pDEARYVJ$V<@$+xZ-Il>s9WeD{n0 z>+#xt=5Fmu_N=z=sO{jmTY%Nlj(DpNI4qpioVxbuS_j+h zT%RqUyGhjBq20Cs>&;Ij{B(~Uc{{WlP_mp$bZlsNm$G}@Hhua|%B@&-Y0>W!s1iJ} zez@<-`lxQ;KRm6W2y6{_`>^s`{wFk~e@oJ;-&Z)-_Ku`^dFR)J*yhL-DYD`=wEfcl z!n70pnFHC9+0b%oxzOZIRoK^ayKc&B$oYi@5N~{a{fa&vW74lTxR{-CH1p0m4z6!s64gWrFE^_hzy0i*8N7?d|gKNCgq# z*rg4Hi_^crp#q&{pP_=OnkxEn?7Ti(uy49u@AC%8V110^LqpW>^?unu)cZ& zrwiMKf*e~u$K$nI#)M9k0vTV(AObFyQv#0+0pZT^>$jdv7R5a;Qqk}^Z=5~me>N1c zD?O<#Xb!RE`xq?}8(P*|URFj(dpimp3j==2k3j!u2-pyu`_j(-A@3VD0U z?V~WT`@S#K;^o+|W+e9+uxn{6sDird(P_}r1BOk_Vm{Xftmsk_bXaXU_WaDcy2)kw zvZ3^Jc6|T$!L7fx`@Ufy<2b^P*s;();_*pa@a)HPPz3qlFI1kp9w?aUXLz3u-; zJ8D3|`^#+xdeyHBh09;ygZFU$jSnqo3B;a7UvZV-J-9P=CN1>d2j!7yW$2%G@4w|t9<;h>d;2RXmDX!k>)tlUVT&e!Ay;GZyiY&*1Q+&4D zTmkxSzk%Jtl_?;APs;iGj|BJD_P|H?MQ>w1{lG%|T)G#hTzISPciWxTRw2p%1`&nZFZ@9p+pHLiOCwz>k^cLps7T6Kk9=!)MYRox3j_sLDl=Wp!~{?Bvo zUN74{bfOhM=r()8pSP1u06VsqRlwIr;Idxf-ivQmfnnZ9oqS1!iKc)*bq)1vl3>dz zvPQw_2%xsQV9jnYqy;#Jti?4nwE(SYK{FL1_4%XR(eL$u=mTTRJ}_$ZG?#xTM=c?P zdjlN^<~X@9V}2VgbjHyaI)G&Hy`=C^1}yZ>{<>IwNhx7K0&)>)-@eCwG5LLRAiu2q zb)<)jnDa}?W`x@Ht_UF9+7W4}^qOU)(xd; zZwtyUZ*JTR^MTr&R=}P;_wm${ELN$>X(lpl4{34X+!)l%9KHPnao8aWSc32H0+t)7zO>`L z75zfg2<-`MDYvlZMen2gRLcRT^E37P{=1_qOHAs@yO2ZNMgc&^h1LLztFH}ss1J!a zB>c-h?h1@7G(Jlm@$c&|8`it;`e0CAm{3i0owGXfX49_gFE*Jl?ucZBKkOBj>p>&`g`41phd_o;Vur3egvSjxv4a z9#rfEIuGkL#kFUFISS zC9S&M{XKoXIX?Yn2bSG|H1D8WFnU8b*L_YJcDo38qGtVtxXT}8JN5bYkZI*8;uFk#t z#@QCxP&97WT;DvNqXAsBE4RG6B%MeYmLfE8mH`QKBHR{pG9!eiSDfO7G>)X0N$jw#8JsGy1s1&G%KtqdV`NxI7K9>#x^k0gXyZ zz*7t8wQN)Ta+Q}7cC}ykGF5_e8!6gm8NZWsQcmMA2O1M6(eP>IAZXQgK0o5gnB~lj zur7nvKW^>Z7)e?j5a_1{^B^VgC1seqd*1y7{9puk;)OuVlWNBJK0BYZEJd9CG4l-d zfBFT~hT3Uyl?)73BDv(dKC>bH6++~JXl9`E-Fo2GhdJ{aJ-x%ciJb}_$5mpuqo?~z z%U*%+ay&xS{cM{Ak^kgl(}WrI~+3-tj$apY^Xg z4&Gdg{PjOk`~Q&2hZ^5|)ipe{v|NSLq5ztF7ZpEXpVcb~ytyqs&Z=lX1VBSjsvj5r zSvnQnGB*w+7lPYe7gh=mHSUlt=zhJ)t7X!(SlZhfg32HcvXySa@}WCb!o;dJdl=Lj z$>>xUGo|HaEisn7NlBrkP7qTrhi37vsuOusHIg%lVL@ZciS>pg&N6ydmL;@}*PIbn zM2$~A{|!;1U}_oIZWj?FQa|dvaO}cKfF9Ze2FDr3AwNc0Km=NiNU=qRAu{{n2OJfG z4=`DJo|Z7N`c!=vL`T{T33zd4m|?UO(Mf{0g0lqMzapf>-Pu{jY>S3CmzO^6~;A*ndkRRd~ufhH6(p# zln2nHowOjL`|3CpRD$&tJtPGs_{ejjwf#`%CgknuUoYJBFcW&jrIp$mQ3PlA_FZdr zVUZ2EhEPvKcNNG(Zwo`q+fMjXUst3NKP3@x!B|RVu$qgEbhJGV@Drc3+9x%I8qG%S zSS{evh@p8mFpel?Lct1r&%PIxzNpffU@})8y=}i2r%x{>DCFq-xX_4do+II-qJkGsJhu>^n+lshlz{#Lui%Yq}Fv;S#-977ca_S(?1D3pQIy$7ua~ z&T^!1MOS=0c$v}jcRXq38jghNBV6BUr8oNsLIyR<#u55*<=|h)xGWjq1aO_ZQV-vN z3`rjsX6z>+YffdNu+v@>PNiL>gf^zuu^|0oP~j0w0LU7ZH8!ogMMn#?6o&dFb){7a zF=WHh;gIyOz2LTf;Z)pOSi=`fq?j=+CVf>`|1T8$v@#YAvUSU3gN|^xfKlW^y)~+p zJeReh95L8oL7qOeM1N^~$9{wLvYdpYLExi7;Pxx)Kiw6dIYi!bR^XZb_z;Vu1mN17qDMHl>m&G2}m0uaLzx#p$2L zoTZc6X)?(~vKw;iBaZTe`sr|Qu)0W1&<1taNfxbUA&}%uqkFWX%vGKlWMuW$h%M5;}mO%r-qtsFmVW`irv$UgAEz$Z$4RYx8Z&}33h7N1|UhwkjjI*6IfiBWXZcu?#p%Yfndh8$o`BOV@8>bUi#y%mRSq~K|SAJ>k6d# zH;M!wN~0_sbEbx&^J^p2$tK!GCE3D}K3Fm}JqR14YJGS<>I3$``iKIpC4e|X?ea-f z{f6CZaK)>ls!xh$QIvbs%2@s_e;%g)5epJ_x0Sc!SBVubZL>IHSQ<+eFFUQZElj3) z&S;gQSXQwn73eiER|-EQ88Y-`qmFogDaGxYwSqNqkbHcKeY(rK8r(_6b59Y1lE?PE zlR8BopIv{`gkIy3D0JZw`Xp?qhD+PS)YA0FKFt!AFOwhlY5iPSu~nKe#0 zVZ{+BMP^nYj|H2cK|1i}rqdvLl|(`3A`+qKf@L97SRHmgZr`CfwK1GJc6V#cn(&3q ztm1JbYYXx6czil^19;fmvV=IB-LVu{F0U7OWS~<1qdOlm8#Qe< z-D?tX6|ROCcI&X*9=j|bP6s!*?EWzcZIK#UNq7UL}f3xvBf-<86-7t z72s$N_mMAQBVS5sjWj#>yAR7m=W4PhcNOjKx4=#WN-SRrBYnxv6^cL_0`i_^$?}1u3Iu`gj$QEaE;J zM%YmXPg)NRE-$x?O5&s4Q7O z1{K*zO+VbF7v4#Mxw?*lpI^j$5GrL!&F3$De{e+imUs?$)mJV~HVL(<2rpgCb3su3 zizM81z>k`F5FBNJJA&ZT&W?1FTbfNHT4v3^qS?Rr#m?r%ar@kUpQ^jvviF)u_;NbTQ=i){i8 z3{{^(V?trFw6=dNH8J#welJXG5i1-ihUBp{V^A#S15cm|?mY4>m*IW`ZpiQaurbi zr;iC`C%pfB@^x`RY?hx~5-agCz+GduMB~B8qpSWLu{I^orFm%bfLJyg#aY^sVaGUm%wtkQu@qix@_p&%C2N@#I zcSG?Md$q7(mTKtE%k3>297kpMi!+cAp?!1x-kw%@jvI=&2n$q?N9pgt-1C)>(?@T% zBNWkYum9omsYh!b$+S2JGxaxQfEf0GE>d~6C264sD~OvXshbCQ|$>-iQY)P(L@lXhg` zY4_7irX$maEE^;!P0b`Ta&sIk>F-be~0; zblGolOT8I;^2I#I(v&*{K^LpuB#dQQ2|5-`Ng&CVf|6#iD{Cu`X362ReQ2|MydtD< zNhB0dm+`qui|Q~fM^{E@xwgxS3Fx|U2MMq}6cqUrtT00Gy9j)`2l3TbwFp0T_=uY# z7J1|&E+7KjWvNx`rAOJa!p#yAE(D2UjSku#-O|hb%>Ru@5AwU(jrh~ksf}qMLq1$- zCx#onO>5$77;8dWr-ke6WR`LMHQZn!>LPS!NH@dl_Vrq7Y^=C6XZF$m@FC)#=ETSS zNc^>D4Yc?y#J4miucq)zvr*(>m(3AFSgM?rbFN}i(~O)XYnE)-XCrgX?3b4uMFvys zfp7@MevIncZp^Msy$-d{mpl(Xjs6Oew88<>#B#F*_mu9Wyd=f_Dl-cdi;1&%6RA3c zx}vwL6BoBA=oDPLO8bl0r}XDQT}Gq2LuCuAmob*St~%ik8q*uJxN!EoLpx($k<=f* zno4ZqzR^VFr-iZ0QTS?>90#c`h2zyuvANlJ3Bjl-k(vytq%wV3bGs7T_qbHCc8ve!Q#tVg8S2fnV&LmYD$>l?j|zg7^=5cL+j4(z~sfFUVX#^h)0! zU2!3_1(2$`f&627%UUUA((IC|!i8m`LLzvO zzID3mtYTY`ELILnJze$c?fifE>JLrdI7YvieKpUeHjN_^hk8d}{6IB?5jDX}G@YWY zmDK{&sP|n?2`h(dYD)*mTpz==mxi?tlQz7n*(*)4`8E?k+|pSs`Gie+aV&Dyw-p+U zMJelfk(E&0BKu^SZ&mC2Bd3Up6vj47jAgg36qlrcYqYnK!-yeSyJWgd3;zs*A1Fzl zxJkP$F51@|&7EM0~s+ZmkVKsw~2(~6^bD^)* zdGd|c6cyP$vv0!ns!LVE>OxgG)hfWx(2SXQf4>XfElBjt*VTPW$$lDsjXzp3E}t!` zuwCYVjVx-~^6DSFvGm9(Htr>$MM7Y5LsP5u@h9`m^{_D>N3gU0w3J!>qa$L0A&PS& zdaz=s!Q5OmzUo&*6&aY1+#<=r!zn3Xp-@Xmh$WpwV?JB}8<=00d0h&Ulq2}KCY?fq zWk?p)T?uA)!^DU(zrH3{39jIscJp{@91?_HzpjP>(pTO$j+?LB&kXTWJA|@Bm@QX$ zlwQJA%Zq|N4KeL{6XC>tQ`qRbnfNj@nbH;-*s|&0w0LpM2?{tzd#v`)3souTqZX6n zQ+-Z6d;y+Fge^)-su`oct{{}|NC20oQbW<>VnF5eJPHa!!}+%Ndi>}0ND1x$xY{Gj zxR$WX2F903A@8P=IV*NuKJ@phT2p?FqH)$ODhNG$m0MD#Nmf91 zzH+5zPQ}yRmOv`CTs)O^q7lWVBcWmf!V@>r3zG%DUz0ZNBDz~mz|9751M+WINAKI1 znHybD{5*^H2Yy_JQq3t+)rYayn>KVad(f1i!p(kWW!_I9mLZU7ZCOF|m)7nzdEGZP z;g&u_0u>X79o>(b&3Q!|-fIsf5WsSOf~GJZD-oaT8>e>K#tZ;9&DVAGieh!OQj7af zl+7}441JgS-Rx=U5PpcQ6fFuOAg`G^_PhV4%`vim1OKIYPrV&}6yk+M7@R8-KJre! zDq}3>yf{o4DtArsy{!{FPt(>PEV(tjuIYifudH5L@G!f7Qk;~|l`jSs7Yak@(w7c1 zOiP2=@N{YmTgsL(!SAqJwa$F;>&CGV^EW0py$2Vo-6}wE58D%GU#N8g`Dj8C-`hAh zJ;ExaKG&&=Cu!khiDjPiHCaDSnFHJ6#HwSB_`8poPh9SwM{jQ2TeBTU6zY2s+k{T0 z1|oza9)1U$(|sk(1c8?<7kMMlmX(oFFADjAGIMV7(ye8d)RqV+>$Za7jeLJjG1}j4 zB4tB@k+FB6mN$AM@YJyXY z$(Q@-6dfYf!O_$dbPos0^Q1SDtXs7|4niGz$ZpvEth!)jGQQaX?U-CK1odl1IOp@| zp0y=Y^_H+#WuY`tS%iijNg9x*eVi%U5_Q8;8;14G@!^|tt=#8$2Yk<&og;~OW7
}K9cr`FmJHWLWjdpHKw!Hb8_7smI`p-PmYcmM32THkHk>dXER zdDYwjJxyhF=q4y1>iq+*_dTf5Z17?3f}0MujXIUuMQFtEe*T9W$iHy|nEEB7tn)by znan?7PK#}Ig~VxB?{;f6_ojUc1uCm^mkK}RptdSMBGv+nXLQk-iPkto%3`mJ(gHh% zNTYb%Kk+Op$0=YTj+osP``@WLztx0MYos~tF3!>P0uxo(nmw8BXECSbo{~y5J{Z}D zZKj;HyiqmeuTRQ}j7of0+4V>-Z7Pxx=?SX)H;zg zb;p)7Q8~IHYG%g}vU_8=WI$v>n^?aQgqF3dbP(;11O=mj^A&9B(twNgRZU=NcHcY) zMjK*Qoi1ETg0hRaik~BnC^Oc|UY^%BEYP8w^z9&en&E6oC+U)aVMr#$-6M+drH*n) z%g7hSI3(pzf$OvlT*T2UAeIe(gjvyWJTWOalnr8@y0We_|HOMzm7*p$Ex2X(aaXFI zRU(>xAfHvaqY6rL4DQw6Ul+5P_CMO-AXIGvRFD9x!+*IuzkQoFD-)7v89hxhU)mJ> zG|z2{qXHjj_I+ijcFs)hNHa1txh9X;#&#iLJu}g}2|Qq@Ju5*Bzt_AB&OYx7l#SrjW-j-4VL>-v_+k-63mD zlYZ|=EZi3@;PecLIJG*pEi!xi6}vmCDHJt;;fNX^ ziLZQlT}=2Bl>xN?<(8&$Mzj zTQwyQHx?z-h~tUcZ*l2eWz@Svo8wr}c21r^J#e0#3iox+CnE47xQmI0aok-?JLQBX zc)vQ}Rzn~GN6m0g#W?K4)|Xe-JxDiF$XcF5&h%euV9d>MZaGk^ zHH9l?nkB!z%#=MzMKS3He})N7Hqv4i&$o?v{yUDMy3l2c4ha`>$7#=R6gON zKdZ@QD3~X-Lnd!Y(V_Mor?*IxD+aa{$%y_vv;JmzvQ2glb<2&=PW9gvUA z?6jd&&<>`W7oyEVFo#R(3mJ8kFzLgt2lNMvh%>k--47Y$Y-^q?awPb)x2iF~}aAQp@x2=b`Z}&2i$4Qs0Erw+5M@X|D zQ`sn|CvjrgMF=&dtg5h=<*f;LFZ_xXn-)+M_y@_XP|ga^h$p4ABimF5}YkzSF8_Z4*?XtsA?aeSQ8k3F)M@ z!6<7ILJotiI!hhfA8A%s%bLrIi?j)>4b>a-ARixIZod05lV-`+?9j!m=8p_j)s502 zv@%2FYQuHYMf5N1Xs>dIe>Nvx&K~b<-sdJhd|HqD_Vc(F{oas}%{Y9dJ9r+VHma|L zph~Whch0dRmk1bLS0U}cInrW&8zfj|*FV$4Wqm{E2nIJXMPO^*a;54iE=WLH1@OeQ zdUkpvsk??!!t1g=+#q z8(J+YBI>m~$IsCmkr0)$`X>jf{858=EUK%FN&aTyoRCj)^}iX|Pjp$7YVyS}33kd8 zhNlL{g}hRCof8_27p*=xwuiV>GATfUM=egO3ljcfP3U$4Wo=w2Y{ZaqGL#T8*z_VJX${n+t?f@gBl&xJPnv6H~*-R#1e1t{@d2 z>kwL)CrRmK9d=ym8)n2_{t1+qYzLEoeW+NT8?bu$?ZXLJGe$d*VxVHL=(*`gp~_K1 zIz2c^0(lsk68)yE-3Vzr7mnl(UkS6f9J|MFU-Q5A%Fdw_(e>Yx2cv#9-pTM@vDafh zmk2BT3SpvBrgjtF!+?F$q(cFAF}}jXRbEo$MMN2h!BNnFs!EF(Lo1w{Xd5AY{tsE- z{8#B4{+Vs#WV@+TlkJ*pd$O&`wkI1W+qP{?c1@hgv*+{O-PiuG|G{%VH?Oy@z7@P# zCNJ47q&M8at!Yi8y>`Gd6*h6Ia&T_d6|A zQ$3byEO3g^7UwWIZnu{Im3R2OIh{dJ8ztZ`w@E%pgu?BgQq_-^=DrQv=vEw%Akjc( zZIX?x(2$*v9@f4iRc$c%F$@1C@6C~u7<&l06(At??vk}_vs|%^C4!4fEh2ZM2;D(f z>&M5aq>q0Ok$OnM$RUDgGXGxKDcBv<=F;p-NsL)WgHz9IqWz7k&B+fl&UKSx+j)?{ z2u?5>ZJoB2SnFd#UGsLf8fllmD}{SANl+=89cCHp4toM4cyuG{L`WkQZCy2OH%^?qbeAUZliz6-XvNAbWa(3QL52p(4 zNCNm99Z6NbCS>MY3&9gm(y?gnDf5Jthxn}QJP`9W{UCy4vRU<_>3^A_=ECR+TOV@r z@7gl&4}e%Qf3~OH29aKiSps?Ch!$aP_skpIdc~DB z(7es1HD94$(kH@KMgx&;(Ngk$fsDYswqtQOx_uAKv0HkTOOb(N{i`UUnH=Mr#U=WjL>JAHoiQNLr1rNB z3K=XJrHfBwG~$V@9UZ{-2bUh(b4}FVys2jP#AI_$p7a(Z{)ntLtZWi;*hGMHc2CP2 zjD3xe8X5iyM~Z4l^ZdLJi1S^@0Ns+!?`rigisfm=jMTlD>*SsCECTl5V9)KUph$2pSN(lWk5@LcPr_=vy20QuH)g-Rv@^f2A#k9sqkn_NX;!63FgM8b!I$Q zflVlJq+?p>DPv@ScC^u@wtMajZHYyXwXr{gDX%#boo`p+>@!$Gs{LXWB5cLcl3<+nSh@$pteCmT!d~&? z#!b*ww`7eON0jQ6&=#8H8PVgJQB6CFsGPQKM2&*|_vfzLn+?=So zmC2$gC&sHx_?n$fH03UQUsn!8E^EKtRddIY$W}$%vI}T;8B;l?s{Sa4NB^s+`6<*~ zf}Czr>W8U3c`gnuyRz;@%(9r^tp)D zr(x<6X*C#!xCp*|Lt{B=p^KFny|W?}`eF{FId;D~r?M}IA13|_8tLcA5;;N%pe==! z3*7j7Bs{fPeYI{7E;DK~pOyQY)%H?){cJI%<%&?wQXpw1YW<$nYQYKpFqDJGACkZR z;YwctDY!b?mXL>I&w+NjNd&{=*Kij44|@E$V!ZI1!F+$MOKQCwQC7w?|5G8fgH;Gf z>IJnf;0Nf#bDFp&E{v$Q_iGRl=EiiO&Vsi1z9_*8<*}&j;0w9MYa_q%T)$$qtX#Lk zx7-#khbqm{9SR%?NX{>N)pN1jaNEhMf24-x>7JPxJt_XKPZE4#@r>?d<(nIC!N7WW z=aQ?`6b3wPN5hGM-42>KgB^v?p|RiYj#1!a%q35%QG`}+zdQNz?*Rsa@zjH$2#3c@AEtTuw_4q8QiKyya=4?A)=>-%#m=N zZ1}bfURnTGjY#=Bh_Q9#5(cEnsL>)-x{9a|0%^g4x(H}7Tt$N# z9kf*eIaQKuHl@7p5IhR1l$1jfXdiLqF0IMosXY&G6*b(=5sFE~#P7=S=}SkkT@Oua z3X^Z@u&fg7-z{Y&sXL)mrp<#T33c>>c$svvs;;TV!*oEq9-hKdg((WFdb1#IzVnF( zKp5QLe(I>h#6E_(V)i<9C_#U}bxT70HLU?JFYgIqS1>#zJ#cBm`Rit!e~awl*mwwj z-$%FaG402xWk2MU&AdQN`k{^d4~$W+ULzLGJ{~^Z-y&qA*wv!UBold*D_}r885n_5 z(Wswxu=s2G=RgLdEcDXt#&jDkM)@eM3YC?3`N*f80_wRfIsHz~a=hs{X~E+`?e z6S3mEV|}vW@Tto{#G_BASKf!$kGu(8A!U2%z4bnKu}MzyAd`)j51#RZzvLbqN#dafDFuJ+Y$QV2Z6Ng+qG zwOmOLH;6NGLA`J%QZEblYC@3R&y-=z1x-C%TQC(u6Dmyvqc2j*KJ1U2+N8)!Tyc_V zz#s>0YZ`U++~L$R%!B2G)o*6dN}p}CCr`6cy`|iwnxVzd!DD5=-g+ zHa)eqWhw1Q%NopFR9#jzb!`nCpLH_$mCG@M9z*sNE_*ShRlxWi`y_almUAq-TR5Z7 znqA-u>~H&lc$W&0^;lF=#NZ$<8c7*XyGEYW}db&mHz-Gj;tnE>3qMOa+)b3^Jn9@GswXHXgsep}|o@#Eo}#i>kL4jJ$=Y{d5HeCY_~JQo6)o~lYxGk@K?QB4GhOkGh~6slwz5L zp>$74k1BiUTb-Doc#;o0VmQo_49p*x+Cdx)-7H1W_d>4E|BK@zIxfMVI%;Cx$>5aN zIjQ{5@(d?Wb$Ps2%rleISUl6EoF9`!&415O@M7qDhSV=LVZ=bbB}Bj}=33Dgbv^0M z$>hks`2|UZgeV|Hpv`=WNw`p-s8qB$&AC9>YyB?zoCHh-3$6b=zMPy%TN1T=hotm7xpDAp?*|O3rZSMRjNliogoW#PAl4$Y+;EGRF^nX7 zp5=FV=^+{XXJ@vIKUN;got)X;!1<_&-n~F3<5afbjzRWPA%PcprkHOW9A5))b2n^$ zAd#A11$JAfG}L?u`D;dCTNI`FORU5UJi1L9y(SUyNREez+=$ezevXKq%=E;6};Fu2b|VsP58`vTZ#(^ek$v!Ie#xm!hyONmdzY9=r`NsTX`h=BTEdI z?2hBv57!cZ{Uv^QL5L^D#Af5wt6V+LIY$k=b1FWji`4afb$@$j^+%C3$f;#DbfR{q zxT&1DV`&V8F8OOF_jxQ!I<>fHg|doQr&uI_-#{Sz!oMuiMV8>e z=0xxfuW!~BL#pa7)%-onV(^bp)DnBm>o(2txb?XKGA1=DPYUP|?ZX$nJ-!ICy&!qh zyx1JPr&2~^W<<#`G{`bblX4@%AP)k==eNH-Uxc%3WT#ucSA`hs|WZfheldu`$_j_jf`3_Poa-^ms4&S9v|2uir1b z?`)fEG}BbJrl+uctnSpT*PPDIm@Cee0*Fi9LCo&z7q=z+8?8#ZBhq25?lI9vG6N10 zY1`d;Q`)YRWCFHmgv!TRl7mQV87*U#A}Mr%7CG~oDQA9;qw{urJCo)>vI}af(?Y%t zw0`{y-^h|2pju`@k~~=fQcE5qd)-S^_%6hj zjrOu3BI`=PP>~`SLemYMzpc68nZ&ceykxwh$7D9sBH;_+)tTUDD{KZ46`!Z}5WA*O z$_`Q5BU-H%RuAzAhu0k(dC(tdB^>S#nFIc@LDX0EeMVj>_z0Lj&(qaJDNk1@Sq&B-`4yv|>YZG*qq?7bkMl+UH?c9BV3 z4v=dSA64}`|9Mz_ypXJsg%KL!n*lwS7<(4f7H%u=$2}YHZy4TmH|OUgbJt;7HE$TV zbkjfOMtPh~c&u7X1y>^FAL$2r4eJb!mr)ts!=RGydNCVc^Njco3iVgf=9sjds!lR( z=athN*=K?Uj?YBk#Q)@NsNt-9NN-wU=RhhvJf;#a+$hW<#jBAdjNvp# zXzo~9O9lnh5>O9m!kgJtke`UI_x1SqLpY1yggK$@R{_L2!jX}{UqOv-O@A$tp=hsH z7se}Dm<-coDe=sNvlMAJxJr7}SYx8`Rh)WW5fRzWQ_;{07|l#_;AGRoE%;3$&+mPa zd9&Gj7Yd>U|nP(}_QdnLlJE)T-lR>pU z2__A`Tg*^Ifa02Dz~@qZ=}#es`=p3(2_`MZ>Us2m<_?VpOS1z3Uu&r$=~Hgk5Vd_}@tu`duE;l0 z#)fn=4;I-KDCJJ2%vY-C!pm-P%`$TJs+d*u`XVt{tkvgH6R3gj?%;`RakMnp?+W_9 zSm<557_d%Q>=&~h>lhuWlYztk*au*3)FX+!IUEQVxDJ)^2}l-pF6SgN?wEdRplL*p zp70Z*G(rCO>2l0eiwtf^V@@KtlNuD_Fs&q-6mlZnMPRph^lPCDXIyh`$05UV+c+N5 z(@>HsJHD02%o=w}$`!SHL14o-hr^4NDFii|ZkiLZhSIP!JuHXkk#V zVum-gBw#)UirG7OeOP%h=OImS5O$4q0gGF^XY%2Pu02})vXMlf6XAca9>^|D3Q088 zwJfy{?qeuwLH(yav{M5{06?&_rp_#+dzrX32CyOmgqC0M1@#-B!ymj=sxaRggWMjs9$7nF_&Y z0B$Y~JHCpNjz+V~hfvNAQr{qOklgEMsVr1j5b3K;3ptPVzkOM!iZTuOKgJ_AWu6lD z2^OXq25B+yonDBv$Bemlu#dsxl0d%;e@5?VDOQGj$$ygmA(e)T8i>TdU?pcvak$&6 zb6$5*U?uZ)DOG5^_=Yb}2nI=1Hx}6@Ra49HX87usX4erz}#CIBF-f>MSj%}f^ z+Z?N5f@iKmc#;MK0b{T8l(-2=@X7W6LGEWcUnl+E9I*VWDZ*%12iMNX{N8Ia25#Tn z1T%YXM+)PKcHW_o?3tV-O9c+SOg+a7<+hk{*YYUA(S2FnIQ|tTPB8OBZL-W;fBb<( zxjnLil3@%S&^JCiteSEo4Wnz48Lx8PtBy<*a-N;6{vVsbXoJS9&XjF&u=&I2=PF{{Rv_8XHhDs!NUFM4 zoLL_Ei7C1~96eD%0B-%0JA0^@40C3F#`X7tCqwl+N??>2Z=XmBK4vJpR=%&@Byz`t zGb%#oD%r~<6eRPZafs4aydI}qfybmJby;JN#?M7vgVJki26Sr{8ph7o!-ry9ZCTAJ zRwVMm@{Ej&(Ue9W)Fwt_XF!=X83%&|o+N=aSfQYN>N4oOX7|y#Io)=EfBSp)Gm{OT zcvow6>9w@3yUGC$z+MCQjrcdTT*&_QOTmbmX8ahHDd>7D&vsqnh>^)y4NNygg6ReT zW8sVoc++u z(&jlO7e;Ra+t>a?sI|YoKFsVLZnZhOc=N3%eS=KH0&g~1XYgjbU#`YjdsQ_7Rwr&o zxKBSPFXvMYQ$~cS0WrUJu}9eS*_TE6VB|mOeu2GDyQPRdqX?63WfE2Ed0nH3sh4?2 zZQFF|X=7%*hMCS7bmscTfUz7ED=LN~95wDN6f|ADoRlc=9b*X**)F;j$qiGh`i!O~ zARqCn*mk%)k*4IO4$?G_JHzUoUEs}kii|rdg?%cxL~f8iMWf`2#C?v!2Ea`|(SR0x z0Yzwkr^&Rp1hYs)r$Zkj6QrjKCQ+GXUFpFMr>b$*@`9y9&$Y|!Q5UI^>?oM9A!U7Q z)x3KOCm7=Oyv4ZE*EnqC#l|lbA$5P`O5|Kg&YW#>#a=|K{)lievb9$RZIDwd!^^%W za-m**-TPX9!Y~Z$)Xs(a<2TJGK@qM2)a9$t~(t|)`jKs33Y=v}Ho7(rzSO-%U zxI}a6GQu<$Zy!35LmNs>3owV`ws@i}a-5|@Q|rz;(&)Utr$=Q#4L6pN&L~y5iFwPR z|Z-9|PTN8A+b3Z>=NFbiu&5NVVW&SA%D~Y<10ow{x ze4E74l{Cu%g-$P)W9v%xTs~TlfrMM0s9Jon(!(7`Nd*&nbH=pN5 zOmI_Bl`p@~DRvkVOIl%xk9FC}o%MTFHXGS2*>8hA)k?4kxzY*^R$Y%bex${#{YaPa zqBOccMiGu`4WO(5kic+W7t<&Uw+^WXXwk3$QBIZfW6=|U}uHeUz{`JA%q5xH^^%Xo@)~RL? zNHM%dvF`d7kDOqoWR3msWeNjo$UN+XLxXO|{J>R(da#pnB6K62k2)BHY8;BZg3oB`IfJQ88M#!1uNR znyP|v{iC_!BQ`MyzO_c4dBwFTC)(AR(L8?mtQE#xvouND*gw2j7n?j5pJhrRgD@7q zM_k+@FG3bCRfn`J7A~R_r)2DIW$5S*{@Xk{zFU_#+yWCSj4vZx zubPnpn~iO~`%Ct&1eeo%%DN@*S9AD^fMlnrdL}a;ktB-%sO4X~6K>l{>E7(;)Qk)y zuAI#im~mE{gR>TC)EY(V7?h=huc)5FqvYf|ke$rSnEBk-XD&Q9_(R_<2v1}aB~2Fg zQpCqk**8d-hisCQO5qH-zdNqvwTKD2TuaGcoZ1O^?H}51(iknVY##n+OUMLs2#^{c z@vh*@{_?Dx0P#?}nk`7x2~+Y`o!2^7|6*0>=VB!G2_VXB&XEfK3>P5%k!HV#O>I7N?Mu_NM-=&yn{$kX!38Jg3h>M`%5cB+6FrS+pQ z+<2gt=wU&t1dyqTngy6d@|57;-VZ^nv)#eG5=%-`ob@l29Y6L0r~vHF8=?YJ9l|=d z3jS$0ZC@gq6O>N^o{#x|xP^Q%^8e)l`{1OJ--~Pm0K))irU&5bB`o7mOg~1NBYc*& zrvJhmGgPq%nk$cUe0&m~%n}Z0&6(&pGas zv%;sV3_6b+di(=lGS8$FU$jqtB8eVYgS#Ag$U@tzUz?A-Zk_sK$%$usLaomoz#JXALE9nz=+vFNC$g`ohFfVyT0LPZdH97BGBeOPs< z@oLHu0)7AJl#&9Vk6&lyrj*D4yohhDTVuP4bnb>AH6 zzxu^JJDaWKk64*1o=UAYe8rVJY{d6sS6G?Kd!E=3%DO?-@^Z6$*sN}4?051E_o*Pv zjf+Vbqgfsoot}SxXZDiNaqjMtM_y0~yNiuSKnNxaAB^ zg!!bW6sGtQ&G)~8QH}t+-Cm))GTm8C$81Q)tN}R;JGktXwrgX(CRuK%@b}Db`S8D< zhc%3be!ZWPQjk#cB5fRlVuwH|lR(sB?Qh8o0{Q;$v?hP)hNTvr=Cvfas;S@w)WHw~ z4wxQ5Ofyr=Y{yH8h<#vIIOw59+cAG~iJE$7mRmec ze4Yl_PDaI$Lo^Xd!+v=zqCzt1@9FA^i8~HiR=>*+7Ts4;^My_$3FH&&zo7c)r%51` zbAq>C3}Kg3`$bKJ+9H{D*eLfPV;ip+B%yiN?V4EojiHKJD~c@DtzdOIh#I@HEH=5` z6mks8M59ucD-scAls6qRxi)$d_!_%fgmzx1>N>fgx&V-?pmxQIu~jlDR7BY^wt+y% zDvnKVFJ5)ZnKTy5)fFYYR*p`mpd<-g^rRb-auV&h$hKCXTRQ@MAMEZUv#hKLF?Wyj z1Hd$ojmoo+poEjbwOUES=n5{g@EMcB;LdzHFMcAK+b{JX#HDZQj_V9JcH51_$F?Ya zMaRgbsv^*;B+FFOk|z-pCBn@qnjWe~isnI-|2C5RiroQAlf%WDC5=Z zt0Qe=f|mu9{*nM_fcL)bBzTRDB&JB{UyeBj14enn3{Wng;11K%_3sWUAr_?<(qq(_ zGlxPS)tnwU_&SK8(?cwSAf2=f-9D$lQMty%(@zB~VdG>nq%KmFdkl>I`pvYtUjImu z4pPx0a+Lqlrqg_7SS2TnivxeV>~s+@9aQrQ`Z1&3{y(TW`K^rR*V@KCpC{MWPxez1 zQ^Du8t;e5#<7yy8jV@L1%<$|`YI5ZmA%pLE(3Zd&h?f_i=lKeVqHVPV%JH{@N@qJ} zMqxPD0<0az(wxplKo-2385!8FkXdenMxzeLD?8Fs9(j>tIv3;G3b!k2F8dmoW<&mt z6gnt$jGc(1i_bwtIbRDlko>Vzx*jltCuKhHLwM!q=$L1=PyA9%OMI0Esko?9f7JFt zz%$_T3br^L*L$M0f43 z?%fo#caGNe#s0UW@mHNa#uB|D~XBuo(bgozg zuPCpE`ksPFd~Ak)1$J$~Xa%)qowGR$uGYRaZfOwerzT2wl4MlXpm>30g!?@+`V`|{4b=qB*4yvG zt9R@f3X*sqQilk!8n2xdR*xC^1~BAbh-M4^-~BujBQ30x+}xgcPwHVt_Uv1DCBTAx z%S4xwTPvYBgCNIm(N~4QzTgSC)Nxq*))k52z-r|LB8gk$pI^K!5FihjQb`DA;){~F zS;OyN9*3C6S#MYzuP$yZqPJU1W9kRU#bedqGO*9=yj@vEi}OHK`&#M^Mm~+bxWD_1 zZ{w>q^wZ{@6!n(sjK=cJoeAhfb2ti*))>sSc-2Uj6oX^U{_fgET>=K>Fs^lBXL&Od zjsCCNHpPHP2W&fhrgZ=hWSfU!xMdf#B>IL9G*E8AlFI97X8mGkcR@h19R`zK*h%r{ zM&3ZVf-x3nI9NlaCCj#58mM?;9HpD0K&;Vql&gjHcn&Hm961%@v7bbv$sqK}jV^HU zHnOi2kPr$ow{nVj8`2@F6loZBz0jkl%NESF*%4 zT(X*q!3<{kAJc#lNQ{L!2s9Td?ZHK3&1O-PCT>zkJc5b)#XbwrDWREeJns(epja#{M3XY$XI){_ij_0r=jF@INST8x;&`a#w9C=A4^zp?not=C$ z$olMQAtHm?*S!kElONp_^fj&ql&zo}Wa0Ub~NM#w`nbR=8+47=uLHd!s{Cla0$ zU$2;6VrL9#o*pVOs50aXR-eNl;kno&&}oC`;sgZE^osfahK2MTS0w~{e!+*V{3d|0 zLWt9GIJ#(#*Su_)l2g4s2In0G$+&pLfwV-{1crHO8Hy$Z>yicnuXzNR~* zxxyOQyeU=Yuqh_yA2uZJGc)j+a}2)0!@)PWs7C&hjJ~`vdJ%EXuv}Zn>(}b|ghOGspTD zP$-3Iv)Yu!86L6h-bx62cJ#*XDM3UHB6mDtUzuH0~(8fAOOKCH#_Z+`a!du!aZ zwc)r~gR;}MeI?OEDqhV$9;{nvrWwnU12v(<>+)(k+SPdzmAHHjWb~pmaA3Y$?!iec z00x%4t9V<>wI=@YBp68}xsQ=B;?CS*)#bx<|JtgvKvQb5eV1?PR3NIZ2i++rmtJZp zy9zW2p)5};`k=X=IZ~@m z``rAPrI#qr&$lH?{)ym)T)jHibZX#(X((JaXaLSj60a=+4{GEDh_{wk?={_ogrFJ5 zI>;38QqwHxOr49+;76z{S3I>swu5VCV&=oQDcsKS>rV(dA%i@Vkbs7YfdGc6m@f^^$o4Upk$Po(~iJZJw&I5E|H3gDhQcO+hJq&65_W$$+N2 zA|{a)NY-oGmz-7}_M-!(qBE#+^ws~AI=uuePt_r`jArCo5(f!ODwj3DzOa{sxd`)^ z*2S#6T6AWz5sONqWOx2f9RPFr5&9Oc6$Pe?)|9oSPL(^}Z3IC)(M(dIx5E^^&jcB8 z`NLF1@;{Nnl2pfW`%1w5T77kP~%fA3p$sW$6EiIGk>7IR%P*Gx& z3rhSU_htS55fOkZQNGj<@T^32=18DYYb3H82n|>8mcFfseA%S)U3^<~0OS_ldo`l8 z+{!ze&@`X8X`Yzq!0694yh6? z->J3>;|-^y!`1EWFB_+uN>ta%R1O3$e%*~>gp``|+U`3z45*S=P`Fd*&We5V;#Qe= zt(4(><6UV%dJ@*L8|h?d7**HUA@F^66Z!#8^6h>I8cB+jHH>s1{uO`WrpW7KI#U?T zs9oOCo~{}a-tc-aD|E*lBynRXr2a0B>_sk)*lSanll}ub=-}&~f=w$b$f_g;dS0SU zKgDC&#TO@RmB!BWQr4JBnEH6Od*ed?Vuo*-$$PV0E4Gk78~d%ih%D$aa6u&VDyaA& zFTxWA=w^%ThA*k95jL3~8oFIV@dOLIVJ_*gzk!DGgR7#3sEI3AH-wImBnpm300gpM2zE14m$x@VEEY6};H7 zj*QMi{0)6_5zA?);lt2K(qiM@a|_^>+M{ru;~)n)1zOQ@Y?QL%!eZx?a-cU!;0|5H zx3ng!=4_*d#9Yp4ou=%233Pr401{^D@MGFu9*o;}X44(jFqc$E+d8)$C(>qCuj3bL z)9Zs!V)~)riM0PS4N}T^L?AF0~#gR|n@@Si_jR`-v5Q z|F*I1^QVxVvynZ8mSfyxdtI)Y0r(4%lCRcAzfV2MVN9ex`pQ2+#2)%+wSiDDwgrHL z2w5Ee7TX81JsY$}Lp3gow;pV+O~y$TBXEz&G_bEhhedbMrenaDw%9x{`YK^mnSEfj zd_YVsGe`-WKvZz9UC&e9NUn5ot02r;oI}wCnOQ8OdU`!rRO}%sK417|4g7URxs>B# zoOFYRslLTma}gtJ4eYl>XDSM@T$Jb`9&kzw3Y(9VBW6;DI^8C#3}A+D3TK2l4bVYFp%p1NNRcj@KwF zJb3xV`98->VrjLEb+MWmn?au1JKXxm@_#7`D($6oz?p-*%!Caup_=G|*rvp~6WtgT z3uejrWRsTDQR?`M^EL>%B^Npl;W%*Qfa9nicmPN%gjH;#AvpClR31U)sLbx%W3IGA z*I!eBj#03`g_;;M=kDcZ9+fAnZHSAg8^2Nt{uGk!b|&JI`2K_{AH9DqYvtWQswI7% z5`sH3T7gNSf*dR7MoFP&E~MIXPDOj6z?fG%xqa5pOv>ECRk1|>?O>d)R4PL3w=*Cs z?*e#PrTA+KD@qkWkEVlrWKBq`T6Tef3{@Lk^S)9JCjM{8QWk0gIfEsdUU>;v@-^qu zi|YBBU<)W1LoxZop5_Y@vFyP)18B|BI~2hes^6XczmVFiFs7saNTwo)WEjyja!hU; zc%$N#-+hG<;|p$#&jNQaxW#eqw_Drk;XnH$ul#Y53m5NkS6>l8IieeBPHUU0_C!l| zV?i*p6i_uthoEGNW_d1OpccJki5L~AFZQ!MW_$yBz{@YiT|ETU&Y0$|3e(5&wCofY zL-2HzuVXXmHWB_Hiy2`-WDZy@k;PwKrVL-?TRFqg#MkCTtqzmQk6MC>uXSLj1z{Oh zg4Hmf)Gl$D71!D1S5pB)NLMk1D^%sDB9q6)r7+gL7c8>HB_L5<>GOyKa_+pWe=KAF-&K#dTjZwr*<(RkBZc(0PqXS z)o|D!m{$=uX`t#~hZV+0cs*`2@AOm-n9bv%<-xD(0Bxm`pOq3>aY%w1fQTfSKcRjq zbzi0^q?Uf)+Q-!IAJargr;L65Y&O!$?kJd#>;zpWytvfwR}KDejq-wJ|NgAaJkYXg zyz8@9szuso@C~XgUUdC`n>%S#50&?^^6BSzYAeA97^pv|6nucm`!lSeU8JKH&kP2( zWU>1&tAyd+=qS{XdN{JmyV6eH*r=ug7UsX|Yz=FjmbR@ML;6dBvWtUcC z`EZsrRXpr9ZqWQLASx==?v4|s&Xr+UH3%hLF>(B|~Gxo|M0)ky~Pd8%TT3xSA_l%r*(Foh#7MO_-Th@AFKNeVCS zX}CzIFhX9}_ce6Hg?<@R4ca@WN3fd4G`25$b5>>Y&#;L;uv zV~d2c0>UkQ4gXLD!&J!vKK?eX13OUzm8y)J|4A}-!_VHaD~d$Ty3 zy0HP(wWr}~GrLFhhorOHRM^_q-ayGc35GNesJj?+&Q;a=XbibpBNfbZrFZo)1C&$5 zvygP!j*S!X>{h;EyQME-am&%NPPg3bM-3~q^Wl+!SWFSJEF}%JQZ=e(9%@87C_+%< zeJah%M&C7rV04KfUoN8Ddb=e}2UZS(JzHN{xzATTOJ%?$Jv{Z@4Th*iY*SHhCV541 zYNYZ_d}#x^KGYcv3`!SIKS+B#jjz?nG;^${^2oN#V$CiH8GWPYR(og1iY5dhHIBiI zw!zH!VXm*-=Y7pG-0CjDXoQUAm>BaS!dj!qWmc*w4oI7?-00cA5z0(zfjedXK)8#fbLrx`GK^{QebWyrga|r3Gqu zQH`EDNS#{YuK(bXIG>se4rRiA9w7mFt<%FLNlS2%4@*XXi*-!7SK97DXofA?n;hsf z)aC1yd7cBxV1!<{$n8fUqv&@H|Az8@T+QbVxpvM7DgqYH>;As*Wu2GQ&%1gUV@~!D z_cNFzW?`G@oeg-LmwJ$(9Mxv#_9L}@>BZ)*en`}-lp7~faXd6-;Yr43iO+H#<=GyG z3=D&;!&mmS2n=MYv|%x(MZg6$`<|SyuvhoeLXo9KaFx( z!*8h)ZR5XS5kzsS{dM+;$V_^$e4i)v8eKW=TmZx-ROmOCMi`L z9S5zLVk)sm^9)TX$)-+Lr4J6yj8090?Y33?CESY@C+bW(eG>N#s10eGH z5G^_b^y>n|-o?<@i=+ClcqMgkBD_hd39;Rc1(8ui&NmAg?Y@)R#H}cBGlIg;z zMdlG8I-l^k*AaNRS`JSJPC_&1W7&L#MKqY_D|eW$aWc~+i<(`_CHxV?@-6>)=;#pO3*oc4=KqcQ8-m!}n& zT94Nxu4HT6J2KSeMSX%E%OqpUN`E1sScbuQaYWbM&h?R>+nX2H=jl;E&!&sA>+CP? zU%lCC&a_ntv!><7-iNjyTrwbV+#rU=4Z3o}l|UuiC>4V{4}c2o^rFN9-R{Kz<(e}H zzLMAtvhmR1sbbP_DiKu$WqbA4*yySx#GJnh7p;%oA_|_1(WPVx1Rc;ZGOCf`=vDMB73e`_jF}(1B zk7IaYZ9Dc8m5poH3TYz90m%4$(501eGBND~XFn=up}C-P0$*3Qo5g4ox*>|3s4`r+ z@;+9)+~!B%h4ZPkf5VRjnVhv$k4*Uv#9<@?hTc)^Vzm~S#mW7NP=yq}dd{RUD{Api zAu>@&vFX`QuW4ery5n=umqPs`D-{ym=25jmTGixDnu9GzDLce02S(MN=*}gzKa#lA zh0~@^P4-A10EshBn4$d^{8~s*E2Sr)q;t*{rk2`9na%GAXMaH?;FEdtA%MW##yI7w zWAumAcq9455WT~Ja*I@86m)AFeFI+|Ns}A@B+h7}>^|O<(c2e)-9EOmEkXfs_u80m z;FGNZxJg#PvFWV|e&I{>B7}Yfc0Vi^U(_!Adr2q$Ba0~jD>D3a8{}2)OE>x8RXYmb zWG`B0JUqDnAe6j~mW&l*>`JLd=x}4&Df(B=(bPIWfz>NGS-Ea8ot0ZqO0zn5@~>|R z>$0acQG!?E^6DOI5szu5>PK=#*YZ!9d4;FEJrDi$Kn>|&Sr(c^L_17%6-=a-5CdwE zl=j6Ru&rqXo93ZXi^h{$WMA`pN?%QQ(G6UODOkRyXZIt}#^cl*{1$c*ZT5e|<=K-6 zR#b>$Ryj`yFO{iTrzJgY6vEFZ*bH9?il=75XSbJ4{*4@&jH+12i&NyQeG9xk0Er~9 z4Tv*pnwAnX++mfVVtIU&CgYN9CoWfBV1K!uKyvF79nWqF>yC+~(b;c;nL}HfbsGMi zm*uH1wlLEpicZcn30AC8It*ot7tMT@Y!1o>qoF-orM%mJfwKp-FXolQungEHJ7aar zg5SU!!{EE`ouBO@h5^>Ar!e86Z}A_jdRO6VxK*mf}DZ^--wl|uze)lLzL&s^f1 zF)>(gd0yBE7NF3lQFT}FdxHAhF_aaW-04hQ2+9nr!sl!~opvc~;59nDw)DlN`G)@4 zuv;gW#3y@y?IWJ?Yj<3{$9&O(>h|iEVikv+JlmuFaSHK{zG;EV_R>Z?Qw*ajl}x?b zrs7~$Ku)*{?)HCXSI;y@c$|_87Zx9GX~F*tiA|l{jvaafAGCA}S=$?KEEWrfPMPIY zNvUO7YP&=eHyGljZ4ZsT1nA!CGnax7*Sd!e8On{bC!kG-B~bL#f}7Bzae|5OO z8~o_o{H`1W3=EV}^_Rd{{twGe{$b^j^KKB^s5pE9TVpVi9FBzLZ zh`Y##5vE-5He2$qRXh_)$uCacJw?sct2wr1{Wa(JXN+_1(=SRQR0F5q4X~KuOc2#2 zgI&k|7iI4lBv~K43$|_Bwr$(CZFf)Gwrx+_wrz9Twr0Aw-h2PCv3Fy?Y*n17PZe?U zTV~>Iyj_~@>bRMBjhEf|uC6|w z?rwa&_&VJ|^kJ}F;+Yx4(|KBd#Gb0ZPUc7+FrqZ?4)LYq@IE>{=7*Ae8&ow1u}jI>c)kQU|?wQG%d)eW-$s>MVshpWmr zVy2cYGIM=(`P4P8(siIWQaD9c-R&n~021Va$6exZ7!%CezKtA4x(0hI1g=Zhf|6=b zY5<(>20@NOjre00cP@9bAR@+N{Fr2P7FMziJhIxyV*) z+jDND9y2t?yzHB?<@LfVA>?CR;18kG%TuPIB}`*C>uYaV{lJL7Q!Tvxl&pd&DRZo% zpW7WxF(oEzgyj(M(WaMgy8GqC6rBaXgi$jIjolYW&oVTHsN1sMjr-3g!lh~0xR`f zz-yS^C3P9|@E*+)wqcPzmwQ_4GryvUjZH)h0pfGnV6kglU@e8%TE}%;)|tE4>YIlV z*HTx4)@h(aFeFmvjtn8GoYCk{km>c?kuKH>RE!EtFF#Q3_aGbSL0?;hq)}!DlLoth zX%7)Z2dge9qSa$Or#-`83}3L^&jjbtrMIYGHp|lGfvmfk$y3QC6Rd}B>FCny7qxR0 z(ujW(#cHyoEE-2*A{MQj=KJIK!{3L}4cyUA>(mzEsE&u{zPRs}n{6R>%_I#O9~Oiq_uS0e{*7g67aU z(9k22+`#LRW1H?m90hOXtWCgC+)w~gjqv74N75@pO9tf=e}L!_fKR&#oktiur|Q|* zH6M?Hl(bJf=VD+_ddV68Ul&2F;WGS|(pD)BXta247Nq~QG zLX+Ss_-rxrF4#XPZs!v{BaOVHm~qs{k+=0R+*B_mJZe3WF<(kE+)~qD>;2tCLd;-Q zQb)7wy9(F{_aFbwv1>5%ZN44<3A=W>B#5vPQ2aw|0|?T1LQ>B-HjFq?8kNOeI{%a! z6bUySoMX`wzjUc5c_T#%^1EQK`bg=1ew_hZW}gT%p}^q|QJN<=IGUDNTlCmxV(K8~ za<$-iu12Nz++J7`%>HXQ)MWf*r#_7^kfX#?)NRQElISw#J;+Q${SNq0SWA+Phq{UH z=`?`2b@LxSg6+$5QHn}jD^B0MWPICLfq-vUw?M|d#wgbTOf?I%cKcp!xnT{Yb3|BP zF84wMFZnm-Ff(yLo1}RL?Dvj1_s{kC*VFaDEX4YYZQy@p|4h0)e3ME!H{}&fUQpJl zzeX~#gEtNMlN3Kh#p$gRu7+b5wH%IdJbS;=+48@6zbI>uv zv4<{3lAuf}RBrVHa9r%SgR}S6ZNFi!w{;dYITeU204oTD<(qiPl-SRUYZ*OW-yY5E zgmkyy39*bnx=~DqXPi}14y1>cAi2JBjxfY_$hJT1j`MuBk5M%^z${m&i=bNl7C5aS zNkxu2-`@*U@>w=S_MTCHLrcPtfN0GGy-`~P(UqPelGpypJq7P>K46y69psizrknIL zhC3nh^6d~Ripu|X#i=5tg%nb*zu&EtNg6Ru0?d~PRo=^ZV21BXCn%N;;-y;-3nj)M zE#Mc%&iz#BjJ5cW!scRT=^Z~)G<)T5yM1AaE0)H-a1uFZrd zvRD|0NxDhA$5}@}Gf9SYHrNh_KlXOq54>P}U#nlL2T^H;&>)LlRXI*?2wxWTv9QMD zx3^Cp9-B3UY=N_+_+V_D)H0g;R7!)bYLQl1_QxWt;fomt9`IhNT1>IV5r$g^)aNn1 zo@jb!hatlz*TOy3qU%^M$xf}-J&ab$Ht78mzv2G@vR}Ka8NZRKL4>F0)eO$n1I*Ep zZv#AgzjGD<5YX6wD8L|3WznXsp#?V%zCdgzd%(ycvGBiJ-bU0|oZ^5BEzM%1%#E*=)1~RQgLwd;z+6oF@mM z{-R`X|LWfy;~1i|VTdskfFB;XejkcYe;|Z z$=TK@u#s?Kw{F4va5GITPMuF6vN74Tbd2Cq!{&{VcMZH%Q{vaK!Do&Ucyk-0=Y&*J z5rCEDg=$T$_o||0-HCb4DbdVJE1q!6qwQq(RvL{jm=FS+I5UWWFO$GN>510`@rIHY z*r?|_!%^KNlL&wIy3%&G>iusrxmXBetbt8h``Fyd|44gL;V-xBh)9;+O}S9FS&(C{^dz96r_)ipbY z6q+NZkq8Ud`RIrLHM9|}=hB*^qAIy-2SNkB$Sa|)i3PQbUwm{(4q1(bPT2(=lWtuj z;A_;04{I+U5odOoBHRp83$a}knKHRpf}!nMyNvr}p?U`&rLx#HYX$R{DI&HcW%SjN z=b(|8Pm5xifUR^&T((((DUh#%+wDMcZuoH8R6@fKgMBF^v*@oHHHj)gVpiTnE6hMF zNXxI}HF4b+vPE}L1GY#QOw#a%%kG6kT6x9$#*FiM46aRmv1V^PZGjX^`;*g_iKBQI z*JId(OT0JE!4IELzt+EPUXFQ_nPrqSxfc2}OU~I!YPzG^WPA$CWO6A2oLxV9yldqW z-US%QQfMiJC4yro9tnzI&@myctDoMlJu&~dGKbCpzFr#O>w{<*GXTDxlUsOI%wI(D z&o`)fm#lLu!?0S7oB zSg^47U{`(|sC}t<1i=K7a5wg%FYB}_+P9A4qxD4oMTEc0j3o>0bBrvvIO%I{o?9(5 zs2~!03d;+2{fw5ryn|DyoLG3wQoCDL%#>sXpXM4Q7?j7Ow;XC6Z#4m-@)mgR`^~cb z?R91vSOTvztGS;<0$4pb_GksL6`5&s000mnp+t^U14J;v0>MT5b}ermg!6XrVa>7-Oa^2W*%_@1 z6_}{z8qwzV3H_hz@4)q&&r~)(J{fCSW=m=EKmYiP(LPQI$6h#t7NixOx#?GmGUH*p zRXn-P<%Cju(A=+Nt`vts?If-KXWvV7ThrzShH_D>LL``#G+;o~4a);Fo?b#9^zSSXVl9MK-zR#o&O8t#k;$=3 z$iQarJ+;A?xdh_wlZm{lb$mzy7~))WY62^tztL8)OPC`&lSlid(c*k=2leC#`$wrv zy6k!@JGpI{q`sC9PMKeAWcbRhX>lo~Q6A)56y-`zb6v?mgxUG+k6Tt;;(0I1{5r@L zT!PG_NiG4MQ|xC02#c*CCqOp7p1jGo0%5ezA{OwY2+E|vw;~!NiG+E5*z|H z7*rU4DXdR3++osGmJBcg8vGj}M(#yn)EOA20YyQ7=Lgfad67~a!Y_K}qanYg$ewO3 zYWhc^-{R}(pTqD?&Z(Ft(F%>FpiPEzo~QHgQBr&=OtH0jd*v(jHgea|vXc;9;8_1w zfI4T~WFA0Si#BO=Pg+;z+HsnD?~a~K6@=9iVvk$scXJzB4qz)}y0VJ5Tmd<7A(8S{ ziuD{x%Ej=BlOC%J&PwX3GJt_eU}>CG*{q)#w4Q8NS0c`ZsG`n{ZsB$7tg(&PYr*(` z6EJx@#Qp#xfZNgRCw@C^5IXU_~gNWQ%XYwHz}(_OpXNc=2act^2_;M2GD5baRpONk3My#`Zs<=4#OOa4)b+7zg5gY1* zGKaH3=an&25P7$RwTVEMx@&nM05$DQ#{p#>~?3ZFH`sP9K$yqfqHX$9cn7* z+w(mEq5N@2n{gm+aGLxl2W zUBNrp2n#2a&~S{EY~|KgXf-WPkilmksV(Zy)pA$285OrISaVLi^)15#4zw?YT>L-X zzrJ2CkWAxOb%F0IfE9TEs3rj9sJotVVlIhBO`S!GIls`2jMolFit96*D)DdEmZb8bHlv0FnV*@X^K_`L zZIV^BeyVFC_T|Q7iSZcaZlqh66?Ui-8qvB}rh}yf{2YkLCTJM}mi@SB1c#NESFhFr zPwM3e*xj^}Xdw&?F0;srf)yldttgO~BL`!Y0i<2HR~@s~_UX41H2C{yXmm>K`0`Ly z_#&_pNE$SBd-_f-F$oKRvQZdJ#P(?VVf$Da5P^w8jw)3@oy3(&R)TXVJ>g<2x#3Xx zp>O->Ts}5tzL_rGAYE2;w6*)=Ssx)WqnML3{W8A`v(DJ5sJMNPnBg_{#8WqARA7Ty z(f78XUAgjm)~4CTJO%v*&lWF}cf#pqPb0#Ff(y-QiDEq8!FF?UsN5_pSj-kO*CVnF zACY|RZUcRI^e@kx+t!$8IMs9C^R}5uJ$uzyp-w`frtZ*>sL6=v%20C_|2<{lf*sXc z!FeZ*`ge?&>3~xLJb2SeJZ4I^ovRqX6%r86g_@)}VG(u*s;QCml#kUrks#~+y~Futl_= zcnqo-+K|k_rDvlfJSFdmB^%m)^`dZJb(L+?D@Q|R6kcnCWSj&twcyRP5i#Wa^`)xf zxiz#(M%YMtN{^NbCu}%9qSV|9PUX5g%v1h2*558Yo{}ZT_kBp|fMxCM`_x=p+L=4f zkJ)6(oZ)v>6Mop65xUQPZhUOo^w!+w`On`B`Hsbj5uCeGKTHd#74a~|#Gte`{5--% zuyR-$ibpU!zF9g{+j{%COwV<@`Y6D$XT^G}$k8l`q&nyf)7$E4+k0Z030*pTl=Gq= zr%gGWKVEwKf7|+eFP&wpf3d$%>B^rg(Ma@%dBs-iB{?EL$9Hd*T1K0m!aTRleqMv*eEfCp~_+3k8uUBIs=# zu#Rw^@uF&+o30~Z5C}^`49cgrzXlaMIp3KI#4vG33O62_jMSQ{ddTCT?^JnSYp90H zqyvwhfI_evFXt=dDgettZ#ueytZh$8NB~ntb3vVzR$kZ{*#@iF2gA;U>-!X-h{C3C z;7{n}kaFJgdv;u6o?cPyw2AIZar2;|K)`PGDxXr15vB)1tf0D_L9Z!x_G6@;8HN^& z=sh%=C+pkS+x6@D>CF*e%ZYHjsyX}d^Tqy@@!Z9~nCl;w2$j@eX2QJ{p1IkK__+u_ z@LBGi+b1B#5^bJ>F7@L8ciJk#;sv~t6-~C`F&9eVQn8U=QB6D2>8Lgu-wZNHFFVGI1JE>3_Jut1z2K=**&g&mgrdY`C0R?ZcqEsdICH%L3(m z!mTdlWCSTMR^*o)q54CIqm~0FrEI9U6jPKn+1)+swz_Js#6j)G$)W_NHSZ#wsvm1} zXa~AJ));|ji&CpD=^QoGZJV2b3(b;PRd{MLNw|40Jm%>BBCLh%s++ZO=dg^ z!LqJ6hRLioUXM0&D+w*OD7KF)Xbvv&!kM|jS~Jcvo$rn#cfjX%XZMB{Yr)zlLQRxI zRk^63PF&JCZ9wOa~qlO&lO!E+iC2*i0TnYO$d^Z4u|Y@TqC3nxBQotgf7;auaN$Swy8i zHu!;=cY)LV`J2bIuqbSf0g({^qHOhGj_|`;oGo9Mm`rCa$E=hMHmJ(sjFT|Yg(LBf zwk$&8YquN_TttnEL*~4A6S|?$Pn*;)o(ZbOOY94r0m83{^cVAQ;bT@FfMOdy5By9E+pZJBTb zS=k({Wa3v}AfPW9Y@U8NG2<^xyebbu!&KKDnA$$xs|lTMMEW{wRjo74ilse}-Bl}% zc2klTEZA}jTneQ@oxH{NT_AoZ$_XEq1s}uKR8(z4I2MUWGFLYe@f~GCj$MTKB=Hl{ z@TIJqxgX8{iRI_X&h}y0b^xZUCdxi~j3POXFH)@M`#RYQ4!VgsT7a`$RbQm-*(#p8 z98+Y4pA$lj>+1d^QY)&*i=jqOFh-J-H%0+7PzAwtlc>f|KvSyUJUi>um?>9^YamQt zf$J=kI@5HlhKChaht*Do94sN$)F2T{ZJdRQEz80mrur2w78Zg&lL^C$x-S(ph<|{S z+9oK-Lvde42__~*4Hy`Wr;;cR1?H^wY!w;bUVvP(}#HBe#m z7PoG%ECynn2*^Ir1X-}R*BW3K>ukqGB07xQI|!JrDB@XdlTbAa&ws$UAE}J!EVQ_` zk+D1EV==%NUq2y#w-v3z*wM1s{=+hlTbcFY*rINRJJI>gm9!wQ=}wy3eMpwtFg=jWkR>0qak9ui->L7X}`1^FQb!t?IsZ8-%j6W75{;PY>#*OdR(`|rQ6it!|Q z2H65DJizf(;K8RRg=?9EIXnut+g*L!7sIup6=z05(pPNI-T&4HiHy^|m2hToi+-?m-NcQ-s#-IS3N zR9gJOw9&eTRfOr9QG8o&@WymY!Zm&aymIn-k`PfbKM!f1#kAAHK2XJMF95KLfR@=B zKxqGS&i0Dr1a?48qTa>~OpU4DB)7b{4*`Ql^y?5LD`cyFv5w3PmlQ2)^vU+& zCg_v+S>s)Q$8)JLe`H$3SnN@nG?tjL34z&peYigcu+u|2;bNOKc)YZoh&5I21uzve z9NeCc2_?+FZ`wn;*a%_xIijjHFFH5FyWS86Ws5!~{-s=AwY~nI@&(i@#!hk0`Y5Jx z*XlamNOgF!u&gaJ`R?i%3Rc)$RGn?I(fmedjL+5vp#7Lo$>JiVF>76*3VgUGz+K}g zZuej_2#AM6gqTn_CF{e9l1_>oy-(8lhwYd{X_9L|{Toy^0*Mpy&I{kxJI>-2JAeox zlq#>*A)vC3;=;vW&P(0?lA@fgmU#NS=^A^RB&-hVojj~BGvdxhN)bSl z0zRUXu~0C7pyKPHu|CgUmyzgRH$sy43H|*(zE}S7`1CwcI88LzT9A+854W0t+QKF>`Hl0mh47skZ(RPp zU~V7RIv9>tAq6^PEZARs8oioN>y|=UW+b?;pKHJO_xbenrpDTH%EEmy2sPs*ZGJf_ zHa!Y_AxEpihHf?Rt5tOR^6=!a!a?ij*EW38nZS{W;tcX=S3AIm52m>Atw^m~=5zyW zK_|YL>lZS_oTs0KRg_DF(yB==iT(LVb1qE2+rDYY2Gocd18v9pQYVV!#AY8z6!OQ3uOGF zpFw;Gt`{Ql)dj7<=c^tQjbl&d0Qm1|JSqC0hj*URGbmxW^d#7Pg?1DQ8%CW16j9Ct z)&w%4P$lgcdI+Qp^<|8#A2YK&s$D25VQg915lMe7k$z$JFu{4Kx8zEcy9uhlC78 z*=O3jp?o#Qo&G02sFIrP`Fa88{ow6VF%4_Y>-F_@h5^_9$H&tJ+l&Rj92R`Owm+}# z3JTT@yE+d}jNcapyTcBryF?wgUv9ne{>H|CHVw=5k6T;z3;5s2YBm$(5LLI@2QDL| zt{xYS`KaKs>eb>s5SNf7g9uSAXJF9h7=2uR{rUVr$-E(6Mpc<+){%3MkqlPrxyU))~^Yrk+%hyJYi;Y#SG zRBu7zmr(Wt5BYv4@F4_$4sMJ&tboZI+OJu=Hit5LSzfjiUNf^IARIxV{C3%0`33q! zCi>l+JrRdn;}^n;Ja!9cHfjRMX5AXPwtl_M_OsGy<{0xu`z+zwikpv-%F`8>EbW-I z7^KV4{qjY|R#R_qKIYmY&p`_)(~VbUqrz%A7Q^XNwRbmZ_+#v7(JZw#pu1+&%O5z; zDU5Z>LLrvz=vk#L;VzB-yF#QWZ`tp-rl)aRB?(DIg-fc|39cCK-tfr6r%McjgKTJ=PFl_7-orvl_{XpDUZ&c4lVN??yoxrR-%OgnQX%9mLSL2%}M|1#}g; zI8{+fp3Z_w&k575WPx}Qc{tToGOnRg0ezx^;2} zmg49(q0A!Mp8uG?9{gQB-keQ;U`6-1U9vNl{{eleICoQI9uBM^}REaYG!HUh_% z(*E+$ghwP=4LNQqvpzwIBB_Vu(_WjeWnr4U3?rGZbwZv80vh^; zyXGi?%RSIRXPM&#Z0kB(yU|(1!@Z7Q^Q;^kikC^ODtB_rL>Sf|hJWqhn z-BiFqZfD=gEi>P(-GUYqE1=8D{zmQgZv(6*AShsJ1RPB`d^r|?d{?3J%MCn&56+iK zN0^&s5wZNQtWt*YMtGz?w|NZSmj?(ldxa4uIUnj^30a)};5^TJRhS+oo_8vMquq-h z)=j=(nes+ay~Y_q513zydK27}i(G<;O1GVO>fEAQtP_pH0u&qTmEB3|ri+C-({m7> zm+WvoOApV_o^R`ROmb1t*O)k~zm}=KiKeX$wsb;T|6PQxksDHJEp3*sD+=3m;wk0E z6n8uP$GVpZNb$cwpe*`f!RU9fJOH9ZBPcfyJwCCY9Ikc22?l0YOs#AgxlR#*Oj^R! z%>hZhKNdW(RDCR;9-)^hMYJaJb6yU*FCF6i0UOa^|6!2sz+`krWT3bgVf7-EnOzWa z0I44RDndC2wuc0Pj|l^}Ls4dZDdJe$s)kOA^f^#l3RLZ!S;_3_2jo`7$(CZf;jxvT zZbbbpW^#M&y;D6iQx;4Aa2Ajou;hFze%YbfyUJh6s1A>sHrqaQWHdd;2(}0K8SeA@ zfBfzF-rk%ZR(*RE_{QIT1}Rhm&-I|H#6yH%OWNuCH+?!!Jo|z0XV~~KQaNt{Ml1b5fs`A}!J&*l?}ESQoK*CzBaARI7CWcf zP`l77+aF22fZ>~RJ!l?jZ>sZo6DIxJxGUW=6C*ZTMP7poax)5?}v`Q4|~6ll@c76 z4@;|}GF485T7q&mxIiv;KHWjyn##|iArAFV8c z30A56dqwm4gl;-YK=}h{vUbxVs+z-vj~Dc}L{Y$;3dlRYi;6k+t&XOsl{bC0hw%zq6!B_`3k>?iyZ4Y1YJ-Uc-6< zz8gS6#~7}xa{8dT9*PwN0JRu*e)0YrokEzdCXX=N9S_ZL5J+)nR%Ov1NFJ&+fVA!+Q2zKW%6v&GzcrR6NOGtMS)#|vW8ez5I`8a9Rf zrP_mmRi2CjgkVsWTm9)3=5U@hFrWH~qP39zmpt#g=S%pJUr!(lJwOYY762_gnc7AG z@Hq*4TajZAVys*+3iyRw85K#4Con)4v`FAd5m6bwftic^{LDqHihPELuozDzLp1~?Uc2#8w%qNO>}oS#TTBw`6vinm;os>y&;RD9C?DOi7w z4T^^9ESSdbRy&*rQe#|+<6Dg<2)Xw$H*I@j^CQ*DhL zlkzzcmhtj!K-|D7$k;ov1B_0}EBVCClL12rqF#p<_i3GAlK*f<(-6^2I%bw~TB&Q2 za+2Brmh#EM(V$Q6t7t_48i>4NmOT?LFoZiV`V`;^3hoO^O^d32HPy(OA_U!ZtBATq zmpqyCF`i)DtK>(B_6Tgt>4DMaq*<)8sasqn;v)E-QM4F&N+-$PWU>(Vz(myV3-s{) zU4x%>XG};ItH%sVK}hNVoLBm(zhH~PkBe&uPvI0HRB9p*_)-}Um8LW)dxmvo+Rz<9 ze%qyFzmkW7Kb-2S2g5ICx@ovg?xh(FN)KUx$5YG`D_S?o&>v2TYd^k9rl^TSkv;in z;x)^*DFJ^FI;-(F4*W=h)h$vR90tis%B$X4Tt&Clg#^2Yz5o956bn7+WNmlHG8U(r zbl(K6t*&eCc@(9ga-44wZ)3HS;Ft^_ZsbDyb;Fnb=)O;Vd=`Sy34rEjp8$7mpJfk# z=E+1Qv$_>fH0~ckhqJuBiuX>wW&0kHCZUhEdh4=-36RUjW+4PoV-{mdB#v?lCl#?< z(%}x+f7>Ar`N2NjWx-p;Yoczo#82XlOrVsB(MQL0sHCnvnxi?U-gDTbYQldsMz+Yl zH!m@(@K!LNbt)sf(F-v5f}LzKx5Ez*lN|3S-y$|hg@c@3eM=lo7*%XcU5tr8#Ar_@KdvX)8 z&BtB7pu=25HiW8QP}>=CMlA<}Il|IdF;qxE2CE&x$PN_q_J2rN5-0?v;6wyt9h(J0 zO^D0u+1Kn(MBT%kXX*-rD-o6N;g6@$+qEp>h?{+ci1bA4y>j6|8AD~};e78j0*Pbzb^OLp zJZ1T^q|*KF>Xt&mfK>`y*;ZANoAOEPldU42jpsG-q{xuYym*(pwRw)>UEL!`&95FM z%Q9Ub^76rhJ%dWkW^y@H(iiI5${UZbmVY(4|AO`6ffE0N)I|Z1`lyf8HULsbC{<|> zye0O`1oO&E=JLxaUklsueg8Dp!HZ0{ggT<7Mo)O<-0(SyR?T_NY! zpe~78J^MpV6E;^0eMYEIpwQ_h!!Vlo09ViCO~Zc<9XoTJO3?w6J-OZQ#3f#1QwPjuoN{p{^#k40Er>)e|q|P zToZHkRWln9(Brr1f5Ws?b4%g-{h5b#cuDWEvB741?U$qpsN~E|JuH~?{{D^2u+~a6 z(3uE!`KRbsW3D7~WYEmn`LeOK zphSTB9*z8TQ=0hqp*=6SJDHjR-m8Rc3xN!~hC+YA9YuV+w6dzQL^vA$j@(Uc&C+R_ zIxwdadLEX}nor*t{ocJ^EkEkS0$WQ2>lx#I z`9~f!)$D<}yz`!j}9Jvb}H+~ftP7l8WC*pD>4i{ok(d`#l;i^}l zlpX}lvi&6*W_7t&uqmKI>Z?qfcb|~CSt;#ub9cn$BBf{cMCcr1tuK{;64UbZ~43tawJw8$d)Akj0JR~aN**=A7 zY$_({E(?3HVrW`X0L2r)`ZJyFww+q!1C$0%m9& ziVwa4(xDH$dmuKHZRt>?TaxneR9c<<3|=Aw;-%lTvMJxikXKg|Bne47hh6Yl+pL57 z;~ToA0lBMd&#GBxw=L<1=e%$L-Qe{I8SRlO$~NDHC{Z7Nid*38#}q1-LkCP$0j|L7 zyBr&VaTTWz$g$Z`Cl0owSSl+N<2$z$n4W>Wg*PYkoA-5zuS^ra`gRRfRQc&C14c7% zMja(QQzK6|HdH`TxY25M?ybcl>uk*U?rqR1C(BT*IiZYaK?;Zm1LQ>qv^Jb0A?h_F ziZ@lyx3XxrOd$LvAVpOjZ-zM5QU}eDCA=damwdTMi%I9Tx6?vHKf4;Vb?aeNpUI1> zjF$$w5#U2i5o?*+J191GM1PsYhrWS&{acBf5dZ{zZ+8U*l3*{7z3uWOSs+07lfV`D zE;i$$F)s@Y(SVf5H#u^DQU+4uFc4(8}fENvHzrcV&2C_X7YinA=0g1tftlT=G$8p_hDt0{Uirevpof|Shp z%R2;7aSp<6WLRB2Eq`TYdP@z!x+=;n`GkodK|B)+J>)j*h7rL+)n4yGH;<;N*&6h& z)aF49!mjbdhG6P4XbL&*#A{x3ZRj=FFkm6&9ts=+o97`q921Rc?PHh%+XsOl?#b!IkX@!Hln7WCF#P;Df@&34mQn;AD53%!6{?ZS6(bv13c`4`#vf??fTa*% z&c8=(tnZ0fG%WENsza&Y_uULs-i11CLZT?T9=d$sM)j=SuqfEH!c%B}x7~762%euZ zQsSA)`{sYwxa8D)2$<&j?4drX=+47!txC5p0pW}dNo;ydJ9OH3x;*aoKcmOpzZXQM zsmvBAO^lV^fij3kh^>adCfPYW-U_AVh zXP5gW{yXpwYO31tHrdPy^b)h1RccXdxN*NIQhtR9;X$zEj$v}y3rt!+_;(hSM+1(& zYJD>%C#aBRotR*v&zr1`OsfBq+-^xjMe!Q+7+8aNe$Pg3M0`xS!F*U%*QiTA3C4$1 zyV%p<+LNP4U;yjJ??!KnZT0Qn9i6&)`u+Ytuh$L{wkGw0@yp2;H)B-v5l}JwCFV** zjmUA}3f*U>042OwGXT=+cr9u!qp?%RQYg z&Z?@mAz1DN0!2M33DuiMd~8$==412Ovo}5F=&HOiaoG3<6eMe+g&^gghh8AUF4RiK zvZEDH;yQ67-^^_+l0mx$ipdC!<#Q8ro8>B`X+VbW-?zz;GJLXT>moOKA?2Uvp?c_k zeq}8T(>KXFIsWO*U9ttX)fTaQzI&A$=TbxZnIlS|ikJ&!KnlDoCVPE4ZrlkuV#OhDf9>-j>ibr7DqsWUN)aO=ORBmHd4Udp{lLxW-rL1@oaEqqTTeu(Y zm$RwrN{;odm`|?vXfgQXkc$I|@KZUM0`G`=EMx?`;;n>u05iVF15`-TDEx^SuCJ}t zo?lnJua_y7uD*hdkkr%?1rR;kvBVm}fo92w{r4VP(kwJn%TGUroitzX2u6A_TPa2r zkT^09VM?dD6b6SKYo?v-V~)@Jlw;ruJ%djf0lI+EH6(Zeko_q1H$4#=b#X1`Aa@wOo@5(;BXTH+4VhjwWb;7rwnU1ip|9Bksh-1M z`4UMa@cvE>N*b{%k5eVmkayB@+OyuBQPxzHl^gjSvcj5FRT5CJ{9AuAib|@ho*L<| zhW=!GaHVSgabWd@A!*XlA$@Z`y>MCvUZq>nX`OvEQD>81!+^|3ZmMWE#npa0H2Hs( z$PX~z|DPptJM>zn4`_W!c}=^`XS)5S3;EW(kxdU53#*4?Z;#uD^=>K;23YH;j5qHMRKzjK3- z#~ru$I1-9@LX1yliPJa}sfeP?fZ_ln1_F=9Eq)VawWxIRSDgtDCce1*zckuqj@GP} z4G;9hgR#G_`1`Dz^!zDbE6xQYY>)zy9Lsg~8h^wsuB)lGYw6D_DIbX_l92qCQr`*yig2%*h_Hw8Wn~D6DGN5$G2#JX$vAxHI|r3JrOa(92rj*7W6~%`|GI1FO&d{ z{yo>gV~lre;v))+S^ZrQ1-|)crs^Fnbi=5yjp(2viHSmVST#kS?M3mH{AG8}AV?mK z^eInTXlY5RQxPrV#d10F)o=f|-DNFRFuyVs zI6DH@&4L^+0p8kM2VHoKVp?3;vIT~`@L?6Vq_2cD0q~|IVgEQe+2obu6*(_&)C}Ca zn^=`!^$3flb#5t67*wDX(s+=r@HVGpTq*{q2(bg4WG5!1Y|{)a^c$*ZQEc@(bV`1U zMe$lXM#AH{?s)n|ch!$e()J#+Vm366wgg9gRHgaFz)plaD9XPO47(^bIg8zDhNqd8 zr#+4HpgVUX(IHW|I=U`3ERVVW#ZVdpFqHmXwU4ik7Hs$T)!z~H`}!OF+|(+1ol8vY zFRCyRE^i!UHS(%0v*tIhO`CJ;(WM7PF+n2l-sj!Bs(Dk~+>$PNk3%F9A`i6KAoyWN z4QiwO6F>9lLM1S%udvyJ=d*Id!rWz&J=*Km(<0B4?%D>Q_RgtIfjN`AxITP1!2?eM z2G2TA7sL)Pa^XQJI-Hl;DI_hZVr*%xn;7m}&|7+H^7rrl`1r;YhPAbZ-L3G1Y!ZSz z*;qm7Vl>M%K9$C$S)#$#2ii*6c2IuLzwdSiQY`+uu`+WJWfh1)N5AgG| z;~~R7Vi~JW%%my7e~e_v?}6*>ZJ429N3H(VWKMCTcOrZK9yCmB;$G8wvfgqU+8XhMIZiN;tvsMR^xt883B`cNqLK)U}REy2|dD*XpD#cw=SBBpkunne-mWy;si zvDX)dMp>KaB$2YZG&r|%-AVJsGmmn8%|rX0QF5x;QMT?{Fo2Ip|2B($)iYz)N|QrT zBP$f{{vOJ@xjHK-V4(NLQ*PkW`fvU7=wtnck|=3eb{0l~-pP$ST?zC61vVF_8=J9{0s|E25N-~ zO^)hqAo-k>q~oh*w9NY>A1J@wB44)Ur=x=9xcOfGQz`3vJQP$4Is|OR1t9k2WyKU< zn5%VX*7xO#dLO}}4r^*=WZXfHdX<)^NN{CrX9)U~tuXh)PSZdX%0UA_>GBQy&tK7@ zEH{9v(^O=8$)P4h65Z(ZFf(Q8S7I)r_7ObXEHW!BYZ1`qdwSc-gp7|E7xMC8kvHe# zLu5PyCMaYu{h*7KI8Mn!=#y6&33;D1RqG4O&yXRN%C3>>_eoZl^@OO$r_5g@hh>#m z^lwBZSxBfm3swL5Dj=We?%IY(nNYX?h1HFJ9>J7YIf$q2RB9rLsK(XLwiS4 zTSGIzU+Ap?%a_d=++01>)!>03L#3cBbCCY`$6rK6gV zUZtgzr<0kXot%+1r&{4;YG7*NV1-PEusB_t!xsPOtXhKu2nz|7HQGjK3=r=>5&yr1 zhol7p5(5bT|3~KkQ({+Rz{B}JMNR^UoCvu7Un0lp$j9JH!}0$z{u%xoT&6~-a>138 zs5`_WJvU|s$9&Zo*DaqJP_Wk)5r@`Uh9`pctd#crDg8n*e0tKdU*|brbNE^R@Y13` z8<59w=KN;wxrH~@AO7(8x9j_avY&*3as0^#i}Tq0{VBooPEb^)!T;yN`NfTrMfVf+wY z)pF+S!E0xKSS`+aJp~_eJ0cEr#FpvjudpgE60HR(3Use1VRzJ(uu{`mC+UOEUS znNG5Rm@pyZ;cIyLmT70y-A^t*iSRXJ_sI!yq)9)~V&>SmIRO98Jh)T{2{@<&!>oNe zaW(8YQ`BkYpsk2jSpIUpbRaa)9=oqgo5}T}8 z*jk9Jn)f22RMZH9C&dJZwJRwM%)zYIVvogFwk1vv zWS3U$X1Mkj001!YILu+-(9`rOOdyJ~C{?NS;IwCwF@(R0k8A@E;>1ZM*zPTY6s6-o zY7v^!<&$ZWg&89|%|?__$9%yl#x3Px^dmE9=!43}I-1O7q%(iDqom5W1Z>zQY3q(2 zLzQ<0uN=}@_}=$)0LkHRmzNN*lfWaWKTiH)%$4{$Z^N7>B6Yoxp4|fGeg2$S_Bq2& zG}K@$Y>`k{^*JMW_vgTqis3U=S@Z_{4qkK$b+QK-bp_Y)sj1%vexL`p#>IF*D zL#_=i<&FiU(N|uT$qG{9PNY6wZ!Knun$|apmHlWz+6X9zO&i^<#p# z$QHa68~IKzf2hs_MhGE)WGm6GSA|N^!TKPEbNi;bwD@rgG1_6D8*LUSdO5uw|fIN)pfj%lW=dclux z@w4wIq`ZKOs2@3~O|{_7hnxHsWpY^^>Wdav*{6_cB+|dC01uK)m9kGN(?|uEaP>;1 z_;$Hqv^DLJthRRVzd(V%p~~e%i#}7bM4_P@+{)b@i|*6>hYv|!91lGqsiyH?8qLKC z^dxCqGs(V<+(GCZixVNmXkV@}+~)a5?T0%jPYlVwPkF=!+4E}ycuhy_PMT#G##rD4WhU)lN;{#RO1t>)V2yXM6AH!GdQOgm zq~vXR??3(nC|__TGu;p%Ape1l{~A#K12uC0U1<7WV9Wn(IGuF@0TKJ(g46#ywfKJ| z5&sKBt=5ro+7oZqITz{t%0F3@9x$((NKT$Z1|P!5$pTrctzZiVSzT(3Hz#V7`FM4! zsbiop3Fzr6qwTOxHs12OY$G5aT^i@tdbL2G>MJ2I`_eUe@#a~5nIg@$(!hRRC8qF8 zn5Fac%{W-4*7&iup;t?$!MOSvmD=^Ay!)qP=h1-QkejL|c2%lGC+z2wAFrSFOFd)M z7um&Bcm~=0wVx69zviKj%a4`14EmBvm+gAOm=E#ppYI{O_s0c!Are(_QKeN)Z=|fD zS9G-!WK9m&<9Q(&eDM4HS}zKzwPXg|8BlQV;;FAU+~r!3-vUZn*#=la%%j%}bm$EE zcmvoia7fK1I-4;ez9`+n^Yl`RKF(f7_dhYNn6l+Q$C6%*u^=q|K2sr*eOjYW^;g;I z6n65Yj)yE%u#(Pq)cPjB%~Q;1FVAT@pkuSSK{h=2B9k{z6nqq4$tJyM+C6x+8>cQk znPH_Ohea9B!R-;ssP-CXK%E+gB>imQ&UwCzkn>V+k*{o&m&#lbut|o1>%tRG;2pxM zN=2%Iw;ELJ_xLpp#^W)^wM%*Z$1Ci*BD(tj0}#ix{0{M+k3(o zSg8{>O(zOv2OX9M@oI85t-G{372A|LPLYkKHDnFcIh?hUSC;~QJpKvwlX)i`Ox=lN zN4Q(GbAfY^ghSeJO4stxP4OZuE{d6-(VOUF?~Qq3o^Yht9rX~SG zhq}>z);^T4*H=WY71Q&;)lHtmt(!J?RnYtb_fX?@+Ad0bq$|s#8dIlsT_$xRvv$vN zZXdfg+B#Rxj@Gn4Q@SoU;u&jZio!xl9}1a=9yTc!H+S}F+QCBwQ7oh9SDvi7m*$t* z`pEk|$4K9^hF(bjTk4htBD^<&Rzt8>mHy9NW0)%S(1)Snu@TA;E6-fAXxZ>Qy$}e> zrleLA>p!e$Z>a>LY*4&7giY|f2=OyFh(Dp5ru$0vf= zJ#(r*Yt&2k`F9ptp7Tz>FcmTy1Q=06Bi%6W@I|GED+NS2ARBEnt_>Y?*YNZ(qOPY7 zQp=r-_EJloKh|&>a>gzdhUWd}8h|l7+uL2W{bt z<84_cBqSXwZ+ho_4Zg|p#?p+mc$2fC~%!uMhyr(n4|Gt}RgiS~hIZ$12q?K8 z*k*f&`8%z^{WX*EihIfR1oqan2W}bNeoO;!T2YD7)OoP+RA0zcH7iwq4iT^L-?=vNYbYtTbB@$ z`xfwTyt$Fd_-w>4-LZCg>TJj7E)%=Ee-!&ZLppDGrXDg}@D6nAs{voxHL6Ko@xaJA zS>8W79>oH@V016cEs1a2xLDQiz@p(87zQP#9@Y)4?q!Fs7fEJqiy`9h_g>g$VRa!r zOu2GH?E0dd(x;Xl)<(hJ3A9*#qVGnwW*vDNgGa*|HT^UtY-aN5EQ$Rv&h1wj_IdX* zIvN?@i4~6I%4PjriS!LDYis$7&HS(dpT5=P8QO~J9L)vP3teZiE1F#lCpu!01rg?e zUI7{hCbj%cT*e@()lYV@K!j>&?+q&K`2|^D3-}#S3Ytz~)M?gRANy^P0UT+v;`ffm z+-zUCvRy;ubo1$~PD(UVfb>>FpM5RkZ_~SW*p_Sf^2!e-BMGPWwBx6S)`!|yQ$o~%~CG3&BkEWL5TcED4Ji$j`*Q1YTT6pAQGCS&H- z9VJ6esd}*_Pk^D-P3bz_ED{vWp9~%_$+P^>9QX0ueW-vQiT2R$z8asLBK zLtfu961fl;q4;=3oD&Bvx6`d~5y|wo$j2XZnYKyni*Q9}&=1r+v;al%!0Ood6aq1k zKP4K%s3ySKpj|?b{ZQl7%vQNW47mCT z5a01?IE%aTA=_WdC9PMRJ)7MS{)Q4wi6_nqoNq{K<5GR+qo2g74CusMp>AS-jGw6X zB=2kBbYa^0cJR0}WUsN`9H=s6Zvlqxez*_UpD1WcJc{{`9r2!O%yF)^0>8T4Aklz@ zBa?B#3!xt1py^S`h^{HEc$ic1Crj}8kC+MqNbV@R(^)hyJH?=*w(wm|vDjo=xw}54 zkJ|}v)D`wFrK3k6sSK|UR;}Y#1(RvLOlp_8G%8&`n2eIEwd;YR!-! zGMX98T|#v(3}9>5s_fAJB4&Te;Bw|J5?M!y;Bq> z2|FfI|FR%+`nNhpZdbI#o#;v3;5v?)?P_zhqNlJOw{r|aJGUxzt@`ZN{{aB6H);Qo z6jndBxe)`aRoD4r9Jcg1#m#Ij^O5WWCc$IcpNHO=AH>i}yM?-B%Frq8P7+dEp+CR* zgHSzC-qzF6p+1v4YvOtIYZmCG9B zEzeaWrN54-NwLY#uvREO%6X9f4oTIK$w(3~3Nj~mC!x!eLso#c7#(h+3p2ufzJ{tDD?XQLW=_QYR0o(7|9w0pPTUeF zOV1i5HISNBK0pcU#2<~`iMS>VzH}MngUlp|Y>>BL6!<$eKTRv?Si$ykQXRMa5=EYU z;Z1&}dJN&XEHr**X;UjcvM)Xd8Oh%R$O~-m*mY7C+2c)KUoJ8;Xy-u(S03@X3M`Jv zoZ*w@aY}NpRD`4ZxvZ_7%UsGohUB^-U;8h*3|Oaja3TKKj3?J0%}}b5{N-&8JqHLi z4Yu_UAYmQ)vaPeQ#9L!CgI7lfdZP=Q5w$3Z+QwREjFWg8YT=sXvi>w3HI!`4IQ>wq zwF>uZ2)r}O5qt5*s-+<$djRc@*;a}KGd=&hWh(&!qZLyXHj!g(QnaussqQw$V0&`r z>+S(50RsQxhY{%Gr*BJzMUh|bb}|&BnVu`Ciy9!D_u-*1@Ze_b*I9wRx;m|VjFGqJ zSkdAY&Y7I)l4qKWA-|xD*Ly;^WxF$gMBg^@SXmC~-3Cp6LUGro0gb%F{t4|R$wX^^ zim4Eo-g0~!S_s4g*ad|55kwwd;}9xq)_9}EXqwB}n5~XR7$cdMkpt7LJ8N9*y48~H z))0%%?z`997_8anInsZRuf(Fzf{C5ROBrAi)nZWdhME|}ApMn5p^wjA@Pk(!NP3v{ zgs|p-Y%K2kt3w@Bc_H+Bngxd9#6n#f*+*%N4h><-|8VQ`ejAF=zN%rrl=m^$6pME5 z+}nO~5^|}Un04|VHxswUo(r2Uzi?IM%90JV^=(wgLPPvf*0Q|~7A`Heae{~V0W{H~1Eq{<|kQGk*xHDs~v*{18Zb{m|zHW{zVWCNHg%#GKjmgSkza}p) zTw@DCU6^gZT)F7Tj=N*V0j3bYXMxpEc}>PsaU5) z=urii0OZ492YK7=oL$Lu9MD8Rq%!C^4}m3vHeQ}R5OlZH4*$!`Gls(ZP0P@hNSz^EH_l_1%Y%Wh$3-n3_9R z-DqvA%GNh-0#dL^>Vz%YI-8-N0(DUDI&VFw1QfT{A`ap3ef=0`jS>3YehrY^x@D$T z^}XVIL8A6z5_ez@x*4mp?WpM?!aF)np>nEROBPU-j?5jhRc6NPnY>t7d%toDYFI*Qs%X zS~AoA`gyD)(RHn~5e9&jf|Dq$O8lid=pwp>OZ#z{x6>kgd#`XCS@(iH5!*rp9HGhx zb3#Y6qJV&tfd9GUsv9kTPV&Aztao%JK{ey4@Z9z3_o)=mI(45>SbI=&yfB@vO866* zlG7%S^QhE84R}J%Lq_e99azbjQ5?)Bo_B{hZX1C1ay1vd zi{G5D53sZO_PYP!pS9p&t8Ql;S(wpItVE(v%R4*1Zp>(zLd zVS6(Qe|??X=^!pTijD&8NoH{c);H62Fuz5WctjC*ZDKK*$4HNE7Fkd#Ij7<$DO2z` zT26?7(aR$Jv3Mqa1r~4uzpXKZpE*5~W7e4knWOrub!og~Z$++`?8CzVbJDc-{8Iw% zkJ@joSo=xx8Vc5&bALL8GDONpK#o2%@LwV&T0;5EwO`daM^Jl#@yz3uWCkjALNSG6 ze0{G+pIAQ3KyyZ&D6RJ_<)Yl69bDP@YX9;K#;|fqX)^Ja>VNX5t<=V`Qd-*DZm$QI z*Wiv|RUT&Y)yw3uZnijC<*+igTVO<1}5OpMd zk;K!D)=Fz<{Ca@&73W@|E6eV)*&LHmZVi7#OtxvB4@;olp)uycj0XSe*S<{HecSOB zkP*sUini+PXK_7eA5BcJYtVrWkK9%wb6#izUZzLYZi>Se7|*^QRZ0qDL^%)fKbk1# zo8kauAO)?&9HOqCR~m>8(=5#1G4~8X)bo1g7n|SjHCA_K>FbZF{g<%fF?yPHhb|+L z7<@rNH}`Q`SCSh)Q8q|d9abI+5q*gux>R}Ba?i(^`lh$*obS?GHhK}I2%A6Ea*G0+ z!O&Gk*%*f%)tv8XdPAk_u?GDS-D2)Ts3|2e^x>^uWt^I<)~6Qz_Ln4>@{#iDT1{7({@kQ_-6drJSfl7GN3CggSt99X4KR7FP{TR5VD*8ZK%gwFN_l-5G z8Zm^2^Xn~T&WJ{gsoPKs!>d3BQS5-RPW}gSq+VcH(gRm8{2@NSc?u$ zRBaeV`_yt$|Bz%#LEU-iw31fne-APX4K(>IBIHn!!|&+&E{NV*jIFPo$42nK_y~}2 zc-JC}PA`lcfTj7BPPRNbn}XImnbHKHs0QnV_#lE!P&{s+5Qpvs(PksbX%jR&G{bFo zOo^}$_IMY6(}fc=PcvZPY`1{)zj%d~sT5)7GfRvC7)tDbp~1=F(yR`7xo5G`n||V6 zkwv>r6pFAZp9N7V?u_mM+krLJWu!E{=3@`(kv=d#B<7xdwf0**S@Zp@)NLicTquqx z_avrWt%s@9rYcXV!j+C2xqk;ag&bBtUiQh23hI|`twT8iIWPp zE<)3)QlE1sV@xL3cp|+O*=yXiJ^v9g;Dm{v>^&i+iHa4J?S~L*tYRfe7Vl>%i<#e0TfCGlkQy~Ps1lBSL0wvtz2voDBQ|7Ce<7}RLZg`m*5yz ziMOd;NoPtF#)zhEz;$cnr}}#EFqgsl$hs>Vr!^nWt_-UM$>c3l6A!PUg2HO?O+JlX z(@^h<--TxdyULD*HV_}GlQ~tn#RT~g%utQ|-ReLQ-<~driM*aO!QcF;2KVbw`v#LE6$t+LB>Tq&Q(_GH%pE zF1Qyhn=^4nw49M{`fay*8wcGiF<+6uMDXd5wR;8sMB5FGSB3{RD$+cgaTYne7Wu{$ zTG>(B(OW9++{ou@he1nxKTO(*i^hK%NUEH%GJ^_ZxNHSd8C?+Qh0mr8#0jAhT>owZbqlGBH>gJt)h z#ZZn1lipNFL#2c=Ld1(%o(E3J*6A0s@}=fvJXx1aT)*pG*%i z!|kNA*FsbNW<NtEnNM&=A#`Ghs`idae)vg_G5q+}JNEY2QE5bP3v4`=A z7eq$qN1zmqnSA7=65Nm`ICndTxb|)ig*)ro4UFKUp5Gxi3@Pk(o)nx`;<{CbC&;aK zapYrsC%4=(vHDQNUJfMF;jPVjKPh?g!n@tS8l^*pCl|zkdAI7+TDvtG*sf50Ytj?^ zpv^eD?RzC#s}kq#?WgXL_1D9u9EOwcsw$(n)RUG%Su$g(Q1&T3<=lHdhk3GKE=hb2 zG$q%q$B<{7b48)mh?&zCIR#V`zm##PwU-$23j#bf(|SBpPropC%Z_|GOQov6UUVi+ zMHVeG=7^!KoC|1WX5}*+)C%3WI-jhU*z+lFWlm?&x}m~d%8#|34PrzJCj2BLvy^4e zxTuI_F{+lG5tS=i7$xoGdKO2_#{>qNaho%kc}CJQ#L&M`L$apJ%(W2}2eJg)No9EB zS^gpJuG-@p`|alW3e%vjI2kpCi(ks}F%PaWU@`_~I|XMg z+c!$Et{q=|{8W=>uR*Udxl~E9-wyk(1dK#-M`ea9bHr>Yic`g;&r zY7oi;Wz?}^5_5I_5w0m}FTOrN54cMQ^c=+C$|tzA#}>bxr%cm2Xp41xSvZR!4joz$ z7Ev%`xs`o--orEMx3Mo#Y-l67$%3c^XDFl8Pq*eK*lK?LBGN_mJB1Im>1gm8cTOqz zIR50jFMtL9Xfx+D15&V+D5osuxn2FW`ZZjgOH}!=P`SETv}H?@)tV0+ka!>#89W6W z=m9%(9Gzz0vvd=9r;5I1s@*e;be*pU@K~VhoXYmeUSret5fAbrEupCZ&DJ+khxHVL z586>)PdPQw*nZa*;l{1WRuYQ67}$3LN2k^pL`EX)Jp3Pp9!N|meMs&qutf=)P7Qa5 zq$QAC9o6D}E>}Hb>=YkvD!m-ap(wPAt2?6Kp;wfPbDZb1#^Z(=YvoNh$2Q@5{jl?S zA7A?G&@yHDe_Fk+V&jUnkw;z34az~#EEDvdMCbYwpCt>fTuPJ#jZGu&*RX1SwKX&? zfAr=UU=Rq+#FJLc$vtD&z3za-G8TX|JEF|X>m#$c1u!m&vP4QK5${ zih8*z#D*Gy#V8rbyjT+&tnNigx~VXvu%Pkd>trYf7l56FJ}miMhwdku-f^gRZb!R_ zas{fH3y%I(SzH6Q8o*vq<|E<*>Pv$VKmGp0pq8#kB-i4Afc%Fk{9iMuivL{<>VHiq z{?8^+|AK;m2>ox7s7}r<#vcEF2virjam#-CU)**DU-??LWEOYez>?Dvi=IN7Wa8#q zPPCH{(k$%vn;u{W3v4K~J4vg=+v@Jz#(FT0K|5BDnd7hQ%L3JNb{s1lvP1ezBjy}!Bm zoyl_GwOf#%y}Q0$n^T8QE}7~+lM4D*$Wgh)mZ*!;8mSFB207$#wQbqnk+w?DllB2u zqCdInrzkuIk29{mzJm`6`WMYL)Y~^<|DPTIUkBrVTXEd~_p|)Z4#dxttw1!j z_Fr0{z&JFnIc6{Lu&5H@n#011V zKCQ?L{z>A06tJH4|sf;+@*-mdRey5G`X3a_-DU+4ILubK z7)wMLG>6QC-mfY1K2O(|Kf|UUp7_45FV0Kt{N5i=JN!I+-}wCA*nuPW@B4i3WADJP z-LLn!ulvfD?UB2d?oW6PsXV_A#BNXhWS_S?J3XJz@u$2V2WJAM+O1Ust%Z?oAGN&^ zks`;T>8Dz{*Zb+q`8a3WOfN&i6r{*g$r%gJxWxlN?hUC?I#hYNb&EmD} z)7~@8SY)wReNu4p4#r74={v9acRIG1yg5ohsR8j%2HfJTsz2B`>)~tdQYw5OSA4!7 z$$n3Vh&Kt{%bz~IYp=Y1A9`Irue@;BX#02k4E=3jZ5759*_;(m!-PTi`=qq{jqdB^>g%KZp4Br?HFYq?#KBJE z{V=tp)HKwI2ot%{NC%Pyu&VFf+{9$y?e(FC_?D~Z!-P_^DAp_2&d6jlA??L9PsgT| zw-8qCE@os!8=hb@k+CLCqKB7;(9N}l#Szx4l~Ih76kRa+wZBy(`iv85Zdqn zxiw_S+MEq|UAwnGN!%ZR;~Mp~Ciji!0bhX=IvxEJD+|CHMux{|%}`vxKF8hjbL36C zXLUd7{#gF9dq?hQ(!psiKxuCC$8n6)WFzj(jksq8Fl88f(Kl(XqlFGSJ)P1-)JSjI z!{gb*>-fWa_-i{Q*f1>)1(!i9!6C9M;L1hbJbX#UtqCBZQQy!AypNQo#+?fBPa@8H-lg z*SN|%?~8C_5TsGL25~w2b2;~Nk;`+bnGRWqOgh&~s97Qc3RY$^5tU0sc zDk4ybt#qEVIT^;AiR;KGC>9Pe1PwKcbqz^!@xRL^16DRBYL4`Mfamq2rViQs8o?us z?jFytC(x^df59{5532VdVoMNq9Y%_PtMuo?qvt2roLVQ1+i$F_yh~v zcUEEq8%T0%U~(23xB&{$1_$f7+Y7=;J!#xi;$Hk}3#-2oyu}_xkcuR+1jh{75s7Cj z#C_@Sz5#K=?y<6%NTn#X8@NGb0%d=!@eYkog!-rc_zrox9$}C5c^~0=SZ60LDh~Wp zpQ01A*{pwrok8P|A~?Q;uD44J;`}MAabQt5o`250_Ly|ee8TG%!;TbD1y8gFJq*_RTtKLwWyvH-p$H({8{Au zW~lcD=u0cy?akvTqhlTp_Y^#}1Qs-@>MFD9Hlx?nWePts5}TR`ZFet$pFiIxm>)L} z7NIQ-{Jhct2?y#guikoZD!&kN#7vhPmqXr2xO0^o+2P)9k-K(_+Mgg zyCdtEc}`R!y@H&D{yW_C(Se zY#z|8P`EUAbGPN=`SJ<<1O#?w4(iK9ME7>>4Qv#Opx;ClNlOP!Y(Mbietb1*XW_u! zLZKeeQH;pln~wR$+c zry8(rSErUs$N$GZ@SxvcVcUZPvIh>b2M1z!4S9{#TaRM{z|57;`Y}-xIUG5x9P`o@ zFEMWVYl|O&fFD7RAE9HIRT%DZs*#)E6i<|6VtuMj6<&qgG2Tfph`>&RXb1k`8uZ~B z;-N0@0z7gcGKOHy-x;%S@0Y4(P`N8AB_NkpN_96y>kuC91{Cf_CJT{oHG~>Q7%FRo ze%aPB?;gS0CCD2ycPpb>cP>)XBZ%93Zq_M)8&`J&Yc(cMPxRLoAtC`Gq8=gQICyPA z^SZe)A+aOcOwRdIqj2AvQ>6gk2ydNr+K>%&7$S5S9dsCpBOkS}uz=BBG!~W=y$U}y zy?(GVL-9*%`e9d8<@E?o=Pr2XE?j3okT|FWErgk3)`w&Us8h7VkDTck@UxnOxcU*q z=yiPr0(}HMeT4J*->3=N(s`>4J;1)vol15oEgfWs)Vm=Vjmyt#NT+8Ir)MyyKp#j@ zS#OsHrXL7l(0U4nOq!?QeExDQIR>$uq=j%o{g6(5phv-Q69Hn@e~F!rY_)SBI(tWr zdwYOAO`NW@FNn=;+@^1lyM2&ueV~`Ya2qg}r$rBI_1KotFzX4%76e%3DU-@kgp|IG zBKir5RnhA+GVJ+T_5y6Zd~J#<5T1y|;XMxAVO1R1Y>_7$g?O8}HKH)CtHPM9&L{{c zWZEFxbbqW7N!V@ot7~0 zaq7nqo%7ct{%nd@HYX|+V8^mN)$T2~jRr!zyTvIlf!={2b5f${y+et8%ApuzEJ{-Cy&r@+mZ|Mr=pSD>&uWt3h7wYvCMUc9jti%pU06t22;QLcNFC7(c<2!DU$7X2q>sH^ssjRuG$T3pRW*z7jg;=p^fyZ`59LJfvi4q;8hC;QqyEuZoIIX+*R;Ew7XeKxF z6YwTRqrGYwW0*d z&SwY*t_epN8$Br$Jt+o#a3iq>FdeUqZi@0^gJYHfFU2Y&lnSI!P17H_K4%d(76(5P ziW`;AonkI2ED5=tWpl|x)ZuYR7$;^?QD@3`Z_Wd;a6rX521hayDjAiI0?=NX!pydg zCY^Wu2*Z)oFK#dU{FE$&t*N^LNK}EuW}84oOb6)FE8WM{iQj3)YFszw&LbE(kcnmCDxkKpJ#tFQ*)SqH(bBQaKf@a=gS z@OhavOf_Kfx+*QGFfmo2l8~ryU2?iOO?#P~L1yiNvJPgUT;D|8L3bAY@DAsGGtqa( z-x{F3`=ulU2zf%>wfuH@jKSfLBp=?U0|Af~+tNbP1cz``Qsi_>2rbC-E5qRF-N8+I z<=!MzQghp40`Tb-JN1jpYKsxU?3NJm1Y zqtej>R?Q-n-18E#+Q5?namXUb=GQ<3Jc{j4-M2rB4E5LO6*={boqNS2a%V|6*nnT4 z6gSpibLsKZO$?4yU531V^12S0s{84z%E<_26gu)qzICbI1<`i$j}5z(at=i>5}Ou? z4dj`zB(P-^Rp{nx@(P^!h0X#ZqkMoi>%p&*vOr}{OmD=x_zh|UGuc~7x*KkX&d59q zA(2!6$Tkh-1k=z zE~xw0xS5ce23r+^g!qLy9kq}4Fx?@X+Y4}c@^QQJaUbM%XBwul8adhn;(d%VsbT%zm!6XOP_lF1SMUBAzh>o7oAs$wH;1q!<{HY><}s{iJvfQ(8yZVR{(JExmZ}O>jePS)fnbf(FBv?eA16mh3X!oFceu{P%SwgcrZ+K1lTiY-4hU+1 zKh(TCG2o|kf~D3@*ykf+@4Qd?)MrHZ_gKPV99ZM*hqJ32%yqBl&W@W$;LQFOYW+Ky z6Uk1V@m4gqn>Lq0H6RGl!QWu!j>r0x5}?^yg6m&I{0<5Y0VMbyE> z!H+w|@s1>0CcM+I zPDAph4ks)&XD4npE!8rTl9X6Lm?^ci5&BhGa-yGFHL(W$z4P&RIf+a>)CTO^U~}Td z!&OQQOY0u0;Sv|-vQoUsIBvcvzB8ih8B>ipcIIKYM=J}g2!wYlz^%NTiYy+in>lfx z8lvtxix6uolYgPEu?so12RWmB%_j98KS-4F5^s>~|M;5D{cXY@a^L-liBuaaJS)1L z5qqCg`y)3ZuaE~iz*X>D>TiA5a9>%#)H2n_hA{n(dabsZ#G>e0S`2nt4S8Bg5$nht zZ&M!Oj$RO5X~Q~=W=dij4X`5SsO(>WHeqw0eJVcvA~};mb{k)bzfJpZ?H}YL*{bqR z9(BT*JoYfkvWV^?xkb^HwAkyE8rZbBPr0G#lx@c=P*;9Fx%P5XIU;jd9%my=v7W$v z1O62khEor~8C1m~<X|}%UgOgG5!NQ;P`U}h{em%(0^g#3ZnH-#^ zZpvDMRL!_Xg&-gbi+OuO5ZN*Q8KD1zO!`!V#e$X?+@-%!)6zU2#mWGjuLOiTe%4H*5bSli8X{%fWvtyPJ{H-@BovHRb z(C2jON)jmNL^yn1qrcb5U}LfbStx5v?w zz{qz%9N{z?-==qldH!`Q$8a%wJ*|!k}S9N&LoCH;dT=07&Di6+; z&%rFj&JM}1KqDp6TEod1-Yb(#t>UZZ z!yqy58fj51gp~cAc^tgsEGX&1q2N@A1LC}x-@f0f+7mw)& zA!2d5M`|0-ElBWX$oIZi$A|az@Wv!APmu6o=4L8EHbqHie%3AYz^>_X1RFeaBycYx zlp%+mb0#5@(Z#<64NYOU6YWP8mG5Pm|KMD&l$zr3-7TXnCG_R^i$l#h8xO=mvJhm> zCyWq8V_)-_jDhSk#y2ExB9i9#byvAkN%g|C1}!lk5zo9yA(12(=Mj`Qce{d8k^~8y>^;V1)*w+P(a`lqghMby?iV@vsASjkWk2w z2hKScQSf9@HM+-U$7fDi39s}arD-VN;g+o-87AEeo-x+i>Q1i4EHUSp%go2DF#qwA zg#5WWCtXLM8Rhv*3aKYPA_S!7^uCtjg;`D3YMh)Ewa=9OQF zX=~g+@*h;ccS`=?XmZZx0C9FL_O6wKrTETGxP7Rh@^`CVaBcum)jPZQpNqrK?~82= zYa`P05fjXtC(hbY)gaN0AqnW$Bj8ewyDX!xKqdNSCs`|J0!m;1`%nFKr`)mnNKaX{8raZ1bpF1s3z zO2*rJVR$H4TxmXrl|{zkEcz)TS=w6X=(lk=5G$Nw)^S=l(`s1KzIW`*9G%zF=pPKt zrnyQ#9M2qQUu2!Y>)z)E#H*`g;2=~_7d*=%#>ot@HPLpU)aDK=Rip?~~elA9uCFEK>E`=otpx*-sPmP|dB3!zxa+)ZQ-e<^WX-xTJ zVDxVm@1E_1xv9Vgh)zXOIAJxqf|1T+%E^S21Nz7jjFH>`Qahm%2 zEHGUZ5G`pGVwc^L%O*jxl>vguBzsR`*w^8`H6Fp3%uD&or@7O7g`hMiLu8c261ERi4#n){Q7i}jO6&E>uUad z#2m|}xK2_rl-)ST^jmo4#D3K1WK?)&gi1T?jJYx=p&V0-QO9bzT zvJ{Q@7Nt>rJ=|31rYBgWJvLKWU(?fpuW}lk1GpG@#ga3LmCS6eL|La32usb6;~OAB zmJ6|-4BP7>>Tw8urdL*uNi(Biu^s(5$G#R(d3dV8=2-X4SoZ+@b#|G`e2g|r>Vi>F z^ZhW%s&JIiL7lF~im;6aW)SSn{!8_8r; zaB*g;n9E=BI#u0?eq%s=1mZ@zcOV-Z@**l$xy0!b(4Z3|v-CL!VDdQWP|;vkrRf&! zxK$g6FbuzwZLT~YBmU4iMCdZ5`v;kdi;r$KL#2D}Cx=WC8{Jl3l)?=5+&-keta8Pv zC@^ztpdiEh#GVTkZRm^{J%F*Luc&`C-fQ*vd6~EWP~)!=85t&DG2X?fmV^?I3aNB?jDF0X3D63+D!7xhlbD5)AUjtU2a|KQ9Qgf;lK1*& zZ7(&D`x&JxWlZJv3^Y?(GLaXn?Lv}>)RhG?IGmgc)j*t8OTj9+O{D2{rjERZR##R| zG*z8{5=!YlQ^TcbLGa@?jg6o{l+FKm837Ln)c%D}K^fgu?X8`d4fbU2X(bsp9c0J4 zb*C&Pxd%y-*DpF3X~`&2uPw(4d#W;`k>CuatI&~BZirOdDJEF@<}VzorOoV2vK{60 z%zhsxCD(+gz!``?z%HFX=|!NU7)eGbR1L~=dgbeV5Oj;GbD?pv!d0iDgPDok>1DqU zl%)~-{ATBs=;>W7b^`H}xGr~G#;9P#y%&a7P(X4l$j}(&5X4>Fq7dp zDBd_|^>oRP<{~l{LNeriOU^~sG5{X1+$$qOHj|8}JP3Zek*#22rxZtQ&&w1;=y8kA z0w7A0ReM4Quz1>jZhga!KN2lgLqU3lrjJ3H^mhD@!1??pY}9VJYKp8&(3q%_+0n&ob0UNjazqAmY;qz>+o+Y;jDS#z0vI|&y|CMV)>r8 zP4Nra_|i>mHp7z;^};02Hbd{-`CX?J)PvbGPi2-oEZCtc@%EF->^y~+F50v6j%<1; zC2xM)_|@%=@9p@LU&U{cwz0|WR~0g9_@2GjP`Cfn>$VO*7odrv)zcPM=P5ZbUe29e zKHE1`a^1NnJS+M=VkaEhQzECPS-C#0Szqv3&2UD!R(xre^7jw(@*H`* zH(cfYG3Q0nY7CyWDU3`a%p$;LIt&aQ zIf!$sKztpb?_uD8BZx)HK~CT^sz3)d!7$o^O#$8zn?WaLfozujP}Sc9v_piEfx!&f z=Ef|bC_EPQ;z@7>iW@*dj>iq4Q@bAAQ@NN6Tt63T%gEq`I&wDw zBZ@_Wfx#5XiAx%rUsx!6o@cso>b_2gVu<B` zOt%pkSjZ=Hfev(pfh~=7oQxEtFf2!Kkr7&;6Tx6$OXGQdDuosn#}OG^$jk6S2X?{0 zmd3LJlmr*{_4Z_h7;1(T)TL60VRs*qfrh+X95q7<=}{7BnCrsH2r$$PIZvNT0fy-| zA_EJ#`vO`-4g*^nXB$uwSQz~j981da6<(lD6AWx=v<{+DSYbE~XHc=Sfvgt;!b?01 K4CcX%Kpp@FB{OCK literal 0 HcmV?d00001 diff --git a/model-desc/navigator-icon.png b/model-desc/navigator-icon.png new file mode 100644 index 0000000000000000000000000000000000000000..2612ffb42538419b3f7478a2aa92fa2a63e29742 GIT binary patch literal 7798 zcmV-+9*Nqx{Y+2_P8@O|e()SiIwxT|TbVlF z2}SvEe2E6cRnL%(%VmJ0I7mOcFjl8yX@{wvsQ1T|ju$7zi6z_YHs!OWH36YHMNbf0 zp5sbW%}KTy=~&*yfns_l;>qViw0LwOx-Kx}n{tjiUgA!Rvm^tr(`x{1qBB=caB_@4 z<}{TRYkfl@1Iev4=chmYY5v6*UtCjBQBhM^SXebOGE$qLpI`2}ZW)Gxyu7^pZ25zZ z;|yRJ%49M<_}r0Br`tP_-hA`T&b#lvdl14Lk;z_D;$8!96OYG~CL5&jmS@xfKl;&+ z3a`KZ`nu`Ur#IkWFGCO(BN+2=z$*}da!fJh7!G6T z#^-Llwqe+Y_uB^s20mW9c5NHhGnB28Cy*=dGmsliI&jAlBq`FO;^~=nh;!3TH|4Eb zwQ5OGQPG(=kY^z{^$5yr9QnDB$yDKe5yk<6Fjk;z9~Ugczot?t3d2rbUVF-M+Aw1a za^fC*y|t&O=lyryd1udUx7{`bK?5SAuCC~Zt?#DynkUNiJTo+zDQG{;BI$z(k zY11p$UVCj{HcQ6PcGuEZuL=lq6;8a&>#o6#j7Zrj{Mj@_9)`ieK|m1)RJPxE0t^F{ zgXQ((wFScmSl8Qg=FE8lf_l@nT=l&+=O+Z#L_sov5tWWX@@UVVJzttOZQ4~hfY;$b z)?p~-0i*$@!Nb`NrKP1FFa!z%lNDW~g*xV{C0JB00Y+B>Y-nf*`uh63E5#FWnOH|3 z*3pg=VLj%3VcxuXufdqeivlW8JxmfeO+?X~xFpV$_R{Rwv13_DNy$wa*S#JGY!-^Q zLaAp6nDX*+C@U)qaEk`R29Ale4rAbm%liBK;n1N&-aVJ=fmKj2gl!@H^*pBeWkW;5 zCNP7f7r|10r68=&a-zx7Nl|MO%{|}1f&U(Yvvhc5q$HD_;Y0*ZRaF%f7Z-cr&_G22 zkrbpTJ;oxD06Tj0D4><@aT>*YoP`slAV2>Iwyg<4TvcCR|1xKVFkq6~OcQxrG*OUP zzpx>o%l6A(zkdDfMT-{QiUaa5s2gU|tYvVBQ|jvKJh3JRJ`RM*07<{6djhMit<4jK zL|G9CD4M(Q{+Ydd_x{&~7hXuFyfz|Cz{&e@anpD}vRQE{@jkE^-L-4i#iMPR;& ziaU?Mp+JK?bLLE_uCBHY_(Xxq1t1+yBJkkBgT8*G$%Gu0!M?nM;_t_c7cc$;CkHcN zCeuA<&YFnJL;|CAk{AE@AI6Ol8)_bEd<0;m)hgWtwZ5J2?|5OEEO zHZlxMM!{ql2}vo=n9$Fxt2#S7J?Dyb(ZXdi(1eFT-&FDp!EGZUP032hX4o zhEE0g6wxZ(f5jD7w4yJNe1%&2NK4N&j**mf(=W+F74EiXl%#H&Y-H@vWFw+JqRC#5;H_M?Y}w_nzWQn!{FgUoB)*3|A8Cv^L=e*1YkdnqFc^5^wa8Oiw(o-b5>Amn+%toLZ z5WseP{&eHUjcHkwDngFygv6Z_5g!2Qf(tIlzvY%&md}_m;|>JpB5pVVR9RW+1LPNQ z9DtfEfHp4IsPO^zO5Ec6OcinYY$+y1stt(Kek{+5tAd!Nl#!DSE5$>5v6Fk>A z;wB1Y@nwB~Dde)b=zDBMFUlvljv}!)p~bApm1CpO+UP4^`AXq;zx&-YDyyn~I5aqT zIsrtM8#_m(73XC|HtO$=8o;#w-Zp(pJ!U! z0$6~vS$Dc1E#^Efy6m#c%5YJ7Q+j0Nd}JQzBpL!3Q6_7Ok8+(V8nGkVu)5m?O(4 zRA|h4Xd>JbwV#xPk^&U<%zIH;lYDetRaiK8@uEe$4j(?e8+Ut&n|PO3y3_#17PrQZ z@R2T)oRo@=3k+}`&Ys&*7T2anS=lR#^Y+xJ?%lh;fsJ|?T_r`-D0Y~Ve3mpG4jN9ou&w1VeA3bbLnGpd zK@4Lps49gs7gTuQMNtx;UD7!Ho}94cIVV3KauSpj7x&}%{5$&hR?}97L9O3GQ|16x#6L+Gyq4kw{zrU8AW6TSjWPJyzc)EZ<81j9a?#aT%EiRe z86h#>kNsI>Ddm0NG6L0N= zV}uj={Km${Z$oe_O=E0w%;sce_*MzZ*{|a)Dd4>!(nWFmIdPqQcgI2a^S(o|mR(ZN z2xtvdTsdw6%P(#c60x;MTt#DqV^xT%;h!L=I<&e8XLO_z+g^pbsDx$+t&3;@CqdASwt+*> zG)M%{SZkw1nWF|GUhHxD-hm<5xU0hhi7ZB)pNtiv%_wdc)t14E`IWJpXS&yEXl&@X z7=wh*S6zDPrK^#n7!11VEq2*KFD`07DI_b=X*eIbX9)u2tyT#n*{Gx(BMmyVk5un47`Fp)d)9vZ9faz~&d(!@r0YOAS;RJ11wQ5y8m_?nos(q3N zNdU~2ho5%-{P|zRgr$5Gi(Ek5Fk2&S@x2JnE)+WikPaG-sR~>_an_sL4j9{>q<`|B zj|yZ@NEJ0SG+YdJ%g#hj%JPyekAU@o_Ws#e(KKoRpG7k@()6t358yzU1}LXMlO-I63K=7|{>W!Z#7Vrs#~RS@T69+Sl^$Pd?MWO$iA>~WzWnmb3lWqRt`K#$ z#cPt8N6I^pPlkj8n}|ckSr*Z@)*jD7G?A%~rhaC>+!!55*PVvR)`^SPchj1fpal^mRjw_m#Nl zomD;!=Fcn%Cbft>CjOKrOZhmK^C5gl(h1fa6nBywTR_gK#)|S)g`q~7ybna%+j?Ph zQ@00{Z2VYa)rzSm3x*_?d9h2^Z7sO;K=1k)^Jc)Qv&zE7Si~Wp*u^V-fL#mWUfNE! zT0IV-tzKl=nWJ?@pQqG~q`jf{c6RvOV*}9&m~L61GDt?_$QQ*Ov;e0*k@NPP`btPb zymO2FOkt>ops1s3MzzpywQa+N-4(va7OB{KCQ%myl%)4|9vl;I;8=mN0tTw-tW=yG+eN_8sf+svr#oc6TMWtlD`|_B?aNP0|O`7j0Y;Y$eRV0hMNX< z3yQZffW|uKd+H_v*d$SMV7%B+%mxWs6sU`0BW5i+0F%sT-ds7 zG=yF#OQ#?GU|XBJZN-4@aFR90WKk|2glsHCvEvr(C#|WX$`#{AQc0g*G<|^QgJqLj zA;SSpM>6ySAVoEblx+L}hnJH{25>xp+FS1N=NR%RIELq>vv(`s} zqD<=~%}w4tR(1qMUM49g?K)szshcS|cbV$T^}W6PD6X-umzp~JBiB>HDt6H$J|JEj zod@FCWsd_Bvtb5;XP8|AiDrRbAIU~Y;zgjOD6fPlO|=;ku5Aq;V#lOq*EZfb2rr!C^Vn&k zz?h!1k=})Mk|{m6HEV{aQFR;)7i0u#bd4$=ymC|`pZAA`hT8Fxwuw7U1-J|9EnIcS z3;<1pyQ1<%>q0w4bB$}vPP@KQBtAbK85|tkKUUc2YX}~kd+ zmOVW^ja5}uBl7U0{EZ$xXtXLnG%_XvoUw#~h|zqb)s2D03>dWvH3Md+XnjaU1dCC+ z$&D_pqNLFOT?(&t>Vs{elSXh$eGk7<#h7MWM(@n(Hu$yf*s)_DRx~W!8NB7_Yi40BDA<4U78mc4XGkmZeI=la9D88b&AT$OXxbO=Pw%Vzc*-1Sch~6!OHCLVjmw=P%LC{&)Pt zfb`*%WN}S@+S}zhR_)}d&P2Tq+BRb%F&PD$86(O1|kH>#_v{~2G=d9rjiWW<$E4*4gDOvj8(vcn^+U=xBeq-3m>zA&!>N(=KKw5JoQ zif4F$+0<((iZTIiND^dTEqf)mxJFLVtseWM{+%7+WL4^6kj4<~q^)ePx)cD!nN)tO z_wC#F0aYY^7cQJh$l`)L2fnnl7CVxk6>$-pabwl^gD63huT7xEhBz^10mZn1m`zq$ zTrB#?@%BaR z#Cp#oBO@)p{`Ifr&w~<~^pLC4gtsIhXogD@+%v-|?$b{{UAb`K!h5Iy{!r@3kt2SG zCQ3=UC26{(ZJI1@;?IFd+_9)TaNxir^XJdM4{u2~uxMkkr!5@`oTIlYq>IQJa7Mg> zz_f6K_*aG}tCQp9xXI+$i4gw)2Lps$)b`R#FFgZxBSAV6G{d+O7}IVc2lnyhXG0$9 zrXSYT)!oXSrBCDOGmojF$?<|88=?;xq&_-$@Zhs(Fx(BJT%@^&?_I;yYqZ=xmoGJi zbk(DeKKcX#<9Tzv-z-4ZHvN9Xv7)40G}&AdMR^orpz#yS9wFv=w{I|dTE$IOhD10yX zkEEXR$YwZzC`8`7van~Kd8T#e&Yds#1!UI-Qz`aN6e4h>HAl32_wEX+7 zl6xfiV6j(0k|~ok%l$O__wRRc72SCL`R5mwmzSSSalAI*e+cr|K-6dYK9)bdBx-MO zf9{@p?pgiD8*k7tB586nw=i%f(;LLq-+9%eX<9RJy1=__+qR9M0kPwfOD;JN8(HfW znl(S!UG#Y-nvk?6lGYrGxh*K-{`-Lk9-u`(1EbeN0AT%~*((~9gB1)3rTjGMB)(6- z{PN448#iuzDEqJ3Jfc~}--~`;i5IQXSU?HV_t8fmt$ysW$M!&Q>;QseEx`iuKBRKw zc?L<2xSG5X0S@cw>7lb^-OHCRPghn}o{bI8lU{Op7UJ_ltbgUNW1@H;LeIjpt5>gn z>4g_wpikZ9h8{al0fIV;$+r9%J7@yojXwv>0D{Ql=iRz>>i~k%bmp07mSMveWY3QK zdrnimUOAS;|7=SFM0-W3hhD<1@t@y+|NYGn_H^5%k_6945+q4-3qt}15C+Z%^MemQ z=wG&MS?9cY^UARkbFnki*a3Sy7M7Duyu-=>u_(tr9XWL9&^oksANj!#ey|sU+~XyI zX#bpC;7anIO(1FO&M{oAj#>0kbs$jf=uDh}9icDU3fR9#oz(v{@v}rU*+~B|2W2PS zk;8`%Z(O@}?a#jd{qNIvu$qIIQ}i!KN;0iciM%n-(-9(*1_0E(G&&^bIS5pHZEfw| z#fukLplMo5-!`%66W@-)XNB19B}Lrm8H-GRXJ_Z@XgEE3=bd+c0%22I0%Y?t=(VU{ zE#KHcaw48h_u7N*y#D&@hfX`~v=(&2mLgCK5gc!YoBaoepBeGT8=GuqGa*2I=<<0R zC*)(d-FDl@5HzthDDpWDC_R?epPV*{Kht|Bs*+b;d8MOK ze?WuiM792S89^K*&U0kY71rF^+WI1HfIhWy+Aa?!*ok;e8DPmCxc&eLfE-0Q-F9uYKyN zr(V7H-h20g{oI^M57~5&q>wco_v7t0&N1DazE<<-z4zYh{qVyNch8}=j=_GKXd!-w{J$U=t~54^_Wimn8X{$>2Wg|3xP=< z^}i}&Gm8pMq7DoVaW-t&(1RV`i(+IudM8HkIs<{3!KY#wBzc`o*OHtN3<`-fo*?p5 zQ}jt5z{&Nyb?eqW@yH{Oyz}6L50XcF1cIVWdJ}AGAqkY<6tIt7U}oCH8(88sr%AVx z-g4)|EBY{tpXSzEZ>>Ayj5BJlzWVB~*VNQphyymqG5jtO2mXJs9C*!T;yCr;mVc^A z{{LFjw^mtj+R$?QKNM+CzxCEzjks?{zdy=AuoaiKTse)+3apCX$|u5C~ug%?G@` zzP|XYU;S$B>8GDwbMCq4u0SK>tcr??6)1+PZHG=KdZdfuM@B}vdV71fp$L9|%a$#l ztY5#ram|`FtzZ^kdfUOY{?Ty`m@T|0-4yI6*hzDb6nQc(rQYeI%32iWS?*bUrWP(- zScnVZk`*gf%slVB^A;{yvSc|fiqF9{*WaMXDj)ADR(9i{*M1v1L$_|)aPrBAq`fB1TPG2DE zO`!#tj~rDnckbM27>X7xT2zjp)#LpFG&<%XX!H*cYmnP!pq?qtn)TjqPGC5ST+(y& z=+U;mzCJoM(}+Oq+q`*mBZAY7_k*~zJcwHhgJ`{JYfLXhP1ai!NKrb7IZJ9*v=QMvtBsG!)>aS||-%*}wA6XYysAY3qmB!QCU=(b3p^o({b!NeW%ecEsjU>0K< zEZ5NH#6aZ=l5PlCD&|gWBLlMca)z0#Moy>2nT`XIR<}c2QZ`PK!0`LDinDPISe`-M z=fpXhauIj7JbLDuX1PgBN%1B{qD-GMpa}r|&XiU@>o&=2MzzDVpacl(EE{MHSSF?n*#;Bk%vBQs z$rNW2fhIkq2is(3>-SP;MYTsypeV52{I z91snfY|;a1OQX~40Z&Eb0YiF8CXj60W8*%@kOmC-!I0mUXIykVIEhH>7M{H+OI|t9 zCUD}w;(IqDoz^n|!G*9*w>gHgCY6pgNU{#s5+}u7M%>$s4--j8s$)oN6H{9J*}Nns zs}